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1 Introduction 
1.1 Hepadnaviridae 
1.1.1 Classification 
 
The family of Hepadnaviridae classifies the non-cythopatic hepatotropic DNA viruses 
which can cause transient and chronic liver infections in humans and animals. The 
common features of all hepadnaviruses are enveloped virions containing 3 to 3.3 kb 
partially double stranded DNA genome. Hepadnaviruses show narrow host ranges 
and infect species only closely related to the natural host [Ganem et al., 2001]. In the 
family of Hepadnaviridae two genera can be distinguished: Orthohepadnavirus and 
Avihepadnavirus. The genus Orthohepadnavirus compromises the members 
recovered from the mammalian hosts, including human hepatitis B virus (HBV) as the 
prototype virus for the family [Dane et al., 1970]. Viruses that are the most closely 
related to HBV (70% sequence homology of the genomes) have been found in 
woodchucks (woodchuck hepatitis virus; WHV) [Summers et al., 1978] and in ground 
squirrels [Marion et al., 1980]. More distantly related viruses, that share the same 
genome organization but almost no sequence homology are found in ducks and 
geese [Mason et al., 1980; Sprengel et al., 1988]. The avian hepadnaviruses are 
grouped in the genus Avihepadnavirus. The representative members of 
Hepadnaviridae family are presented in table 1.1. 
 
Tab. 1.1 The representative members of Hepadnaviridae family 
Genus/Virus  Host Reference 
Orthohepadnavirus    
Hepatitis B virus HBV Homo sapiens Dane et al., 1970 
Woodchuck hepatitis virus WHV Marmota monax Summers et al., 1978 
Ground squirrel hepatitis virus GSHV Spermophilus beecheyi Marion et al., 1980 
Arctic squirrel hepatitis virus ASHV 
Spermophilus parryi 
kennicotti 
Testut et al., 1996 
Woolly monkey hepatitis B virus WMHBV Lagothrix lagothricha Lanford et al., 1998 
Avihepadnavirus    
Duck hepatitis B virus DHBV Anas domesticus Mason et al., 1980 
Heron hepatitis B virus HHBV Adrea cinera Sprengel et al., 1988 
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1.1.2 Morphology of the virion 
The hepadnaviral virions are spherical enveloped particles approximately 40 to 
47 nm in diameter (Fig. 1.1A). The outer envelope consists of host-derived lipids and 
is spiked with these viral glycoproteins: the preS1- (large surface antigen; L), preS2- 
(medium surface antigen; M) and S-protein (small surface antigen; S). The sphere 
contains the nucleocapsid with a diameter of 22 to 25nm that is built from the core 
protein. The capsid encloses the viral DNA genome together with the viral DNA 
polymerase that has reverse transciptase and RNase H activity [Robinson et al., 
1976]. 
Except for fully developed virions (known as ‘Dane particles’, after their discoverer) 
two other morphological forms can be distinguished in the sera of hepatitis B 
patients. The most abundant are small, spherical particles 17 to 25 nm in diameter. 
Filamentous forms of 20 nm diameter and variable length that lack the nucleocapsid 
are also observed (Fig. 1.1B). Both particles are non-infectious and only consist of 
the lipids and the viral surface antigens [Robinson et al., 1976]. The number of those 
subviral particles can exceed that of infectious virions by factor 103 to 105 [Ganem 
et al., 2001]. 
BA
L-HBs
M-HBs
HBs
HBc
DNA
 
Fig. 1.1 The structure of hepadnaviral virions and subviral particles 
A. Schematic illustration of the HBV virion. The outer envelope contains viral surface 
glycoproteins (L-, M- and HBs). The inner nucleocapsid is built from single capsid 
protein (HBc). The viral DNA contains a terminal protein (solid oval) domain of the viral 
polymerase attached to the negative strand and a short RNA (wavy line) attached to 
the positive strand. Dashes indicate single-stranded gap region on virion DNA [modified 
from Ganem et al., 2001]. 
B. Electron micrograph of hepatitis B particles including virions and subviral particles 
(spheres and filaments) [Ganem et al., 2001]. 
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1.1.3 The genome organization and viral transcripts 
Hepadnaviruses have small genomes of partially double-stranded relaxed circular 
DNA from 3 to 3.3 kb in length. The strands of DNA molecule are not perfectly 
symmetric and the circularity is maintained by 5’-cohesive ends [Sattler et al.; 1979]. 
The complete DNA strand has a negative sense-orientation. Its 5’-end is covalently 
linked to the terminal protein (TP) domain of the viral polymerase [Gerlich et al., 
1980; Ganem, 1982]. The positive strand is shorter and bears a capped 
oligoribonucleotide at its 5'-end [Lien et al., 1986]. The regions of 11-nucleotides 
short direct repeats (DRs) are located at 5’-ends of both negative and positive 
strands (DR1 and DR2, respectively). These repeats are involved in priming the 
synthesis of their respective DNA strands [Lien et al., 1986; Seeger et al., 1986].  
The genomes of hepadnaviruses show a highly compact coding organization. 
Approximately half of the sequence is translated in more than one open reading 
frame (ORF) and non-coding regions are not present in the genome [Galibert et al., 
1979; Miller et al., 1989]. As shown in Fig. 1.2, four ORFs encoding seven viral 
proteins are present in the DNA: 
1. ORF P: encodes the viral DNA polymerase that has reverse transciptase and 
RNase H activity as well as the terminal protein found on negative-stranded 
DNA [Bosch et al., 1988]. 
2. ORF preC/C: encodes the structural core protein and “e” antigen [Galibert 
et al., 1982]. 
3. ORF S/preS: contains three start codons for viral surface glycoproteins: 
L (preS1/preS2/S); M (preS2/S) and S [Heermann et al., 1984; Ganem et al., 
2001]. 
4. ORF X: encodes the regulatory “x” protein, that is required for viral infectivity in 
vivo and regulates, directly or indirectly, the viral and host gene expression 
[Galibert et al., 1982; Ganem et al., 2001]. 
The negative strand DNA is the template for the synthesis of the viral mRNA 
transcripts. The viral RNAs include pregenomic RNA (pgRNA) that serves as 
a template for viral DNA synthesis and translation of ORFs preC/C and P, as well as 
three subgenomic mRNAs (two for Avihepadnaviridae, excluding “x” protein 
transcript) necessary for translation of the envelope proteins and “x” protein [Seeger 
et al., 2000].  
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Fig. 1.2 Genome organization of HBV 
The inner circle represents two strands of viral DNA (+DNA and –DNA), with terminal protein 
at the 5’-end of the negative strand (black sphere) and capped oligoribonucleotide at 5’-end 
of the positive strand (black half sphere). The locations of direct repeats DR1 and DR2, as 
well as two enhancers EN1 and EN2 are indicated. Boxes represent four viral protein-coding 
regions with arrows indicating direction of translation. Pre-core(PC)/core, polymerase, X and 
the envelope genes (L, M and S) open reading frames are shown. The outer circle 
represents three major viral RNAs: core(C)/pregenomic RNA, preS/L mRNA and the 
S mRNA (the “x” protein mRNA is not shown). The common 3’-ends of mRNAs are indicated 
by letter A [Seeger et al., 2000]. 
 
1.1.4 The replication cycle  
Little is known about the early stages of hepadnaviral life cycle in hepatocytes. It is 
assumed, that the enveloped virion binds to the cell surface and is internalized into 
the cell by endocytosis. The specific cellular receptors for hepadnaviruses remain 
unknown. The virus–host membrane fusion process is probably mediated by a pH-
independent mechanism [Rigg et al., 1992; Kock et al., 1996] and results in release 
of the viral nucleocapsid into the cytoplasm. The nucleocapsid is transported to the 
nucleus where the viral genome is delivered. The question whether the whole 
nucleocapsid or just the viral DNA is translocated into the nucleus remains without an 
answer.  
In the nucleus, the partially duplex, relaxed circular DNA (RC DNA) is converted into 
episomal, covalently closed circular DNA (cccDNA) [Tuttleman et al.,1986]. This 
requires repair of the single-stranded gap, removal of the 5'-end terminal structures 
(RNA and TP) and covalent ligation of the strands. The cccDNA serves as a template 
for the transcription of the viral mRNAs and pgRNA. The viral transcripts are 
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polyadenylated and transported into the cytoplasm where they are translated into the 
proteins (core, polymerase, surface glycoproteins, “e” and “x” proteins). The 
pregenomic RNA is packaged together with viral polymerase into core particles 
where it acts as a template for reverse transcription of the negative-strand DNA 
[Buscher et al., 1985; Moroy et al., 1985]. Next, the synthesis of the positive-strand 
occurs. The particles are transported back to the nucleus where the DNA is 
converted back to cccDNA (process named “recycling”). This process leads to the 
increase of the cccDNA pool in the nucleus [Tuttleman et al.,1986]. Alternatively, the 
progeny nucleocapsids bud into the endoplasmic reticulum (ER) or proximal Golgi 
membranes to acquire their glycoprotein envelope [Roingeard et al., 1990]. The 
mature virions are secreted out of the cell through the vesicular transport pathway. 
The steps of hepadnaviral replication cycle are schematically illustrated on Fig. 1.3. 
 
Fig. 1.3 Replication cycle of HBV 
The HBV virion binds to the cell surface and is internalized into the cell by endocytosis. The 
nucleocapsid is transported to the nucleus where the viral genome is delivered. In the 
nucleus, the partially duplex, relaxed circular DNA is repaired into covalently closed circular 
DNA (cccDNA). The cccDNA serves as a template for the transcription of the viral mRNAs 
and pgRNA. The transcripts are transported into the cytoplasm where they are translated into 
the viral proteins. The pregenomic RNA is packaged together with viral polymerase into core 
particles where it acts as a template for reverse transcription of the negative-strand DNA. 
Next, the synthesis of the positive-strand occurs. The pool of the nucleocapsids is 
transported back to the nucleus (process named recycling). Alternatively, the progeny 
nucleocapsids bud into the ER or proximal Golgi membranes to acquire their glycoprotein 
envelope. Finally, the mature virions are secreted out of the cell through the vesicular 
transport pathway [Ganem et al., 2001]. 
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1.2 Clinical outcomes of HBV infection 
The outcome of HBV infection varies greatly from person to person (Fig. 1.4). HBV 
causes a spectrum of liver diseases ranging from self-limiting acute hepatitis to 
chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). HBV is transmitted 
through contact with infected body fluids such as: blood, blood products, sexual 
contact, or perinatally from an infected mother to the newborn [Ganem, 1982]. The 
average incubation period (time from exposure to the appearance of jaundice) of 
acute hepatitis B is 90 days [Krugman et al., 1979]. Over 90% of perinatal infections 
are asymptomatic, while the manifestations of the disease are noted in 30-50% of 
adolescents and adults [McMahon et al., 1985]. The symptoms of acute hepatitis B 
include nausea, fever, vomiting, abdominal pain, jaundice and hepatomegaly. 
Occasionally, acute HBV infection may lead to the extensive necrosis of the liver and 
to fulminant hepatitis that is fatal in 80% of the cases [Berk et al., 1978]. In most of 
the individuals acute HBV infection is cleared spontaneously, however, 5-10% of 
adults develop a chronic infection. By contrast, 40-90% of the children which are born 
to HBV infected mothers will progress to develop a persistent liver disease 
[McMahon et al., 1985]. Chronically HBV-infected patients may remain asymptomatic 
or encounter periodic flares-up of symptoms of acute hepatitis B. Approximately 15-
25% of HBV chronic carriers will die prematurely from liver cirrhosis and 
hepatocellular carcinoma [McMahon et al., 1990; Beasley et al., 1991]. 
 
Acute hepatitis B
Resolution 
of infection
Fulminant
hepatitis
Chronic
hepatits
Death Cirrhosis
HCC
Resolution 
of infection
Resolution 
of infection
 
Fig. 1.4 Spectrum of liver diseases caused by HBV infection 
HBV causes a spectrum of liver diseases ranging from transient acute infection, to fulminant 
hepatitis up to chronic infection, that may result in liver cirrhosis and hepatocellular 
carcinoma (HCC) development. 
 
Introduction 
 
7 
 
The World Health Organization (WHO; 2010) estimates that about 2 billion people 
worldwide have been infected with HBV. Over 360 million are persistently infected, of 
whom 1 million die each year from HBV associated liver cirrhosis or HCC. 
1.2.1 Serologic markers of acute and chronic HBV infection 
As presented in Fig. 1.5A, the first serologic marker of HBV infection is the hepatitis 
B surface antigen (HBsAg) that becomes detectable approximately 6 weeks after 
exposure. Subsequently, hepatitis B “e” antigen (HBeAg) can be detected. The first 
detectable antibodies in the sera of patients are immunoglobulin M (IgM) antibodies 
directed against the HBV core protein (anti-HBc). Elevated levels of IgM-specific 
antibodies correlate with the onset of serum transaminases level abnormalities. The 
increase in transaminases, mostly in alanine transaminase (ALT) during acute 
hepatitis B varies from 3 to over 100-fold above the “normal” levels. Approximately 6 
months after infection, anti-HBc IgM antibodies become undetectable [Cohen, 1987]. 
Nevertheless, the IgG-specific antibodies to hepatitis B core antigen (HBcAg) persist 
lifelong and are found in individuals with chronic infection (Fig. 1.5B), as well as 
those who resolved the HBV infection (Fig. 1.5A). The seroconversion of HBeAg to 
anti-HBe antibodies indicates the reduction in viral replication and beginning of the 
resolution of the disease [Hoofnagle, 1981]. The termination of the infection occurs 
with disappearance of HBsAg and the appearance of neutralizing anti-HBs antibodies 
[Chisari et al., 1995]. Anti-HBs antibodies provide protection against re-infection with 
HBV. 
Chronic HBV infection is defined as either the presence of HBsAg in the serum for at 
least 6 months or the presence of HBsAg in individuals who have undetectable IgM-
specific anti-HBc antibodies. Chronic HBV carriers do not develop anti-HBs and 
HBsAg persists for decades [Bortolotti et al., 1990]. HBeAg is usually present in the 
early phases of chronic HBV infection. For a high proportion of patients HBeAg 
becomes undetectable years after the establishment of chronic HBV infection and 
may reappear during the flare-ups. In some patients the seroconversion of HBeAg to 
anti-HBe is observed [Liaw et al., 1987]. During the chronic HBV infection 
a persistent mild elevation in serum ALT is observed in up to 90% of the patients. 
The transaminases may become markedly elevated during the relapse of the disease 
[Hollinger et al., 2001]. 
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Fig. 1.5 Serologic patterns observed during acute (A) and chronic HBV 
infection (B) 
The periodical appearance of HBV proteins: HBsAg and HBeAg, as well as HBV specific 
antibodies: anti-HBs, anti-HBc (IgM / total) and anti-HBe in the sera of patients during acute 
and chronic HBV infection is shown. The time period of serum ALT elevation is demonstrated 
as orange boxes above the graphs. 
 
1.3 Prophylaxis and treatment of HBV infection 
1.3.1 Hepatitis B vaccine 
The currently available prophylactic hepatitis B vaccine is a yeast-derived 
recombinant vaccine that contains one of the viral surface antigens (small, HBsAg; or 
medium, M-HBsAg). A series of three intramuscular administrations is recommended, 
with the second injection at least one month after the first dose and the third injection 
given six months after the first dose. Following the course of the vaccination, the 
evaluation of protective anti-HBs antibodies titers should be performed. The full 
response to the vaccination occurs in about 85-90% of the vaccinees. The long-
B 
A 
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lasting protection of at least 25 years has been proved in those who showed an 
adequate initial response to the primary course of vaccinations [Vandamme et al., 
2007].  
The hepatitis B vaccination is highly recommended in infants born to HBV-infected 
mothers, health-care workers, or immunocompromised individuals. In 1997, the 
World Health Organisation recommended the integration of hepatitis B vaccine into 
the national immunization programmes in all countries.  
1.3.2 Treatment of chronic HBV infection 
Currently, the two types of antiviral therapies are approved: treatment with pegylated 
interferon alpha 2a (PEG-IFNα) or nucleoside analogues, such as adefovir, entecavir 
(ETV), lamivudine, telbivudine and tenofovir [Conjeevaram et al., 2003; Janssen 
et al., 2005; Lau et al., 2005; Dienstag, 2008]. Nevertheless, the efficacy of those 
therapies in preventing liver cirrhosis and HCC is still limited. Treatment with PEG-
IFNα leads to a sustained antiviral response in only one third of patients, regardless 
of combining the therapy with nucleoside analogues. On the other hand, the 
treatment with nucleoside analogues significantly suppresses HBV replication that 
leads to a decrease of necroinflammation in the liver. However, those antivirals can 
not completely eradicate the virus. After withdrawal of the drug, the rebound of 
viremia is observed in the majority of patients. Furthermore, the long-term treatment 
is subsequently associated with the appearance of drug-resistant HBV strains that is 
often the cause of therapy failure [Raney et al., 2003; Locarnini et al., 2006].  
1.4 Immunological control of HBV infection 
It is well documented that an appropriate adaptive immune response is required to 
efficiently control the HBV infection. The T cell-mediated immune response directed 
against hepatitis B virus antigens, predominantly core antigen (HBcAg), is crucial for 
the resolution of the infection [Ferrari et al., 1990; Penna et al., 1996; 1997; Guidotti 
et al., 1999; Maini et al., 2000; Thimme et al., 2003]. HBV-specific CD8+ T cells are 
able to clear HBV-infected hepatocytes by secretion of TH1 (helper T cell response 
type 1) antiviral cytokines such as interferon gamma (IFNγ) and tumor necrosis factor 
alpha (TNFα) and direct cytotoxic mechanisms (perforin/granzyme, ligand-ligand 
induced cell death, e.g. Fas-Fas-L) [Guidotti et al., 1996; McClary et al., 2000; 
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Trapani et al., 2002]. An early, vigorous, polyclonal and multi-specific cellular immune 
response against the viral proteins is associated with the clearance of hepatitis B in 
acutely-infected patients. In contrast, chronic HBV carriers demonstrate weak, 
transient or often undetectable CD8+ T cell response that correlates with HBV 
persistence [Jung et al., 1991; Penna et al., 1991; Rehermann et al., 2005; Yang 
et al., 2010]. Humoral immune response, especially neutralizing anti-envelope 
antibodies, play a key role in preventing HBV spread to non-infected hepatocytes 
[Chisari et al., 1995; Rehermann et al., 2005].  
Recent studies indicate that several mechanisms may be involved in the loss of the 
function of HBV-specific T cells during chronic hepatitis B. It was shown that high-
level viremia negatively influences the virus-specific immune responses. High viral 
replication in the liver with a viral load higher than 107 copies/ml is correlating with 
hyporesponsiveness of virus-specific CD8+ T-cells in patients with chronic hepatitis B 
[Webster et al., 2004]. Moreover, the prolonged exposure to viral antigens occurring 
during the chronic viral infections can trigger the T cells to become tolerant and prone 
to apoptosis. The interaction between programmed death 1 (PD-1) receptor and its 
ligand PD-L1 (also known as B7-H1) plays an important role to prevent an 
overreaction of the immune system [Okazaki et al., 2006]. Recent studies revealed 
that inhibitory molecules such as PD-1 and CTLA-4 are markedly up-regulated on 
virus-specific T cells, resulting in exhaustion (e.g. lack of IFNγ production and 
proliferation) [Wherry et al., 2007]. Simultaneously, this mechanism can contribute to 
the development of the chronic infection by impairment of the effective anti-viral 
response. This hypothesis was previously proven for hepatitis C virus (HCV) [Urbani 
et al., 2006] and human immunodeficiency virus (HIV) infection in humans 
[Trautmann et al., 2006] and more recently for HBV [Boni et al., 2007; Maier et al., 
2007]. Furthermore, several studies imply that functional defects of antigen 
presenting cells (APCs), mainly dendritic cells (DCs), may contribute to the impaired 
T cell response in chronic hepatitis B patients. In vitro studies showed that DCs 
isolated from HBV chronic carriers produce lower amount of antiviral cytokines, such 
as type I interferons and TNFα, in comparison to healthy controls. In addition, those 
DCs are less efficient in T cell activation and stimulation of T cell proliferation [Van 
Der Molen et al., 2004]. The novel report demonstrated that myeloid DCs from 
chronic HBV patients express an increased level of inhibitory PD-L1 molecule and 
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therefore may downregulate functions of HBV-specific T cells [Chen et al., 2007]. 
Several investigations underline the significance of CD4+ CD25+ regulatory T cells in 
pathogenesis of persistent viral infections [Li et al., 2008]. In HCV and HIV-infected 
patients it was shown that regulatory T cells may downregulate HCV- and HIV-
specific CD8+ and therefore influence the disease progression [Weiss et al., 2004; 
Rushbrook et al., 2005]. The role of regulatory T cells in HBV infection is still not 
clear. Nevertheless, the increased numbers of CD4+ CD25+ regulatory T cells were 
detected in the blood and the liver of patients with chronic severe hepatitis B [Xu 
et al., 2006]. In addition, the liver itself is an organ with tolerogenic properties that 
might contribute to the immunological tolerance during chronic HBV infection 
[Bertolino et al., 2001; Bowen et al., 2004]. Finally, viruses developed the strategies 
to efficiently evade the host immune response resulting in persistent infections. HBV 
immune escape due to the mutation of CD4+, CD8+ and B cell epitopes in a given 
HLA background have been observed in patients [Liu et al., 2002; Ni et al., 2008]. 
1.5 Clinical trials of therapeutic immunization 
Over the last 20 years, continuous efforts have been undertaken to develop 
a therapeutic vaccine for chronic hepatitis B to enhance the virus-specific immune 
responses and overcome persistent HBV infection.  
Numerous clinical trials of therapeutic immunization exploited the conventional 
prophylactic HBsAg-based protein vaccines. These studies demonstrated reductions 
in viremia, HBeAg/anti-HBe seroconversion and HBV-specific T cell responses in 
some patients. However, the anti-viral effect was only transient and did not lead to an 
effective control of the HBV [Pol et al., 1994; 2001; Couillin et al., 1999; Jung et al., 
2002; Dikici et al., 2003; Ren et al., 2003; Safadi et al., 2003; Yalcin et al., 2003]. 
Combination of the HBsAg protein vaccines with antiviral treatment with lamivudine 
did not lead to a satisfactory improvement of the therapies [Dahmen et al., 2002; 
Horiike et al., 2005; Vandepapelière et al., 2007].  
The strategies designed to specifically stimulate HBV-specific T cell response were 
also not successful. The lipopeptide-based vaccine containing a single cytotoxic 
T lymphocyte (CTL) epitope derived from HBV nucleocapsid was able to induce 
a vigorous primary HBV-specific T cell response in naïve subjects [Vitiello et al., 
1995]. However, in HBV chronic carriers the vaccine initiated only poor CTL activity 
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and had no effect on viremia or HBeAg/anti-HBe seroconversion [Heathcote et al., 
1999]. The DNA vaccine expressing small and middle envelope proteins proved to 
elicit the HBV-specific cellular immune response in chronic HBV carriers. However, 
this effect was only transient [Mancini-Bourgine et al., 2004].  
Yang et al. presented the novel DNA vaccine for treatment of chronic hepatitis and 
combined the immunizations with lamivudine treatment [Yang et al., 2006]. The 
multigene vaccine contains five different plasmids encoding most of HBV antigens 
and human IL-12 gene as a genetic adjuvant. The combination therapy led to 
a sustained antiviral response in 6 out of 12 HBV chronically-infected patients. The 
responders were able to clear HBeAg and had undetectable viral loads at the end of 
a 52-week follow-up. Those effects were correlating with a detectable T cell response 
to at least one of the HBV antigens. Nevertheless, further studies are needed to 
evaluate this strategy on a larger cohort of HBV chronic carriers. 
The therapeutic vaccine based HBsAg complexed with human anti-HBs was 
proposed by the group of Wen et al. [Wen et al., 1995]. Immunogenic complexes (IC) 
stimulate robust T cell response by increasing uptake of HBsAg through Fc receptors 
on APCs and, therefore, modulate HBsAg processing and presentation. It was 
demonstrated that this vaccine administered to HBeAg-positive patients led to 
a decrease of HBV DNA in the serum, HBeAg seroconversion and development of 
anti-HBs in part of the subjects [Yao et al., 2007]. Currently, the IC-based vaccine is 
the only one that entered phase III of clinical trials in chronic hepatitis B patients 
[Xu et al., 2008]. Even though the IC-based vaccine led to antiviral effects, clearance 
of HBV was not observed in treated patients. It seems that the vaccine alone is not 
sufficient to achieve the full control over HBV. Therefore, some steps have been 
undertaken to combine the IC-based vaccine with nucleoside analogues treatment 
[Yu-mei Wen, personal communication]. The ongoing clinical trial will show, whether 
IC are effective as a therapeutic vaccine in chronic hepatitis B.  
1.6 The woodchuck as a preclinical model for pathogenesis and therapy 
of chronic hepatitis B 
The Eastern woodchuck (Marmota monax) is naturally infected by woodchuck 
hepatitis virus. WHV and HBV show a marked similarity in the virion structure, 
genomic organization and the mechanism of replication (section 1.1), but differ in 
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several aspects e.g. regulation of transcription [Di et al., 1997]. WHV causes acute 
self-limiting and chronic infection similar to HBV infection in the pathogenesis and 
profiles of the virus-specific immune response [Menne et al., 2007]. This feature of 
the woodchuck model makes it so significant for investigation of the new therapeutic 
approaches in chronic hepatitis B. 
Experimental infection of neonates or adult woodchucks with WHV reflects the 
outcome of HBV infection in humans (Tab. 1.2). In adult woodchucks infection with 
WHV usually leads to the resolution of infection and only 5-10% of animals will 
develop the chronic hepatitis. The exposure of woodchuck neonates to WHV results 
in development of chronic WHV infection in 60-75% of the cases [Cotte et al., 2000]. 
The continuous replication of WHV in the liver during the chronic infection is nearly 
always associated with the development of HCC in the woodchucks [Popper 
et al.,1987; Tennant et al., 2004]. After diagnosis of HCC the survival prognosis of 
the animals is estimated on about 6 months, like in humans. The common features of 
HBV- and WHV-induced carcinogenesis give the opportunity to examine the new 
anti-HCC therapies in the woodchucks [Gerin et al., 1991].  
Tab. 1.2 Clinical features of HBV and WHV infection 
 HBV WHV 
Course of infection   
Epidemic 
360 million people infected 
worldwide 
 
Endemic in some woodchuck 
population in North America 
 
Vertical transmission 
The most common: from 
mother to newborn 
chronicity rate: 45-90%  
 
Neonatal woodchucks infected 
by WHV inoculum 
chronicity rate: 60%-75% 
  
Horizontal 
transmission 
Transmitted by body fluids, 
90% of individuals recover  
Adult woodchucks infected by 
WHV inoculum, 
90-95% of animals recover 
  
Clinical features of 
chronic infection 
Variable HBV DNA levels:  
104-1012 copies/ml 
HBsAg levels: 50-300 µg/ml 
liver transaminases elevation  
 
WHV DNA levels: 
109-1011 copies/ml 
WHsAg levels: 100-300 µg/ml 
liver transaminases elevation  
 
Disease progression   
Liver cirrhosis 
2-5% in HBeAg-positive 
patients (genotype dependent) 
  
Not common 
Hepatocellular 
carcinoma 
5-year cumulative HCC 
incidence in patients with 
cirrhosis: 16% (data in Asia)  
 
Nearly 100% of chronic infected 
animals have HCC after 3 years 
according to: Chisari et al., 1995; Cote et al., 2000; Rehermann et al., 2005 
Introduction 
 
14 
 
1.6.1 Evaluation of WHV-specific T cell response 
For many years, the studies on immunopathogenesis of WHV infection in 
woodchucks were restricted to the determination of humoral immune response 
[Roggendorf et al., 1995]. The lack of appropriate methods to evaluate antigen-
specific T cell response was a serious limitation of this model.  
The proliferation assay for peripheral blood mononuclear cells (PBMCs) based on 
incorporation of [3H]-thymidine by cellular DNA, routinely used for human and mouse 
system, has been ineffective in the woodchuck PBMCs [Korba et al., 1988; Cotte 
et al., 1995]. The failure of this approach is consistent with the fact that woodchuck 
lymphocytes do not express the thymidine kinase gene [Menne et al., unpublished 
results]. This obstacle had been overcome by usage of the alternative radioactively-
labeled nucleotide 2[3H]-adenine. The development of 2[3H]-adenine-based 
proliferation assay enabled to detect the T helper lymphocyte responses after 
stimulation of woodchuck PBMCs with WHV core, surface and “x” antigens (WHcAg, 
WHsAg and WHxAg, respectively) In addition, using the 2[3H]-adenine-based 
proliferation assay in PBMCs from acutely infected animals, several T helper 
epitopes within WHcAg [Menne et al., 1998] and WHsAg were identified (Fig. 1.6) 
[Menne et al., unpublished results]. 
Recently established, a novel CD107a degranulation assay for woodchuck PBMCs 
and splenocytes made a significant breakthrough in studying pathogenesis of 
hapadnaviral infections in the woodchuck model [Frank et al., 2007]. Several studies 
demonstrated that detection of CD107a, as a degranulation marker, is a suitable 
method for the determination of antigen-specific cytotoxic T lymphocytes [Betts et al., 
2003; Rubio et al., 2003]. The assay enables detection of WHV-specific CTLs basing 
on their granule-dependent effector function. The recognition of the infected cells by 
CTLs results in the exposure of CD107a molecule on the CTL surface. In the 
woodchuck system, CD107a molecule can be stained by cross-reactive anti-mouse 
CD107a antibody, what enables the flow cytometric analysis of the woodchuck CTLs. 
The introduction of those immunological tools for studying the T cell response in 
woodchucks revealed a significant similarity between the pathogenesis of WHV 
infection in woodchucks and HBV in humans. It was demonstrated that acute self-
limiting and resolved WHV infections correlate with robust multifunctional T helper 
and cytotoxic T cell responses [Menne et al., 1998; Frank et al., 2007]. Moreover, this 
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efficient cellular immune response to viral antigens results in the liver injury and is 
necessary for viral clearance. With the novel CD107a degranulation assay one 
immunodominant CTL epitope within WHcAg (aa 96-110) [Frank et al., 2007], and 
one CTL epitope within the WHsAg (aa 220-234) [Frank et al., unpublished results] 
were characterized. In contrast to self-limiting infection, WHV chronic carriers 
demonstrate weak or no virus-specific T cell response against the identified epitopes 
[Menne et al., 1998; Frank et al., 2007]. 
1                         210                           250     300                            350                                      400          431
preS1/S2 WHsAg
220-234
1                                               50              100                                150                               188
WHcAg
TH epitopes
CTL epitope 96-110
1-20 28-47
100-113
112-13197-110
TH epitope
CTL epitope
100-119 120-139
226-245 341-360
 
Fig. 1.6 Position of woodchuck CD4+ and CD8+ epitopes in WHcAg and WHsAg 
Woodchuck helper T cell epitopes (TH) are demonstrated as stripped boxes and CTL 
epitopes are shown as solid boxes. The aa position of the epitopes within WHcAg and 
WHsAg is given above the boxes. Immunodominant epitopes’ sequences are labelled in 
italics. 
 
1.7 Therapeutic immunization approaches in the woodchuck model 
Up to date, several studies of diverse therapeutic vaccinations have been carried out 
in woodchucks. The pioneer investigations of the therapeutic vaccines based on 
WHV core [Roggendorf et al., 1995] or surface antigens in combination with a helper 
peptide FIS [Hervas-Stubbs et al., 1997], or with potent TH1 adjuvants like 
monophosphoryl lipid A [Lu et al., 2003] did not lead to satisfactory results. Those 
experiments proved that vaccinations could induce specific B- and/or T-cell 
responses in chronic WHV carriers. However, this alone was not sufficient to achieve 
the control of virus replication.  
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It is assumed that high level viremia, during chronic hepatitis B, can inhibit the 
induction of HBV-specific T cell immune response by therapeutic vaccination. 
Therefore, reduction of viral load by the nucleoside analogues pre-treatment might 
support the efficacy of immunization to enhance the virus-specific immune 
responses. This hypothesis was tested in three experimental trials of the combination 
therapies in chronic WHV carriers. 
The first study performed by Hervas-Stubbs et al. was based on lamivudine therapy 
[Hervas-Stubbs et al., 2001]. Five chronically WHV-infected woodchucks were 
treated orally with the drug for 23 weeks. At week 10, after decline of WHV DNA by 
3-5 logs, three animals were vaccinated with 3 doses of serum-purified WHsAg 
combined with T helper FIS peptide derived from sperm whale myoglobin. The 
vaccination induced T helper responses against WHV antigens, shifting the cytokine 
profile from TH2 to TH0/TH1. However, no beneficial effect on WHV viral load and 
WHsAg levels was observed in comparison to non-immunized animals. After 
withdrawal of the lamivudine treatment the values of viremia returned to the pre-
treatment levels. 
The second trial evaluated the therapy with a very potent antiviral drug: clevudine   
[1-(2-fluoro-5-methyl-β-L-arabinofuranosyl)-uracil] combined with a WHsAg-based 
immunization [Menne et al., 2000; 2002]. A large cohort of thirty 1-2 years-old 
chronically WHV-infected woodchucks was enrolled in the study. Half of the animals 
were orally treated with clevudine (10 mg/kg/day) for 32 weeks; the other 15 
woodchucks received placebo. After withdrawal of clevudine treatment, 8 animals 
from each group were vaccinated with the four doses of formalin inactivated alum-
adsorbed WHsAg and 7 were injected with the saline as a control. Combination of 
the drug and vaccine therapy resulted in marked reductions WHV DNA (6-8 logs) and 
WHsAg in serum during the 60-week monitoring period, in contrast to the vaccine 
only and placebo groups, where both markers remained at high levels. Combination 
therapy did not enhance anti-WHs response beyond those measured for vaccine 
alone. However, treatment with clevudine and vaccine together led to more sustained 
and robust lymphoproliferative responses to WHsAg and additionally to WHcAg, 
WHeAg (woodchuck hepatitis “e” antigen) and WHxAg. Moreover, combination 
therapy delayed the onset of the liver disease and prevented HCC development in up 
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to 38% of treated chronic WHV carriers in the long-term follow up study [Korba et al., 
2004].  
Recently, a novel therapeutic approach for treatment of chronic hepatitis B in a 
woodchuck model was described. The therapy combined the antiviral treatment with 
immunization by plasmid DNA and antigen-antibody immunogenic complex vaccines 
together [Lu et al., 2008]. DNA vaccines are considered to stimulate both humoral 
and cellular immune response, polarizing T cells in the direction of TH1 response 
[Michel et al., 2001]. Immunization of the naïve woodchucks with the plasmids 
encoding WHV core and preS2/S genes (pWHcIm and pWHsIm, respectively) 
induced the lymphoproliferative responses against the antigens and provided a 
protection against WHV challenge [Lu et al., 1999]. In addition, the DNA vaccine 
expressing HBsAg proved to elicit the vigorous T cell response in chronic HBV 
carriers, however, this effect was only transient [Mancini-Bourgine et al., 2004]. The 
HBsAg/anti-HBs IC vaccine is currently under investigation in chronic HBV patients 
[Wen et al., 1995; Yao et al., 2007; Xu et al. 2008].  
To evaluate the efficacy of the above mentioned immunotherapy in woodchucks, 
firstly 10 chronic WHV carriers were treated with 15mg of lamivudine, daily for 21 
weeks. At week 10, four animals were pretreated with cardiotoxin and then received 
three immunizations with DNA vaccine containing three plasmids expressing WHsAg, 
WHcAg and woodchuck IFNγ (pWHsIm, pWHcIm and pwIFN, respectively). 
Simultaneously, the other four woodchucks received three doses of the combination 
of DNA vaccine and WHsAg/anti-WHs immunogenic complex. Two chronic WHV 
carriers served as lamivudine monotherapy control. Lamivudine treatment resulted in 
only a slight decrease of WHV DNA levels in the woodchucks serum (0,7 and 0,32 
log, respectively). Surprisingly, the DNA vaccination did not lead to any additional 
therapeutic effect beyond that observed for lamivudine treatment alone. In contrast, 
the triple combination of antiviral treatment, plasmid DNA encoding WHcAg, WHsAg 
and wIFNγ and IC vaccines was able to decrease WHV viral load up to 2,9 log and 
the serum WHsAg up to 92%. Moreover, three of the four treated animals developed 
anti-WHs antibodies. Nevertheless, these effects were not sustained and all 
parameters reached the baseline levels shortly after withdrawal of lamivudine 
treatment. In addition, the vaccination did not induce WHV-specific T cell responses 
in the majority of woodchucks, even in animals which exhibited virological response. 
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Significant lymphoproliferative response against WHV antigens were detected only in 
one animal after three immunizations with DNA vaccine [Lu et al. 2008]. The study 
demonstrated the benefit of using the combinatory therapy in chronically WHV-
infected woodchucks. However, the transient therapeutic effects, suggest that this 
strategy needs further optimization.  
A new strategy evaluated the potency of an entecavir treatment and increased 
number of immunizations [Lu et al., unpublished results]. Chronically WHV-infected 
woodchucks were pretreated with the entecavir for 21 weeks; 10 weeks in a daily and 
11 weeks in a weekly manner. During the weekly administration of the drug, one 
group of animals received 6 immunizations with two-plasmid DNA vaccine (pWHsIm 
and pWHcIm), the second group received a combination of DNA vaccine together 
with purified WHV core and surface antigens, and the third group remained 
untreated. The entecavir therapy resulted in rapid and significant decease of the viral 
load and WHsAg levels in serum of the animals. The effect was especially 
pronounced in animals that additionally received vaccines. In woodchucks treated 
only with entecavir the increase of viremia was observed already during the weekly 
administration or immediately after withdrawal of the drug. By contrast, in both 
groups of animals, that were immunized with DNA or DNA/proteins vaccines, the 
delay before the rebound of WHV replication was significantly prolonged. In addition, 
entecavir treatment was effective to suppress WHV replication and enhanced the 
induction of WHV-specific T cell responses. An increased CTL activity was detected 
in individual woodchucks after DNA or DNA/proteins vaccinations. Moreover, two 
animals completely eliminated the virus from the blood and were WHV DNA negative 
in the liver [Lu et al., unpublished results]. 
The results of therapeutic immunization trials in the woodchuck model are 
summarized in table 1.3. 
 
Introduction 
 
19 
 
Tab. 1.3 Studies on therapeutic vaccinations in the woodchuck model 
Ø – no adjuvant 
Vaccines Application Adjuvant Outcome Reference 
WHcAg intramuscular Ø Viral elimination in 1 of 6 animals Roggendorf et al., 1995 
 
WHsAg and TH-peptide intramuscular TH-peptide 
Transient anti-WHs antibody response 
Two woodchucks died 
 
Hervas-Stubbs 
et al., 1997 
WHsAg and TH-peptide in 
combination with lamivudine intramuscular TH-peptide 
No induction of anti-WHs antibodies 
Detectable T-cell responses to WHV 
proteins 
 
Hervas-Stubbs 
et al., 2001 
WHsAg in combination with clevudine  intramuscular alum 
Reduction of serum viral loads and viral 
replication in liver 
Induction of anti-WHs and detection of T-
cell responses to WHV proteins 
Delayed occurrence of HCC 
 
Menne et al., 
2000, 2002 
WHsAg intramuscular monophosphoryl lipid A 
No reduction of serum viral load, 
Development of antibodies to the preS 
region of WHsAg 
 
Lu et al., 
2003 
Plasmid DNA expressing WHsAg, 
WHcAg, and woodchuck IFN-γ in 
combination with lamivudine 
intramuscular Ø Transient reduction of serum viral loads Lu et al., 2008 
WHsAg/anti-WHs immunogenic 
complex and DNA vaccines in 
combination with lamivudine 
intramuscular Ø 
Transient reduction of serum viral loads 
Transient appearance of anti-WHs 
antibodies and WHcAg-specific T cell 
response 
 
Lu et al., 
2008 
Plasmid DNA encoding WHsAg and 
WHcAg in combination with entecavir intramuscular Ø 
Plasmid DNA encoding WHsAg and 
WHcAg in combination with protein 
WHsAg/WHcAg vaccine in 
combination with entecavir 
 
intramuscular Ø 
Transient reduction of serum viral loads 
Viral elimination in 2 of 6 animals 
 
Lu et al., 
[unpublished results] 
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1.8 Adenoviridae 
1.8.1 Classification 
Adenoviridae is a family of non-enveloped viruses containing 34-44 kb linear double-
stranded DNA as genome. Up to date over 100 members of the Adenoviridae family 
have been identified which infect a wide range of mammalian hosts, including human 
(genus Mastadovirius), reptiles (genus Atadenovirus), amphibians (genus 
Siadenovirus) and birds (genus Aviadenovirus) [Buchen-Osmond, 1997]. 
So far, 51 human adnenovirus serotypes have been distinguished. The serotypes 
have been classified into six subgroups (A – F) on the basis of their ability to 
agglutinate the red blood cells, oncogenicity in rodents, and the sequence 
homolology of their genomes (Tab. 1.4).  
 
Tab. 1.4 Classification of human adenoviruses [modified from: Shenk, 2001] 
Subgroup Hemagglutination groups 
Representative 
serotypes 
Tumours in 
animals 
A IV little or no agglutination 12, 18, 31 high 
B I 
complete agglutination of 
monkey erythrocytes 
3, 7, 11, 14, 16, 21, 34, 
35  
moderate 
C III 
partial agglutination of rat 
erythrocytes 
1, 2, 5, 6 low or none 
D II 
complete agglutination of rat 
erythrocytes 
8-10, 13, 17, 19, 22-30, 
32, 33, 36-39, 42-47 
low or none 
E III 
partial agglutination of rat 
erythrocytes 
4 low or none 
F III 
partial agglutination of rat 
erythrocytes 
40, 41 unknown 
 
Adenoviruses can infect and replicate at various sites of the respiratory tract, as well 
as in the eye, gastrointestinal tract, urinary bladder, and liver. Approximately one-
third of human adenovirus serotypes is associated with various human diseases. 
Adenoviruses are known to induce respiratory infections (serotypes form groups B, C 
and E), infections of the eye (groups B and D), infections of urinary tract (group B) 
and gastroenteritis (group F) [Horwitz, 2001]. 
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1.8.2 Morphology of the viron 
Adenoviruses are icosahedral particles that are 70-100 nm in diameter. The virion 
contains a protein shell (capsid) surrounding a DNA-containing core. The capsid is 
composed of 252 subunits (capsomeres) of which 240 are hexons and 12 are 
pentons (Fig. 1.7A). Each penton contains a base that is projecting the fiber whose 
length and number varies among the serotypes [Vayda et al., 1983; Signas et al., 
1985]. The capsid is a complex structure built of seven known viral proteins: 
polypeptide II (hexon), III (penton), IIIa, IV (fiber), VI, VIII and IX. 
The core of the virion contains four proteins that interact with the viral DNA. 
Polypeptides V, VII and X maintain the structure of the viral genome and its proper 
position within the capsid. The fourth protein present in the core is the terminal 
protein (TP), which is covalently bound to the 5’-ends of the viral DNA (Fig. 1.7B). 
The terminal protein serves as a primer for DNA replication and mediates interaction 
of the viral DNA with the nuclear matrix [Rux et al., 2004]. 
 
A B
 
Fig. 1.7 The structure of adenoviral virion 
A. Electron micrograph of adenovirus serotype 5. Icosahedral capsid and six of twelve fibers 
that are present on each viral particle are shown [Shenk, 2001]. 
B. Schematic illustration of the virion. The respective viral polyproteins that build the capsid 
layer and the inner core of the virion are indicated. Terminal protein (TP) is covalently 
attached to the 5’-ends of viral DNA [Shenk, 2001]. 
 
1.8.3 Genome organization, replication mechanism and viral transcripts 
The adenoviral genome consists of a 34-44 kb single linear, double-stranded DNA 
molecule with short inverted terminal repeats (ITRs) on its ends which play an 
important role in genome replication. The viral genome carries five early transcription 
units (E1A, E1B, E2, E3 and E4), two delayed early units (IX and IVa2), one late unit 
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transcribed by RNA polymerase II. The transcription of those genes leads to 
generation of multiple mRNAs that are differentiated by alternative splicing 
[Pettersson et al., 1986]. The viral chromosome also carries one or two (depending 
on the serotype) VA genes transcribed by RNA polymerase III. The products of early 
genes are necessary for late viral gene expression and replication of viral DNA. In 
addition, they induce cell cycle progression, block apoptosis and antagonize with 
a variety of host antiviral mechanisms. The late viral genes encode the structural 
proteins that build the progeny virions [Shenk, 2001]. 
The ITRs of the viral chromosome serve as replication origins. The replication is 
initiated at one of the termini of the genome, and one strand serves as a template for 
the synthesis of the daughter strand. The other displaced strand circularizes and 
serves as a template for the generation of the second duplex DNA molecule [Lechner 
et al., 1977]. This mechanism allows for the most effective usage of once initiated 
replication machinery. 
1.8.4 The replication cycle  
The attachment of the adenoviruses to the cell is mediated by the fiber protein. The 
carboxy-terminal domain of the fiber protein forms a knob that binds to the cellular 
receptor. Most of the known human adenovirus serotypes (except of group B) interact 
with coxsackie and adedenovirus receptor (CAR). The serotypes from group B, such 
as human adenovirus serotype 35 (Ad35), bind to CD46 [Bergelson, 1999]. The 
internalization of the virion via clathrin-mediated endocytosis is mediated by 
interaction of the viral penton base with αVβ3 and αVβ5 integrins [Wickham et al., 
1993]. In the acidified environment of the endosome the partial disassembly of the 
particle occurs. The interaction of the viral capsid protein pVI with endosome 
membrane results in the release of the uncoated particle into the cytoplasm. The 
particles are transported along the microtubules to the nucleus by means of motor 
proteins e.g. dynein [Suomalainen et al., 1999]. The viral DNA is translocated into the 
nucleus through the nuclear pore complex. The cell entry process of adenoviruses is 
presented in Fig. 1.8. 
In the nucleus, the replication of the genome and expression of the viral proteins 
occurs. After their production, the viral proteins accumulate in the nucleus where the 
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assembly of the virions occurs. The release of the progeny virions is associated with 
the host cell lysis [Shenk, 2001]. 
 
Fig. 1.8 The cell entry pathway of adenovirus 
The fiber of adenovirus attaches to the primary receptor (CAR or CD46, step1). 
Subsequently, the virion is internalized via clathrin-mediated endocytosis, which is mediated 
by interaction of the viral penton base with αv integrins (step 2). In the low pH of the 
endosome the virion begins to disassemble (step 3) and uncoated particle is released to the 
cytoplasm by disruption of the endosomal membrane (step 4). The virion is transported by 
the microtubule motor dynein along microtubules to the nuclear pore complex (step 5). At the 
nuclear pore the viral DNA is imported into the nucleus (step 6) [Nemerow et al., 2009]. 
 
1.8.5 Recombinant adenoviruses as vaccines 
Recombinant adenoviruses have been one of the intensively investigated viral 
vectors for therapeutic purposes. The development of novel methods for the 
manipulation of the viral genome resulted in the three generations of recombinant 
adenoviral vectors (Fig. 1.9). Various deletions in the genome led to an increased 
capacity, allowing the insertion of multiple transgenes [Danthinne et al., 2000]. 
Several trials imply the usefulness of these vectors in gene therapy of genetic 
diseases and cancer [Khalighinejad et al., 2008; Kuhlmann et al., 2008; Matthews et 
al., 2009; Wirth et al., 2009]. For many years, the first generation replication-deficient 
E1 or E1/E3-deleted adenoviral vectors have been explored as the prophylactic 
vaccines against many human pathogens such as Ebola virus, HIV, severe acute 
Introduction
 
24 
 
respiratory syndrome (SARS) virus and Bacillus antracis (antrax) [Xiang et al., 1996; 
Shiver et al., 2002; Fitzgerald et al., 2003; Tatsis et al., 2004; Zakhartchouk et al., 
2005; Richardson et al., 2009]. 
Ad5 WT
1st generation
2nd generation
3rd generation
(gutless or
helper-dependent)
E1 E2 E3 E4
Transgene
capacity:
≥ 8,2 kb
≥ 14 kb
> 37 kb
ITR Ψ ITR
∆E1 ±∆E3
ITR Ψ ITR
±∆E2A±∆E2B ±∆E4∆E1 ±∆E3
ITR Ψ ITR
ITR Ψ ITR
 
Fig. 1.9 Genome structures of the first, second, and third generation of 
adenoviral vectors 
Wild-type adenoviral sequences are labelled in black. The localization of the early genes (E1-
E4) is represented by arrows. Deletion sites are shown as a thin line or as striped boxes for 
alternative deletions. ITR: inverted terminal repeats; Ψ: packaging signal [modified from: 
Danthinne et al., 2000]. 
 
Adenoviral vectors have several advantages that can be beneficial for potent 
therapeutic vaccines. First of all, adenoviruses are relatively susceptible for genetic 
modifications and can be easily produced in high titers. After transduction of the cells, 
the adenoviral genome is not integrated into the host DNA and stays in the episomal 
form. As a result, the risk of the possible activation of the cellular oncogenes is 
minimal. Adenovirus-based vaccines proved to elicit vigorous and sustained humoral 
and T cell responses to the incorporated antigen that is considered to be crucial in 
clearance of persistent viral diseases [Shiver et al., 2002; Fitzgerald et al., 2003; 
Tatsis et al., 2004; Zakhartchouk et al., 2005]. The benefit of adenoviral vectors as a 
vaccine carrier is not only limited to a stable delivery of proteins of interest. Several 
findings on additional immunostimulatory effects, e.g. induction of the innate immune 
response, that originate from the nature of adenoviruses itself, may enhance the 
vaccine efficacy. The capsid of adenoviruses demonstrates immunostimulatory 
properties, that is why the co-administration of the adjuvant is usually unnecessary. 
Those vectors can directly transduce DCs causing their maturation and upregulation 
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of MHC and costimulatory molecules on their surface, thus lead to enhanced antigen 
presentation. Moreover, it was shown that AdV-transduced DCs are secreting 
antiviral cytokines, such as IFNα, TNFα and IL-6 [Morelli et al., 2002]. Interleukin-6 is 
one of the most important factors that suppress the function of the regulatory T cells 
[Wan et al., 2007].  
Nevertheless, apart from the above-mentioned advantages modified adenoviruses 
have one serious limitation. Thus far, vectors that were so comprehensively 
examined as the vaccines have been based on the human adenovirus serotype 5 
(Ad5) [Tatsis et al., 2004]. This serotype is the most common in the human 
population. Anti-Ad5 neutralizing antibodies are detectable in 45-90% of adults 
[Farina et al., 2001]. The pre-existing immunity directed against Ad5 is considered as 
a main reason of failure in the phase I clinical trial of a protective HIV-1 vaccine. The 
STEP study guided by Merck pharmaceutical concern, based on 3-dose regimen of a 
trivalent Ad5 vaccine, suggested that the immunization might increase the risk of 
HIV-1 infection in the subjects with high neutralizing anti-Ad5 titers [Buchbinder et al., 
2008; McElrath et al., 2008]. Moreover, even single immunization may induce 
immunity to the vector in seronegative individuals.  
The negative effect of the pre-existing or Ad5-induced immunity against the vaccine, 
mostly when the therapy requires multiple dosages, may be overcome by 
heterologous prime-boost regimen. The utility of the rare human serotypes (e.g. 
serotype 35) [Gao et al., 2003; Barouch et al., 2004] or recombinant adenoviruses of 
non-human origin has been recently tested [Bangari et al., 2006]. In particular, 
subsequent priming immunizations with plasmid DNA vaccine followed by a booster 
vaccination with AdV seem to be a very promising strategy. DNA prime – adenovirus 
boost regimen proved to induce more robust and potent immune response in 
comparison to plasmid DNA alone and provided protection against the pathogen 
infection in several animal models of infectious diseases [Sullivan et al., 2000; Gao 
et al., 2003; Casimiro et al., 2005; Xin et al., 2005]. Furthermore, a clinical trial of 
multiclade HIV-1 DNA plasmid-Ad5 boost vaccine, HIV-uninfected individuals 
demonstrated high immunogenicity even in the presence of high anti-Ad5 antibody 
titer. In addition, the vaccine proved to be well tolerated in the participants of the 
study [Kibuuka et al., 2010]. 
Aim of the study
 
26 
 
2 Aim of the study 
The currently available treatment of chronic hepatitis B with IFNα and/or nucleoside 
analogues does not lead to a satisfactory result. On the one hand, therapy with IFNα 
results in sustained antiviral response in only one third of the patients. On the other 
hand, the treatment with nucleoside analogues can significantly suppresses HBV 
replication in the majority of patients, however it cannot completely eradicate the 
virus and needs a lifelong therapy. Therefore, there is a need to develop new 
therapeutic strategies for the treatment of chronic HBV infection. 
The natural occurrence of chronic infection with WHV in woodchucks, that is closely 
related to HBV, allows to evaluate new therapeutic strategies in this preclinical 
model. It is well known that in the chronic hepadnaviral infections an appropriate 
virus-specific T cell-mediated immune response, predominantly against core antigen, 
is absent. Therefore, the therapeutic vaccination strategy which is able to boost an 
antiviral T cell response may be a promising option to terminate the viral persistence. 
It was shown that vaccines based on viral proteins (surface or core antigen) are not 
successful in chronic hepadnaviral infection in woodchucks and in patients. Plasmid 
DNA vaccines inducing a strong T cell response against CTL epitopes in the core or 
surface antigens prevented hepadnaviral infection. However, they were also not 
effective as therapeutic vaccines in chronic carriers. Nevertheless, the application of 
DNA vaccine expressing WHcAg in combination with antivirals in chronic WHV 
carriers led at least to a prolonged control of the viral replication. A significantly better 
induction of WHcAg-specific T cells using more potent vaccines, such as 
recombinant viral vectors, may be required to achieve sustained antiviral response. 
The aim of the study was to evaluate the innovative therapeutic vaccination based on 
improved DNA vaccine and recombinant adenoviral vectors expressing WHcAg in 
chronic WHV carriers. The application of the new vectors, an optimized vaccination 
regimen, and the addition of a potent antiviral treatment (entecavir) may be an 
effective strategy to achieve: (1) improved WHV-specific immune responses, (2) long 
term viral control, and (3) resolution of chronic WHV infection. 
To achieve this goal, several steps had to be accomplished: 
1. Generation of a new DNA plasmid vaccine and recombinant adenoviral vectors 
with increased WHcAg expression. 
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2. Investigation on the magnitude of CD8+ T cell response using the improved 
vaccines in comparison to previously used constructs in vivo. As more potent 
immunological tools to efficiently evaluate the immunization strategies are 
available for the mouse model, the preliminary experiments were performed in 
mice. To effectively characterize CD8+ T cell response in C57BL/6 and WHV 
transgenic mice, the identification of CD8+ T cell H-2b-restricted epitopes within 
WHcAg was required.  
3. Evaluation whether heterologous DNA prime – AdV boost immunization elicits 
a more robust, multifunctional and effective CD8+ T cell response in C57BL/6 
mice, as compared to DNA vaccination. 
4. Evaluation whether heterologous DNA prime – AdV boost immunization elicits 
effective humoral and cellular immune responses that lead to suppression of 
WHV replication in WHV transgenic mice. 
5. Investigation whether immunization of naïve woodchucks using optimized 
recombinant adenoviral vectors induces CTL response and provides protective 
immunity against WHV infection. 
6. Finally, evaluation whether heterologous DNA prime – AdV boost in combination 
with entecavir treatment leads to a more sustained antiviral response in chronic 
WHV carriers than previously performed studies. 
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3 Materials 
3.1 Laboratory animals 
3.1.1 Wild-type mice 
Ten weeks old C57BL/6 female mice (genotype H-2b/b) were purchased from Harlan 
Winkelmann Laboratories (Borchen, Germany). The mice were kept under specific 
pathogen-free (SPF) conditions and had free access to drinking water and standard 
food. 
3.1.2 WHV transgenic mice, strain 1217 
WHV transgenic mice (Tg) were created on C57BL/6 background (genotype H-2b/b) 
by Prof. Bill Mason’s group (Fox Chase Cancer Center, Philadelphia, Pennsylvania, 
USA) and further bred at the animal facility of the University Hospital Essen. 
 
The 1217 strain mice carry a wild-type WHV transgene integrated into Chromosome 
10. Those mice are characterized by WHV replication and presence of viral 
transcripts in the liver, as well as secretion of WHV particles into the bloodstream. 
 
All 1217 WHV Tg mice used were sex-matched and 10-12 weeks of age at the 
beginning of experiments. The mice were kept under SPF conditions and had free 
access to drinking water and standard food. 
3.1.3 Woodchucks (Marmota Monax) 
Naïve and chronically WHV infected woodchucks were trapped in the state of New 
York and Delaware. Woodchucks were purchased from North Eastern Wildlife (Itaca, 
New York, United States of America) and maintained according to the guidelines of 
the animal facility of the University Hospital Essen.  
 
3.2 Anesthetics 
Isofluran       Delta Select, Germany 
Ketamine 10%      Ceva Tiergesundheit, Germany 
Xylazine 2%       Ceva Tiergesundheit, Germany 
T61        Intervet, Germany 
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3.3 Virus stock 
WHV stock used for the experiments was obtained from the serum of chronically 
WHV infected woodchucks and stored at -80oC. 
3.4 Bacteria strains 
Eschrichia coli Top10 ………………………...... F’mcrA ∆(mrr-hsdRMSmcrBC) 
(Invitrogen, Germany)     φ80lacZ∆M15∆lacX74 nupG recA1 
araD139 ∆(ara-leu)7697 
galE15 galK16 rpsL(StrR) endA1-λ  
Escherichia coli BJ5183 ..……………..........… endA1 sbcBC recBC galK met thi-1 
(Stratagene, Germany)     bioT hsdR (StrR)  
Escherichia coli DH5α ..................................... supE44 ∆lacU169 (φ80lacZ∆M15) 
(New England Biolabs, Germany)   hsdR17 recA1 endA1 gyrA96thi-1 
relA1 
3.5 Eukaryotic cell lines 
BHK-21 
Baby Hamster Kidney fibroblast cell line; was used in transfection experiments. 
 
HEK-293A 
Human kidney epithelial cell line; expresses adenoviral E1 gene products; was used 
in generation and propagation of recombinant adenoviruses. 
 
3.6 Chemicals and reagents 
Acetic acid, Cesium chloride, EDTA solution pH 8.0, Saccharose, Salmon sperm DNA, 
SDS (sodium dodecyl sulphate), Tween 20…………………..   AppliChem 
FACS Clean, FACS Flow, FACS Rinse, Yeast extract…….. Becton Dickinson 
Ficoll……………………………………………………………… Biochrom AG 
Entecavir…………………………………………………………. Bristol-Myers Squibb, USA 
Ionomycin, PMA (phorbol-12-myristat-13-acetate)…………. CalBiochem 
Polyethylenimin (PEI)…………………………………………... CellnTec, Switzerland 
D-PBS, TBE ultrapure 10x, Trypan Blue, Trypsin EDTA…… Gibco Invitrogen 
Percoll……………………………………………………………. GE Healthcare, UK 
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2[3H]adenine, [32P]-dCTP…………………………………….... Hartmann Analytic 
SSC ultrapure 20x, SSPE ultrapure 20x................................ Invitrogen 
Boric acid............................................................................... JT Baker, Netherlands 
Cardiotoxin………………………………………………………. Latoxan, France 
Potassium chloride, Potassium dihydrogenphosphate, Sodium acetate, Sodium azide, 
Sodium carbonate, Sodium chloride, Sodium dihydrogenphosphate, Sodium 
hydrogencarbonate, Sodium oxide.........................................   Merck 
Glicine, Tris-Base……………………………………………….. MP Biomedicals 
Microscint 20…………………………………………………….. Perkin Elmer, USA 
Murine IL-2 Roche 
Acrylamide solution, Ethidium bromide, Hydrogen peroxide, LB-Agar (Luria/Miller), LB-
Medium (Luria/Miller), Milk powder, Phenol...........................   Roth 
BSA (bovine serum albumin) fraction V................................. Serva 
β-mercaptoethanol, Agarose, APS (ammonium persulfate), Brefedin A, Bromophenol 
blue, Chlorophorm, Concavalin A, DMSO (Dimethyl sulfoxide), DTT (Dithiothreitol), 
Ethanol, Glycerol, Hydrochloric acid, Isopropanol, Methanol, OPD tablettes (o-
Phenylenediamine), Orange G, TEMED.................................   Sigma 
 
3.7 Antibiotics 
Ampicillin       AppliChem, Germany 
Kanamycin       AppliChem, Germany 
Penicillin/Streptomycin     PAA Laboratories, Austria 
 
3.8 Cell culture media 
The media for cell culturing were provided by Gibco Invitrogen, Germany and PAA 
Laboratories, Austria. Fetal Calf Serum (FCS) was provided by Biochrom AG, 
Germany. 
 
Murine splenocytes ……………………………… RPMI 1640 medium 
10% FCS 
1% Penicillin/Streptomycin 
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Woodchuck PBMCs ……………………………… AIM-V medium 
10% FCS 
1% Penicillin/Streptomycin 
BHK cell line ………………………………………. MEM medium 
10% FCS 
1% Penicillin/Streptomycin 
HEK-293A cell line ……………………………… DMEM medium 
10% FCS 
1% Penicillin/Streptomycin 
3.9 Bacterial culture media 
SOC medium………………………………………... Invitrogen (Germany)  
LB-Medium……………………………………..……. 1% (w/v) Trypton 
      0.5% (w/v) Yeast extract 
…..170 mM NaCl 
      pH 7,2 -7,5 
LB-Agar................................................................. 1,5% (w/v) Agar in LB-Medium 
 
Media were sterilized by autoclaving for 10 minutes at 121oC and 202,7kPa. 
Ampicillin was added at a final concentration of 100 µg/ml and kanamycin was added 
at a final concentration of 50 µg/ml.  
3.10 Buffers and solutions 
PBS (pH 7,4) ...……………………………………. 8 g NaCl 
0,2 g KCl 
1,44 g Na2HPO4; KH2HPO4 
1 L H2O 
Carbonate buffer (pH 9,6) ……………………….. 3,18 g Na2CO3 
5,88 g NaHCO3 
0,2 g NaN3 
1 L H2O 
Blocking solution (ELISA) ……………………….. PBS 
5% (v/v) FCS 
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T-PBS washing buffer (ELISA / Western blot).... PBS 
0,5% (v/v) Tween 20 
OPD-substrate solution (ELISA) ……………….. o-Phenylenediamine (1 pill) 
10 ml PBS 
10 µl H2O2 
STOP solution (ELISA) ………………………….. 0,5 N H2SO4 
FACS buffer I ……………………………………... PBS 
0,1% (m/v) BSA 
0,02% (m/v) NaN3 
FACS buffer II (mice) …………………………….. PBS 
1x PermWashBuffer 
0,1% (m/v) BSA 
0,02% (m/v) NaN3 
FACS buffer III (woodchucks) …………………... PBS 
1x PermWashBuffer 
5% (m/v) BSA 
0,02% (m/v) NaN3 
DNA loading buffer ……………………………….. 5.5 mM Orange G 
1.2 M saccharose 
1x TBE buffer (pH 8,4) …………..………………. 100 mM Tris Base 
90 mM boric acid 
1 M EDTA 
Buffer P1, pH 8,0 (plasmid preparation) ............. 50mM Tris Base 
12mM Na2EDTA H2O 
100 mg RNAse 
1L H2O 
Lysis buffer P2 (plasmid preparation) ................ 200 mM NaOH 
35 mM SDS 
Neutralisation buffer p3 (plasmid preparation) ... 3 M potassium acetate 
150 ml acetic acid 
1 L H2O 
TE buffer (pH 8,0) ………………………………. 1 % (v/v) 1 M Tris-HCl 
1 mM EDTA 
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1x SDS sample lysis buffer ….…………….……. 62.5 mM Tris-HCl, pH 6.8 
2% (m/v) SDS 
10% (v/v) glycerol 
50 mM DTT 
0.01% (w/v) bromophenol blue 
Blocking solution (Western blot) …...…………… PBS 
5% (m/v) milk powder 
10x SDS running buffer ..………………………... Rotiphorese 10xSDS PAGE 
Roth, Germany 
Transfer buffer (Western blot) ….……………….. 72 g glycine 
15 g Tris Base 
25 ml 20% SDS 
1L H2O 
Denaturation buffer (Dot blot / Southern blot)….. 0,5 M NaOH 
1,5 M NaCl 
Neutralization buffer (Dot blot / Southern blot).... 0,5 M Tris-HCl 
1,5 M NaCl 
20xSSPE buffer (pH 7,4) ….…………………….. 3 M NaCl 
0,2 M NaH2PO4 
0,02 M EDTA 
20xSSC buffer (pH 7,0) ………………………….. 3 M NaCl,  
0,3 M sodium citrate  
Hybridization buffer (Dot blot / Southern blot)…. RapidHyb buffer 
(GE Healthcare, UK) 
Washing buffer I (Dot blot / Southern blot)….….. H2O 
2x SSC 
0,1% (v/v) SDS 
Washing buffer II (Dot blot / Southern blot)….…. H2O 
0,1x SSC 
0,1% (v/v) SDS 
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3.11 Enzymes and commercial Kits 
CombiZyme DNA Polymerase Mix   Invitek, Germany 
Cytofix / Cytoperm Kit     BD Pharmingen, Germany 
DecaLabel DNA Labelling Kit    Fermentas, Germany 
Effectene Transfection Reagent Kit   Qiagen, Germany 
ELC Western Blotting Detection Kit   GE Healthcare, UK 
GoTaq Polymerase (+ 5× reaction buffer)  Promega, Germany 
Lipofectamine Transfection Reagent Kit   Invitrogen, Germany 
Platinum SYBR Green Kit     Invitrogen, Germany 
QIAamp DNA Mini Kit     Qiagen, Germany 
QIAprep Mini-, Midi-, Maxi-, Gigaprep Kit  Qiagen, Germany 
QIAquick Gel Extraction Kit    Qiagen, Germany 
Rapid Ligation Kit (containing T4 ligase)  Fermentas, Germany 
Restore PLUS Western Blot Stripping Buffer  Thermo Scientific, USA 
Restriction endonucleases    NEB, Germany 
Vivaspin AdenoPACK 100 Kit    Sartorius, Germany 
 
3.12 Standards 
Smart Ladder      Eurogentec, Belgium 
GeneRuler 1kb Ladder Plus    Fermentas, Germany 
Roti-Mark Prestained     Roth, Germany 
 
3.13 Plasmids 
pWHcIm and pWHsIm 
The expression plasmids encode WHcAg (pWHsIm) and WHcIm (pWHsIm) under 
control of a CMV-IE promoter. Both plasmids were constructed on the basis of 
pcDNA3 vector (Invitrogen). Both plasmids pWHcIm and pWHsIm were used as DNA 
vaccines in immunization trials. Plasmids were kindly provided by Prof. Mengji Lu 
(Institut für Virologie, Universitätsklinikum, Essen). The vector map is included in the 
Appendix section (10.3; Fig. 10.1) 
 
 
Materials
 
35 
 
pCG 
The plasmid pCG is an expression plasmid that contains a β-globin intron sequence 
between CMV-IE promoter and the polyadenylation signal. The plasmid was kindly 
provided by Prof. Ulf Dittmer (Institut für Virologie, Universitätsklinikum, Essen). The 
sequence of WHcAg was cloned into the pCG vector and newly created pCGWHc 
plasmid was used as a DNA vaccine in immunization trials. The vector map of 
pCGWHc is included in the Appendix section (10.3; Fig. 10.2). 
 
pShuttle 
pShuttle is a cloning vector used for generation of recombinant adenoviruses using 
AdEasy system. The gene of interest (WHcAg) was subcloned into pShuttle and the 
pShuttle/WHc plasmid was used for homologous recombination with adenoviral 
backbone plasmids. The vector map of pShuttle/WHc is included in the Appendix 
section (10.3; Fig. 10.3) 
 
pAdEasy-1 and pAdEasy-1/F35 
Adenoviral backbone plasmids used for generation of recombinant adenoviral vectors 
using AdEasy system. The pAdEasy-1 plasmid contains the genome sequences of 
adenovirus serotype 5 and pAdEasy-1/F35 is a chimeric vector that encodes fiber 
shaft and knob domains of adenovirus serotype 35. Both plasmids are characterized 
by deletion in E1 and E3 region of AdV genome. 
 
3.14 Antibodies 
Antibodies used for the flow cytometric analysis of murine splenic lymphocytes and 
woodchuck PBMCs are listed in tables below (Tab. 3.1 and Tab. 3.2, respectively). 
Characteristics of the antibody-coupled fluorochromes used for flow cytometric 
purposes are presented in table 3.3. The other antibodies and conjugates are 
gathered in table 3.4.  
Materials
 
36 
 
Tab. 3.1 Monoclonal antibodies and dyes used for flow cytometric analysis of 
murine lymphocytes 
Antibody Clone Manufacturer 
7AAD - BD Pharmingen 
CFSE - Invitrogen 
CD4 PE rat anti-mouse antibody L3T4 (RM4-5) BD Pharmingen 
CD4 PerCP rat anti-mouse antibody L3T4 (RM4-5) BD Pharmingen 
CD4 AF700 rat anti-mouse antibody L3T4 (RM4-5) eBioscience 
CD8a FITC rat anti-mouse antibody 53-6.7 BD Pharmingen 
CD8a PE rat anti-mouse antibody 53-6.7 BD Pharmingen 
CD8a eF450 rat anti-mouse antibody 53-6.7 eBioscience 
CD43 PerCP rat anti-mouse antibody 1B11 eBioscience 
CD107a FITC rat anti-mouse antibody 1D4B BD Pharmingen 
IFNγ FITC rat anti-mouse antibody XMG1.2 eBioscience 
IFNγ APC rat anti-mouse antibody XMG1.2 BD Pharmingen 
IL-2 PE rat anti-mouse antibody JES6-5H4 eBioscience 
TNFα APC rat anti-mouse antibody MP6-XT22 eBioscience 
 
Tab. 3.2 Antibodies and dyes used for flow cytometric analysis of woodchuck 
lymphocytes 
Antibody Clone Manufacturer 
7AAD - BD Pharmingen 
CD3 polyclonal rabbit anti-human antibody - 
DakoCytomation 
(Denmark) 
αIgG PE polyclonal donkey anti-rabbit antibody - 
Abcam  
(United Kingdom) 
CD4 FITC monoclonal mouse anti-human antibody L200 BD Pharmingen 
CD4 PE monoclonal mouse anti-human antibody L200 BD Pharmingen 
CD4 PerCP monoclonal mouse anti-human antibody L200 BD Pharmingen 
CD107a FITC rat anti-mouse antibody 1D4B BD Pharmingen 
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Tab. 3.3 Charasteristics of fluorochromes 
Fluorochrome Abbreviation 
Absorption 
(nm) 
Emission 
(nm) 
7-aminoactinomycin D 7AAD 488 647 
Alexa Fluor 700 AF700 633 723 
Allophycocyanin APC 633 660 
Carboxyfluorescein succinimidyl ester CFSE 488 520 
eFluor 450 eF450 405 455 
Fluorescein isothiocyanate FITC 488 518 
Peridinin-chlorophyll-protein complex PerCP 488 675 
Phycoerythrin  PE 488 575 
 
Tab. 3.4 Other antibodies and conjugates 
Antibody Clone Usage Manufacturer 
CD28 monoclonal hamster anti-mouse 
antibody 
37.51 co-stimulation BD Pharmingen 
anti-mouse IgG (HRP conjugated) - ELISA Sigma 
anti-mouse IgG1 (HRP conjugated) X56 ELISA BD Pharmingen 
anti-mouse IgG2 (HRP conjugated) R19-15 ELISA BD Pharmingen 
Protein G (HRP conjugated)  - ELISA Sigma 
mouse monoclonal anti-HBcAg 
(10E11): cross-reactive with WHcAg - Western blot 
Santa Cruz 
Biotech., USA 
mouse monoclonal anti-β-actin - Western blot Sigma 
anti-mouse IgG/IgM (HRP conjugated)  Western blot Dianova 
 
Monoclonal mouse anti-WHcAg antibodies 6C5C8E4, used for Western blotting 
analysis, were kindly provided by Prof. Mengji Lu (Institut für Virologie, Universitäts-
klinikum, Essen). 
3.15 Peptides 
Peptides used for in vitro stimulation of murine and woodchuck lymphocytes were 
synthetized by EMC microcollections (Germany). The list of WHV core- and surface 
protein-derived peptides is included in the Appendix section 10.2. As negative control 
the peptide YILEETSVM derived from human cytomegalovirus (CMV) was used.  
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Lyophilisates of peptides were diluted in PBS containing 10% DMSO to the 
concentration 1mg/ml, aliquoted and stored at -20oC. 
3.16 Membranes and films 
Hybond N+ membrane     GE Healthcare, UK 
PVDF membrane      Millipore, Germany 
High performance chemiluminescence film  GE Healthcare, UK 
Glass fibre filters      Perkin Elmer, USA 
3.17 Oligonucleotides 
All oligonucleotides used in the study were synthesized by Biomers (Germany). The 
nucleotide sequence, annealing temperature (Tann) employed for PCR and usage of 
the oligonucleotides are presented in table 3.5. 
 
Tab. 3.5 Oligonucleotides 
Primer Orientation Sequence (5’→3’) Tann[oC] Usage 
pCG KpnI sense 
CATGGTACCTAATCGACTCACTATAGG
GAGACC 
60 cloning 
pCG BglII anti-sense 
CATAGATCTAGCTCCTCGAGTTCATAA
GAGAAG 
60 cloning 
WHc XbaI sense 
AGCTTCTAGACCATGGACATAGATCCC
TATAAA 
56 cloning 
WHc SbfI anti-sense 
AGCTCCTGCAGGAATTCGGCTTCATTG
AAGATCAGCAGTT 
56 cloning 
wc1 sense TGGGGCCATGGATATAGATCCTTA 50/60 real-time PCR 
wc2 anti-sense CATTGAATTCAGCAGTTGGCAGATGG 50 PCR 
wc149s anti-sense AAGATCTCTAAATGACTGTATGTTCCG 60 real-time PCR 
coreS sense GGAACATACAGTCATTAGG 50 sequencing 
coreAS anti-sense GCAGTAGCAGTGTCCACCA 55 sequencing 
pShuttleS sense TAACGCCAATAGGGACTTTC 55 sequencing 
pShuttleAS anti-sense TTGTGATGCTATTGCTTTATTTG 55 sequencing 
pShuIn2S sense GCAAGTGTGGCGGAACACATG 55 sequencing 
pShuInAS anti-sense CAGGACCCTCAACGACCGAG 55 sequencing 
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3.18 Materials and equipment 
Beakers Schott, Germany 
Capillaries (heparinised) Hirschmann Laborgeräte, Germany 
Cell culture flasks (T25; T75; T175, T300) Greiner bio-one, Germany 
Cell culture plates (6- and 24-well) Greiner bio-one, Germany 
Cell strainers (70µm)  Falcon BD, Germany 
Chamberslides (8-well) NUNC, Denmark 
Cryo-tubes (2ml; 5ml) Greiner bio-one, Germany 
Combitips (0,5ml; 2,5ml; 5ml) Eppendorf, Germany 
Dishes Greiner bio-one, Germany 
Disposable scalpels HMD Healthcare, UK 
Disposable syringes (1ml) TERUMO, Belgium 
Disposable syringes (2ml; 5ml; 10ml) B.Braun, Germany 
Erlenmeyer flasks Schott, Germany 
FACS tubes Becton Dickinson, Germany 
Flat-bottom 96-well microplates Falcon BD, Germany 
Forceps (pointed and curved) Oehmen, Germany 
Leucosept tubes Falcon BD, Germany 
Light cycler capillaires 20µl  Roche, Germany 
Hybridization Tubes Amersham Bioscience, USA 
Microcon colums YM10 Millipore, Germany 
MicroSpin colums S-200 GE Healthcare, UK 
Needles (0,4x19mm ; 0,9x40mm) Becton Dickinson, Germany 
NUNC Immunoplates (96-well) NUNC, Denmark 
Parafilm American National Can, USA 
Pipette tips (10µl ; 200µl ; 1000µl) STARLAB, Germany 
Plastic sterile pipettes (5ml; 10ml; 25ml) Greiner bio-one, Germany 
Reaction tubes (1,5ml; 2ml) Eppendorf, Germany 
Scissors Oehmen, Germany 
Screw-cap tubes (15ml; 50 ml) Falcon BD, Germany 
S-Monovette tubes (K3E and Z, 9ml) Sarstedt, Germany 
TopSeal-A: 96-well microplates Perkin Elmer, USA 
U-bottom 96-well microplates Falcon BD, Germany 
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Balance Vibra AJ-2200CE Shinko Denshi, Japan 
Bio-imaging system (Gene Genius) Syngene, USA 
Centrifuge Megafuge 1.0R Heraeus, Germany 
Centrifuge Avanti J-26XPi Beckman Coulter, Germany 
Centrifuge : Ultracentrifuge Optima L-70K  Beckman Coulter, Germany 
Cyclone (Storage Phosphor Screen) Packard, USA 
CO2 incubator Thermo, Deutschland 
ELISA Expert Plus Microplate Reader Biochrom, UK 
Electrophoresis chambers BioRad, Germany  
Electroporator Gene Pulser BioRad, Germany 
FACSCalibur flow cytometer Becton Dickinson, Germany 
Fridge / Freezer (-20oC) AEG, Germany 
Freezer (-80oC) Thermo Forma, Germany 
Laminar flow KOJAIR, Germany 
LightCycler 2.0 Roche, Germany  
LSRII flow cytometer Becton Dickinson, Germany 
Harvester Packard, USA 
Heating block (Thermo Stat Plus) Eppendorf, Germany 
Hybridization oven BINDER, USA 
Microcentrifuges  Eppendorf, Germany 
Microscope (inverted) ZEISS, Germany 
Microscope (confocal, Leica DM IRE2) Leica Microsystems, Germany 
Osmotic pumps (ALZET 2ML4) Durect, USA 
Single-, multichannel pipettes, multipettes  Eppendorf, Germany 
Shaker (Duomax 1030) Heidolph, Germany 
Spectrophotometer (Gene Quant pro) Amersham Bioscience, USA 
Thermocycler Biometra, Germany 
Thoma cell counting chamber Marienfeld, Germany 
Top Count NXT Packard, USA 
Transblot SemiDry transfer cell BioRad, Germany 
UV transiluminator FLX-20M MWG-BioTech, Germany 
Vaccum blotter 785 BioRad, Germany 
Vortex Genie 2 Bender & Hobein AG, Switzerland 
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4 Methods 
4.1 Molecular biology methods 
4.1.1 Amplification of DNA inserts using Polymerase Chain Reaction (PCR) 
The amplification of the DNA inserts was performed using CombiZyme DNA 
Polymerase Mix (Invitek). CombiZyme is a cocktail of recombinant Taq DNA 
polymerase with a thermostable DNA polymerase providing a 3’-5’ proofreading 
activity. Insert-specific primers introducing restriction sites necessary for further 
cloning were used. The reaction mixture components and the PCR conditions are 
presented in tables 4.1 and 4.2, respectively. 
 
Tab. 4.1 The PCR reaction using CombiZyme Mix 
Reagent Concentration Volume [µl] 
10× OptiPerform Buffer III  1× 5 
MgCl2 2,5 mM 2,5 
dNTP-Mix 0,25 mM 1 
5× OptiZyme Enhancer 1× 10 
sense / antisense primers 0,4 µM each: 2 
CombiZyme DNA polymerase 3 U 0,75 
H2O - 22,25 
DNA  0,5 
  total: 50 
 
Tab. 4.2 The PCR conditions 
PCR step Temperature [oC] Time [min] 
Number of 
cycles 
Denaturation 94 4 1 
Denaturation 
Annealing 
Elongation 
94 
60 / 56* 
72 
1 
1 
2 
30 
Final elongation 72 8 1 
*The annealing temperature for pair of primers pCG KpnI + pCG BglII  
   was 60oC and for pair of primers WHc XbaI + WHc SbfI was 56oC. 
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4.1.2 Agarose gel electrophoresis 
DNA fragments were separated in a horizontal 1-2% agarose gel containing 
0.5 µg/ml of ethidium bromide. The electrophoresis was carried out in 1× TBE buffer 
at 130 V for approximately one hour. The visualization of the separated DNA 
fragments was performed using a UV-Bioimaging System (Syngene).  
4.1.3 DNA extraction from agarose gel 
Restricted plasmids or amplified DNA fragments were separated by agarose gel 
electrophoresis. The fragments of interest were cut out of the gel and purified with the 
QIAquick Gel Extraction Kit (Qiagen) according to the manufacturer’s protocol. The 
elution of purified fragments was performed in 30 µl of H2O. 
4.1.4 DNA restriction digestion 
Plasmids and PCR-products were restricted either with a single endonuclease or with 
a combination of two enzymes. In that case, the set of restriction enzymes that work 
optimally in the same reaction buffer and temperature (usually 37oC) was chosen. 
The PCR products used for restriction were previously purified by extraction from the 
agarose gel. For preparative purposes 100 µl of restriction reaction was prepared 
and incubated overnight at the optimal temperature. The control digestion of 
successful cloning was carried out in 10 µl reaction for 1 h (Tab. 4.3). 
 
Tab. 4.3 Restriction of plasmids and PCR-products 
Reagent Preparative digestion Control digestion 
DNA 
5-10 µg of plasmid 
30 µl of purified PCR product 
1 µg of plasmid 
Enzyme I 2 µl 0,5 µl 
Enzyme II 2 µl / - 0,5 µl / - 
10× buffer 10 µl 1 µl 
10×BSA (if required) 10 µl 1 µl 
nuclease-free H2O added to: 100 µl added to: 10 µl 
 
The products of the restriction reaction were separated by agarose gel 
electrophoresis and purified using the QIAquick Gel Extraction Kit (Qiagen). The 
linearized plasmids were precipitated by phenol-chloroform method. 
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4.1.5 Phenol – chloroform precipitation 
For phenol–chloroform precipitation of the linearized plasmids two 100 µl restriction 
reactions were performed. After the digestion, the reactions were mixed by vortexing 
with 400 µl of phenol, incubated on ice for 5 minutes, and centrifuged (16 000× g, 
3 min). The upper phase containing DNA was transferred to a fresh tube, mixed by 
vortexing with 400 µl of chloroform, and centrifuged (16 000× g, 3 min). Again the 
upper phase containing DNA was transferred to a fresh tube and mixed with 40µl of 
3 M sodium acetate (pH 7) and 1200 µl of absolute ethanol. The mixture was 
incubated overnight at -20oC. The next day, the tube was centrifuged (16 000× g, 
30 min), the supernatant was discarded and pellet was washed with 100 µl of 70% 
ethanol (16 000× g, 10 min). The pellet was left to dry and afterwards suspended in 
20 µl of nuclease-free H2O. 
4.1.6 Ligation of DNA fragments 
Purified, linearized plasmid and insert DNA were ligated using T4 DNA ligase. For 
reaction, 2 µl of linearized plasmid, 6 µl of purified insert, 1 µl of T4 ligase and 1 µl of 
10× optimal ligation buffer (Rapid Ligation Kit, Fermentas) were used. The mixture 
was incubated 20 min at room temperature and used for transformation of competent 
E.coli cells. 
4.1.7 Transformation of E.coli 
4.1.7.1 Transformation of chemically competent E.coli strains 
Transformation of chemically competent E.coli strains (Top10, DH5α) was performed 
according to manufacturer’s instructions. Briefly, 50 µl aliquots of bacteria were 
thawed on ice, mixed gently with 2-3 µl of ligation mixture and incubated on ice for 
30 min. To improve DNA absorption by bacteria, a heat shock for 30 s at 42oC 
followed by a subsequent incubation on ice for 2 minutes was performed. Afterwards 
200 µl of SOC medium (Invitrogen) was added to the cells and the mixture was 
incubated on a shaker for 2 hours at 37oC. Using a sterile spatula the complete 
mixture was spread over an LB-agar plate containing a selective antibiotic (100µg/ml 
of ampicillin or 50µg/ml kanamycin). The plates were incubated overnight at 37oC. 
Methods
 
44 
 
4.1.7.2 Transformation of E.coli strains using electroporation 
Homologous recombination between pShuttle plasmid (carrying the gene of interest) 
and adenoviral genome was carried out in electrocompetent E.coli strain BJ5183. 
The strain used in the experiments was previously transformed with pAdEasy-1 
plasmids. The pShuttle plasmid was linearized using PmeI restriction endonuclease 
and desalted on a Microcon YM10 column (Millipore) according to manufacturer’s 
protocol. For transformation 5 µl of linearized pShuttle plasmid and 50 µl of bacteria 
were mixed and transferred to an ice-cold 2-mm electroporation cuvette. The electric 
pulse (2500 V, 200 Ω, 25 µF) was delivered in a Gene Pulser Electroporator 
(BioRad). The mixture was suspended in 200 µl of SOC medium (Invitrogen) and 
spread over a kanamycin LB-agar plate. The plates were incubated overnight at 
37oC. The correct recombinant plasmids were selected by HindIII restriction 
digestion. 
4.1.8 Plasmid DNA purification using commercial kits 
One bacterial colony was picked up from the LB agar plate, using a sterile pipette tip 
and transferred into the flask with LB-medium containing selective antibiotic. The 
volume of 2 ml of the culture was used for Mini, 50 ml for Midi, 250 ml for Maxi and 
2500 ml for Giga preparations. After overnight incubation on the shaker at 37oC the 
plasmid DNA was extracted using QIAprep Kits (Qiagen) according to manufacturer’s 
protocol. The DNA concentration was quantified by spectrophotometric OD260nm 
measurement as follows: 
 
Concentration [µg/ml] = OD260nm × dilution factor × 50 
 
Purified plasmid DNA was checked by control restriction digestion (section 4.1.4). 
4.1.9 Plasmid DNA purification using CsCl gradient ultracentrifugation 
Preparative purification (MaxiPrep) of recombinant adenoviral plasmids was 
performed using CsCl gradient ultracentrifugation. The correct recombinant plasmids 
were retransformed to DH5α E.coli strain and the cultures of 300 ml were prepared. 
After overnight incubation at 32oC, the cultures were centrifuged (6 000× g, 10 min) 
and the pellet was suspended in 10 ml of buffer P1. Next,15 ml of lysis buffer P2 was 
added and mixed. After 5 minutes incubation 25 ml of neutralization P3 buffer was 
added, mixed and the tube was centrifuged (5 000× g, 10 min). The supernatant was 
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filtrated into a fresh tube, mixed with 0,7 volume of isopropanol and centrifuged at 
4oC (12 000× g, 30 min). The pellet was resuspended in 4,1 ml of buffer P1 
containing 4,6 g of CsCl and 40 µl of ethidium bromide. The solution was transferred 
into an ultracentrifuge tube and centrifuged for 4 h at 70 000× rpm (Rotor NVT100). 
Afterwards, the band stained with ethidium bromide was collected using a syringe 
and washed with 90% buthanol in 10% TE buffer until the dye was removed. The 
DNA phase was mixed with 0,7 volumes of isopropanol and centrifuged (12 000× g, 
30 min). The pellet was washed with 70% ethanol, dried and resuspended in 200-
500 µl of TE buffer. Recombinant adenoviral plasmids were linearized using PacI 
restriction endonuclease and used for transfection of HEK-293A cells (section 4.2.7). 
4.1.10 DNA sequencing 
Sequencing was performed at the DNA-Sequencing Service (Universitätsklinikum 
Essen). Non-standard primers designed for sequencing are listed in the Materials 
section (Tab. 3.5).  
 
4.2 Cell culture 
4.2.1 Thawing and cryoconservation of cells 
Cryotubes containing cells were taken out from the liquid nitrogen and thawed quickly 
in a warm water-bath. Cells were washed twice in 10 ml of the culture medium. 
Afterwards, cells were suspended in 10ml of fresh medium, placed in 25 cm2 flask, 
and cultured at 37oC in humidified atmosphere containing 5% CO2. 
 
For cryoconservation, the cell suspension was centrifuged in 50 ml tubes (300× g, 
5 min) and washed once with sterile PBS. The pellet was suspended in 1 ml of 
culture medium supplemented with 25% FCS and 10% DMSO. Cells were frozen 
slowly overnight in -80oC and then transferred to a liquid nitrogen tank. 
4.2.2 Passaging of cells 
The medium was removed and cells were washed twice with 10 ml of sterile PBS. 
Then 2 ml of Trypsin-EDTA was added to cover the bottom of the 75 cm2 flask. After 
approximately 2 minutes when the cells started to detach from the bottom 8 ml of 
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fresh medium was added. Cells were placed in fresh flasks in 20 ml of culture 
medium in the given concentration. 
4.2.3 Culture of BHK-21 cells 
Adherent BHK-21 cells were grown in monolayers in MEM (Minimum Essential 
Medium) medium supplemented with 10% FCS and 10 U/ml penicillin-streptomycin. 
Cells were passaged twice a week at a dilution 1:10. 
4.2.4 Culture of HEK-293A cells 
Adherent BHK cells were grown in monolayers in DMEM (Dulbecco’s Modified Eagle 
Medium) medium supplemented with 10% FCS and 10 U/ml penicillin-streptomycin. 
Cells were passaged twice a week at a dilution 1:5. 
4.2.5 Counting of viable cells using Trypan blue exclusion microscopy 
Trypan blue is a negatively charged dye that only interacts with the cell when the 
membrane is damaged. Therefore, all the cells which exclude the dye are viable. 
Aliquots of cell suspension were diluted with 0.4% Trypan blue stain and 10 µl of the 
diluted aliquot solution was transferred onto a Thoma hemocytometer. The viable 
cells were counted and the number of cells per ml was calculated as follows:  
 
number of cells / ml = number of cells in the large square × dilution factor × 104 
4.2.6 Transfection of BHK cells 
4.2.6.1 Using Effectene reagent 
Up to 5×104 BHK-21 cells per well were plated on a 24-well plate and incubated at 
37oC till the cells reached confluence of 80%. Cells were washed with sterile PBS 
and 350 µl of the culture medium was added per well. Cells were transfected with 
1 µg of plasmid using the Effectene reagent (Qiagen) according to manufacturer’s 
protocol. As a negative control cells treated only with Effectene reagent were used. 
 
For 8-well chamberslides up to 1×103 BHK-21 cells per well were plated and 
incubated at 37oC till the cells reached confluence of 80%. Cells were washed with 
sterile PBS and 200 µl of the culture medium was added per well. For one well a half 
volume of the transfection mixture prepared for a well of 24-well plate was used. 
Cells treated only with Effectene reagent served as the negative control. 
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4.2.6.2 Using Lipofectamine reagent 
Up to 1×106 BHK-21 cells per well were plated on a 6-well plate and incubated at 
37oC till the cells reached confluence of 80%. Cells were washed with sterile PBS 
and 1,5 ml of the Opti-MEM medium was added per well. Cells were transfected with 
1 µg of plasmid using the Lipofectamine reagent (Invitrogen) according to 
manufacturer’s protocol. As a negative control cells treated only with Lipofectamine 
reagent were used. After 5 h the Opti-MEM medium was replaced with fresh culture 
medium. 
4.2.7 Transfection of HEK-293A cells with recombinant AdV plasmids 
Transfection was performed using polyethyleneimine (PEI). The reagent is forming 
a complex with DNA which is absorbed by the cells through endocytosis process. Per 
one 25 cm2 culture flask of HEK-293A cells the transfection mixture containing 6-8 µg 
of PacI-linerized AdV plasmids (pAd5WHc or pAd5F35WHc), 10 µl of PEI and 500 µl 
of serum-free DMEM medium was prepared. The mixture was incubated for 10 min 
and added on the cells (90-95% confluent). The cells were cultured in DMEM 
medium supplemented with 2% FCS and after 6 h the medium was replaced for a 
standard culture medium. 
4.2.8 Production and purification of recombinant adenoviral vectors 
Approximately 14 days after the PEI transfection, the content of the 25 cm2 culture 
flasks in which cells were completely lysed by replicating adenoviruses was collected 
and centrifuged (300× g, 5 min). The supernatant was collected in a fresh tube and 
the cell debris were subsequently frozen and thawed (liquid nitrogen – warm water 
bath) to release remaining particles. The supernatant was used to infect fresh     
HEK-293 cells cultured in 75 cm2. In the next rounds of the production 175 cm2 and 
finally 300 cm2 culture flasks were used.  
 
The recombinant adenoviral particles were purified from supernatant of five 300 cm2 
culture flasks using Vivaspin AdenoPACK 100 Kit (Sartorius) according to the 
manufacturer’s protocol. 
4.2.9 Determination of the infectious adenoviral particles titer 
The titer of infectious adenoviral particles was determined using TCID50 (tissue 
culture infectious dose 50) assay. For that purpose, HEK-293A cells were plated in 
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a flat-bottom 96-well plate (1×104 cells per well) and infected in every row with 100 µl 
of serial logarithmic dilutions of the purified virus stock. After 5-10 days the cytophatic 
effect (CPE) in every well was monitored. The ratio of CPE-positive wells for every 
dilution was determined and the TCID50 per ml of the virus stock was calculated as 
follows:  
TCID50/ml = 101+d (S-0,5) × 10 
 
Where: d = Log 10 of the dilution; S = the sum of CPE ratios for every dilution 
To transform TCID50/ml value in PFU (plaque forming units) per ml the following 
formula was used: 
PFU/ml = [TCID50/ml]-0,7 
4.2.10 Infection of HEK-293A cells with recombinant adenoviral vectors 
Up to 5×106 HEK-293A cells per well were plated on a 6-well plate and incubated at 
37oC till the cells reached confluence of 80-90%. Cells were washed with sterile PBS 
and 1,5 ml of culture medium containing 5×107 PFU (MOI 10) of Ad5WHc or 
Ad35WHc was added. After 2 h the medium was replaced with 3 ml of fresh culture 
medium. Cells treated only with medium served as negative control. 
 
4.3 Protein-biochemical methods 
4.3.1 Immunoblot analysis (Western Blot) 
4.3.1.1 Preparation of the cell lysates 
The cell lysates were prepared 24 h after transfection with WHcAg-expressing 
plasmids (section 4.2.6) or 36 h after infection with recombinant adenoviral vectors 
(section 4.2.10). The medium was removed and cells were washed twice with PBS. 
The cells were suspended in lysing buffer (200 µl per well of 24-well plate; 350 µl per 
well of 6-well plate) and denaturated for 20 min at 95oC. The cell lysates were stored     
at -20oC. 
4.3.1.2 SDS-PAGE 
Proteins were separated using standard discontinuous, one-dimensional SDS-PAGE 
(Sodiumdodecylsulfate Polyacrylamide Gel Electrophoresis). The ingredients needed 
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for preparation of 15% separation gel and 5% stacking gel are presented in the 
Tab. 4.4. 
 
Tab. 4.4 Reagents used for preparation of SDS gels 
Reagent Stacking gel (5%) Separation gel (15%) 
30% Acrylamid solution (29:1) 360 µl 2,5 ml 
1,5M Tris-HCl (pH 8,8) 27 µl 1,3 ml 
10% SDS 22,5 µl 50 µl 
10 % APS 12,5 µl 50 µl 
TEMED 2,5 µl 2 µl 
H2O 1,6 ml 1,1 ml 
 
Up to 10 µl of the cell lysates were loaded per well and 5 µl of Roti-Mark Prestained 
(ROTH) as a molecular weight marker. Proteins were separated approximately 1,5 h 
at 130 V. 
4.3.1.3 Immunoblotting 
The proteins were transferred to PVDF (polyvinylidene fluoride) membrane using 
semi-dry transfer method. The membrane was pre-incubated in methanol and placed 
together with the SDS gel between three layers of Whatmann paper soaked in the 
transfer buffer. Transfer took place for 15 minutes at 7,5 V using SemiDry-transfer 
blotter (BioRad). The membrane was turned towards anode and the gel towards 
cathode. After the transfer, the binding sites on the membrane were blocked using 
5% milk powder solution. After 1 h incubation at room temperature on the shaker the 
blocking solution was removed and the membrane was washed twice for 10 minutes 
with T-PBS. The WHcAg-specific mouse monoclonal antibodies: 6C58E4 or cross-
reactive HBcAg 10E11 were diluted 1:2000 or 1:1000, respectively, in T-PBS and 
incubated with the membrane for 1 h incubation at room temperature on the shaker. 
After washing three times for 10 minutes wit T-PBS membrane was incubated with 
secondary peroxidase-conjugated anti-mouse IgG (dilution 1:20000 for 6C58E4; 
1:2500 for 10E11) and washed three times for 10 minutes wit T-PBS. The presence 
of WHcAg was detected on radiographic film (High performance chemiluminescence 
film, GE Healthcare) by using ECL Western Blotting Detection Kit (GE Healthcare) 
according to manufacturer’s protocol.  
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The membrane was kept overnight at 4oC in T-PBS solution and the next day the 
detection of β-actin as an internal control of the protein content in the lysates was 
performed. The membrane was stripped using Restore PLUS Western Blot Stripping 
Buffer (Thermo Scientific) according to manufacturer’s protocol. The membrane was 
developed as described above. As the first antibody β-actin-specific mouse 
monoclonal antibodies diluted 1:5000 were used. The secondary antibody was 
peroxidase-conjugated anti-mouse IgG (dilution 1:15000). 
4.3.2 Immunofluorescence staining 
Immunofluorescence staining of WHcAg was performed 24h after transfection on  
a 8-well chamberslides (section 4.2.6.1). The medium was removed and the 
chamberslides were left to dry. The cells were fixed with ice-cold 50% methanol for 
20 min at 4oC. Afterwards, methanol was removed and chamberslides were left to 
dry. The cells were incubated with 100 µl of polyclonal rabbit WHcAg-specific 
antibodies (diluted 1:80 in PBS) in humidified chamber for 1 h at 37oC and washed 
two times with PBS. Next, cells were incubated with 100 µl of secondary FITC-
conjugated anti-rabbit IgG antibodies (diluted 1:80 in PBS) in humidified chamber for 
1 h at 37oC and washed two times with PBS. The chambers were removed and the 
slide was left to dry for 10 min in the darkness. The slide was fixed using Dako 
Cytomation Mounting Medium. The pictures of the cells were taken using a confocal 
laser scanning microscope in magnifications 40× and 100×. 
 
4.4 Animal experiments 
All animal experiments were carried out in accordance with the “Guide for the Care 
and Use of Laboratory Animals“ and were approved by the local Animal Care and 
Use Committee (Animal Care Center, University of Duisburg-Essen, Essen, Germany 
and the district government of Düsseldorf, Germany). 
4.4.1 Anesthetization 
For blood withdrawal and immunizations mice were anesthetized for several minutes 
with Isofluran vapors. Mice were placed in a glass jar filled with Isofluran-soaked 
kerchiefs until the animals got numb.  
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For blood withdrawal, immunizations and surgeries the woodchucks were deeply 
anesthetized by intramuscular injection of 4ml of 10% ketamine mixed with 1ml of 
2% xylazine. 
4.4.2 Blood withdrawal 
Blood withdrawal from the anesthetized mice was performed by retroorbital punction 
using 3mm heparin-coated glass capillaries. The blood was collected in 1,5 ml 
Eppendorf tubes. 
 
Blood withdrawal from the anesthetized woodchucks was performed from the hind 
limb veins (Vena saphena) using 0,9 × 40 mm needles. The blood samples were 
collected into S-Monovette Serum and EDTA-blood tubes. 
 
Serum samples were obtained by centrifugation of blood (6000× g, 10 min) and 
collection of the supernatants. Sera were stored at -20oC.  
4.4.3 Immunization trials 
Intramuscular (i.m.) injections of mice were performed into the Tibialis anterior 
muscle of the hind limbs using 0,4×19 mm needles. DNA plasmids and recombinant 
adenoviral vectors were diluted to the given concentration in 100 µl of sterile PBS 
and equal volume of 50 µl was injected into each muscle. 
 
Intramuscular injections of woodchucks were performed into the Tibialis anterior 
muscle of the hind limbs using 0,9×40 mm needles. DNA plasmids and recombinant 
adenoviral vectors were diluted to the given concentration in 1 ml of sterile PBS and 
equal volume of 500 µl was injected into each muscle. 
 
Seven days before the intramuscular DNA immunizations animals were pretreated 
with cardiotoxin (Latoxan; 10 µM in sterile PBS) to increase the effectiveness of the 
gene transfer [Davis et al., 1994]. Cardiotoxin solution was injected into the Tibialis 
anterior muscle of the hind limbs. Mice received 100 µl (50 µl per limb), whereas 
woodchucks received 1 ml (500 µl per limb) of the cardiotoxin solution.  
4.4.3.1 Immunization of C57BL/6 with pCGWHc and pWHcIm plasmids 
Ten weeks old female C57BL/6 mice were injected intramuscularly with cardiotoxin. 
One week later animals were intramuscularly vaccinated with 100 µg of pWHcIm or 
pCGWHc. Mice intramuscularly injected with 100 µl sterile PBS (50 µl per leg), 
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served as controls. Overall three vaccinations were performed in two weeks intervals. 
Mice were sacrificed two weeks after the last immunization. 
4.4.3.2 Immunization of C57BL/6 in heterologous DNA prime – AdV boost regimen  
Ten weeks old female C57BL/6 mice were intramuscularly injected with cardiotoxin. 
One week later animals were subsequently vaccinated twice in a two-week interval 
with 100 µg of pCGWHc plasmid. Four weeks after the second DNA immunization 
groups of mice were immunized with 2×109 PFU of Ad5WHc or 2×109 PFU 
Ad35WHc or 100 µg pCGWHc as a reference. Mice which were immunized twice 
with 100µg of “empty” pCG and boosted with 2×109 PFU Ad5 expressing GFP served 
as controls. Mice were sacrificed two weeks after the last immunization. 
4.4.3.3 Immunization of 1217 WHV transgenic mice in heterologous DNA prime – 
AdV boost regimen 
Ten to twelve weeks old sex-matched groups of 1217 WHV Tg mice were injected 
intramuscularly with cardiotoxin. One week later animals were subsequently 
vaccinated for two times in two-week interval with 100 µg of pCGWHc plasmid. Four 
weeks after the second DNA immunization groups of mice were immunized with 
2×109 PFU of Ad5WHc or 100 µg pCGWHc as a reference. Mice which were 
immunized twice with 100 µg of “empty” pCG and boosted with 2×109 PFU Ad5 
expressing GFP served as controls. Mice were sacrificed two weeks after the third 
immunization. The group of mice immunized twice with pCGWHc in combination with 
Ad5WHc was boosted for a second time with 2×109 PFU of Ad35WHc. The 
vaccination was performed four weeks after Ad5WHc immunization and mice were 
sacrificed two weeks later. 
4.4.3.4 Immunization of naïve woodchucks with plasmid DNA or recombinant 
adenoviral vectors  
Two naïve woodchucks (number: 58059 and 58063) were injected intramuscularly 
with cardiotoxin. One week later animals were subsequently immunized for three 
times with 1 mg of pCGWHc plasmid. The first two immunizations were performed in 
two-week interval, the third immunization was performed 4 weeks later. The 
experiment was repeated on naïve woodchuck number 70096. The animal was 
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pretreated with cardiotoxin solution and one week later the woodchuck was 
immunized for three times with 1 mg of pCGWHc in two weeks intervals. 
 
Two naïve woodchucks (number: 46949 and 46957) were intramuscularly immunized 
with 5×109 PFU Ad5WHc and four weeks later boosted with 1×1010 PFU of 
Ad35WHc. Two weeks after the last immunization all vaccinated woodchucks were 
challenged with WHV (section 4.4.4). Two naïve woodchucks (number: 58055 and 
58056) were only infected with WHV and served as controls. 
4.4.3.5 Therapeutic vaccination in combination with ETV treatment of WHV 
chronically infected woodchucks 
Seven chronically WHV infected woodchucks (number: 61786, 61787, 61789, 61791, 
61792, 61793 and 61795) were treated for 23 weeks with the nucleoside analogue 
entecavir (ETV). Initially, the drug was administered for 12 weeks, by means of the 
osmotic pumps (DURECT) implanted surgically under the skin of the animals. The 
pump releases subcutaneously approximately 0,2mg of ETV per day. Pumps were 
exchanged every 4 weeks; overall 3 pumps were implanted. From week 8 to 23 of 
the therapy subcutaneous injections of 1 mg of ETV were performed twice a week. At 
week 7, five of the seven ETV-treated animals (number: 61786, 61787, 61789, 61792 
and 61793) were injected intramuscularly with cardiotoxin. Starting from week 8 the 
animals received subsequently 9 intramuscular immunizations, as follows:  
 
• week 8, 10 and 12:        0,5 mg of pCGWHc + 0,5 mg pWHsIm plasmids  
• week 14:                        1×1011 PFU Ad5WHc + 0,5 mg pWHsIm plasmid 
• week 16:                        1×1011 PFU Ad35WHc + 0,5 mg pWHsIm plasmid 
• week 19:                        1×1011 PFU Ad5WHc + 0,5 mg pWHsIm plasmid 
• week 22:                        1×1011 PFU Ad35WHc + 0,5 mg pWHsIm plasmid 
• weeks 25 and 27:          0,5 mg of pCGWHc + 0,5 mg pWHsIm plasmids 
 
4.4.4 WHV infection 
Woodchucks were infected with 1×107 WHV strain 8 genome equivalents (GE) by 
intravenous injection (Vena saphena) using 0,9×40 mm needles. Virus aliquots for 
injections were prepared in 500 µl of sterile PBS.  
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4.4.5 Organs removal 
Mice were anesthetized with Isofluran and euthanized by cervical dislocation. Then, 
the abdominal cavity was opened using sterile scissors and forceps. Spleens and 
lymph nodes were removed into the Petri-dishes filled with 5 ml of ice-cold PBS. 
 
For removal of the livers, woodchucks were anesthetized with ketamine/xylazine and 
euthanized by intracardiac injection of T61. Liver samples were collected and frozen 
in the liquid nitrogen. Afterwards, the samples were stored at -80oC.  
 
4.5 Preparation of single-cell suspensions of murine splenocytes 
Spleens were homogenized thoroughly with a syringe plunger, and single-cell 
suspensions were prepared using a 70 µm nylon cell strainer. Subsequently, cells 
were washed twice in 50 ml of sterile PBS and resuspended in 10 ml of RPMI 1640 
medium supplemented with 10% FCS and 10U/ml penicillin-streptomycin. Cell 
counting was performed manually using a Thoma hemocytometer and Trypan blue 
exclusion microscopy (cell dilution 1:20) [section 4.2.5].  
 
4.6 In vitro stimulation of murine splenocytes 
4.6.1 In vitro stimulation of murine splenocytes for intracellular cytokine 
staining and CD107a degranulation assay (7 days incubation) 
Up to 2×106 of isolated splenocytes per well were plated in 96-well flat-bottom plates 
in 200 µl of RPMI 1640 medium supplemented with 10% FCS and 10U/ml penicillin-
streptomycin. For stimulation, peptide pools or individual peptides were added to a 
final concentration of 2 µg/ml per peptide. The list of WHcAg-derived peptide amino 
acid sequences used for in vitro stimulation is included in the Appendix section 
(Tab. 10.1 and Tab. 10.2). Unstimulated cells and cells stimulated with CMV-derived 
peptide (YILEETSVM) served as a negative control. After 2 days of culturing, 10 U/ml 
of recombinant murine IL-2 was added. 
 
Restimulation of splenocytes for intracellular cytokine staining (section 4.9.1) was 
performed after 7 days of in vitro stimulation. Cells were transferred to 96-well round-
bottom plates and restimulated for 6 h with 200 µl of medium containing peptide 
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pools or individual peptides in a final concentration of 2 µg/ml per peptide. Cells were 
restimulated in the presence of 1 µg/ml of α-CD28 antibody as unspecific T cell 
receptor (TCR) costimulator, and 5 µg/ml of brefeldin A, that blocks secretion of 
extracellular proteins, such as cytokines. As a positive control cells stimulated with 
400 ng/ml of PMA and 10 µg/ml of ionomycin were used. 
 
For CD107a degranulation assay (section 4.9.1) cells were restimulated for 5 h in the 
presence of FITC labeled anti-mouse CD107a antibody (1:200) to detect 
degranulation, 1 µg/ml of α-CD28 antibody, and 5 µg/ml of brefeldin A for intracellular 
IFNγ detection. 
4.6.2 In vitro stimulation of murine splenocytes for intracellular cytokine 
staining (6 hours incubation) 
Up to 1×106 of isolated splenocytes per well were plated in 96-well round-bottom 
plates in 200µl of RPMI 1640 medium supplemented with 10% FCS and 10U/ml 
penicillin-streptomycin. For 6 h stimulation, peptides were added to a final 
concentration of 2 µg/ml. Unstimulated cells and cells stimulated with CMV-derived 
peptide (YILEETSVM) served as a negative control. For intracellular cytokine staining 
(section 4.9.1) cells were incubated in the presence of 1 µg/ml of α-CD28 antibody, 
and 5 µg/ml of brefeldin A. As a positive control cells stimulated with 400 ng/ml of 
PMA and 10 µg/ml of ionomycin were used. 
 
4.7 Isolation of PBMCs from peripheral blood of woodchucks 
Peripheral blood mononuclear cells (PBMCs) were separated by Ficoll density 
gradient centrifugation. For that, PBS-diluted blood was transferred into 50 ml 
Leucosept separation tubes, containing 15 ml of Ficoll. After centrifugation (1200× g, 
10 min) the PBMCs-containing middle layer between Ficoll and plasma phases were 
transferred to a fresh tube. Subsequently, cells were washed twice in 50 ml of sterile 
PBS and resuspended in 10 ml of AIM-V medium supplemented with 10% FCS and 
10 U/ml penicillin-streptomycin. Cell counting was performed manually using Trypan 
blue exclusion microscopy (cell dilution 1:10) [section 4.2.5].  
 
Methods
 
56 
 
4.8 In vitro stimulation of woodchuck PBMCs 
4.8.1 In vitro stimulation of woodchuck PBMCs for CD107a degranulation 
assay 
Up to 1×106 of isolated PBMCs per well were plated in 96-well flat-bottom plates in 
200 µl of AIM-V medium supplemented with 10% FCS and 10 U/ml penicillin-
streptomycin. For stimulation, WHcAg epitope c96-110 (KVRQSLWFHLSCLTF) and 
WHsAg epitope s220-234 (AGLQVVYFLWTKILT) were added to a final concentration 
of 2 µg/ml per peptide. Unstimulated cells and cells stimulated with CMV-derived 
peptide (YILEETSVM) served as a negative control.  
 
Restimulation of PBMCs for CD107a degranulation assay (section 4.9.1) was 
performed after 3 days of in vitro stimulation. Cells were transferred to 96-well round-
bottom plates and restimulated for 5 h with 200 µl of medium containing WHcAg and 
WHsAg epitopes in a final concentration of 2 µg/ml per peptide. Cells were 
restimulated in the presence of FITC labeled anti-mouse CD107a antibody (1:100) to 
detect degranulation. 
4.8.2 In vitro stimulation of woodchuck PBMCs for proliferation assay 
Up to 5×104 of isolated PBMCs per well were plated in triplicates in 96-well flat-
bottom plates in 200 µl of AIM-V medium supplemented with 10% FCS and 10 U/ml 
penicillin-streptomycin. For stimulation, WHcAg- and WHsAg-derived peptides were 
added to a final concentration of 5 µg/ml per peptide. The list of the peptides used for 
in vitro stimulation was included in the Appendix section (Tab. 10.3 and Tab. 10.4). 
Unstimulated cells and cells stimulated with CMV-derived peptide (YILEETSVM) 
served as a negative control. As a positive control cells stimulated with 2 µg/ml of 
concavalin A were used. 
 
After 5 days of in vitro stimulation proliferation assay with 2[3H]-adenine was 
performed (section 4.10). 
4.9 Flow cytometry 
Flow cytometry is a technology that simultaneously measures multiple physical 
characteristics of cells such as relative size, relative granularity and relative 
fluorescence intensity. The cells are transported in the fluid stream to the measuring 
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cell where they are examined by the laser beam one after another. Using monoclonal 
antibodies conjugated with a fluorescent dye, flow cytometry enables to identify 
a particular cell type within complex cell populations based on their individual 
antigenic markers.  
4.9.1 Staining of cells for flow cytometric analysis 
For estimation of intracellular production of the cytokines, murine splenocytes were 
restimulated for 6 h in the presence of BFA and α-CD28 antibody as mentioned in 
sections 4.6.1 and 4.6.2. The degranulation capacity of murine splenocytes and 
woodchucks PBMCs was determined by detection of CD107a molecule on the cell 
surface. The staining of CD107a was performed by adding the specific antibody 
during the 5h restimulation period (sections 4.6.1 and 4.8.1). After the incubation 
time, cells were centrifuged (300× g, 5 min) and the culture medium was removed. 
Cells were washed with 200 µl FACS buffer I (PBS + 0,1% BSA + 0,02% NaN3).  
First, the molecules expressed extracellularly were stained for 15 minutes at 4oC 
using antibodies diluted in 100 µl FACS buffer I per sample. The exclusion of the 
dead cells and cellular debris was performed using the dye 7AAD (7-amino-
actinomycin). The dye stably interacts with cellular DNA of cells in which the cell 
membrane was disrupted. Therefore, 7AAD-positive cells are marked as dead cells. 
The dye was added to the sets of antibodies during extracellular staining. Cells were 
washed with 200 µl FACS buffer I. 
Second, the cells were fixed and permeabilized for 20 minutes at 4oC using 100 µl of 
Cytofix/Cytoperm Solution (BD Pharmingen). Cells were washed with 200 µl FACS 
buffer II (PBS + 1x PermWashBuffer + 0,1% BSA + 0,02% NaN3).  
The intracellular staining was performed for 25 minutes at 4oC using antibodies 
diluted in 100 µl FACS buffer II for murine cells and 100µl FACS buffer III (PBS + 
1x PermWashBuffer + 5% BSA + 0,02% NaN3) for woodchuck cells.  
Finally, cells were washed twice with 200 µl FACS buffer II, suspended in 250 µl 
FACS flow and measured on FACSCalibur or LSRII Flow Cytometers. Approximately 
200 000-250 000 events were acquired for murine splenocytes and 100 000-150 000 
events for woodchuck PBMCs. The data were analyzed using FlowJo software.  
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Sets of antibodies and dyes, dilutions and the suspending buffers used during 
various stainings are gathered in tables 4.5-4.8. 
 
Tab. 4.5 Intracellular IFNγ staining of murine splenocytes 
Staining Antibody Fluorochrome Dilution Buffer 
 anti-mouse CD8 FITC 1:100  
Extracellular anti-mouse CD4 PE 1:150 FACS buffer I 
 7AAD - 2µl/sample  
Intracellular anti-mouse IFNγ APC 1:200 FACS buffer II 
 
Tab. 4.6 Multifunctionality assay of murine splenocytes 
Staining Antibody Fluorochrome Dilution Buffer 
 anti-mouse CD8 eF450 1:100  
Extracellular anti-mouse CD4 AF700 1:150 FACS buffer I 
 
7AAD  
or: CD43 
- 
PerCP 
2µl/sample 
1:200 
 
 anti-mouse IFNγ FITC 1:200  
Intracellular anti-mouse IL-2 PE 1:200 FACS buffer II 
 anti-mouse TNFα APC 1:200  
 
Tab. 4.7 CD107a degranulation assay of murine splenocytes 
Staining Antibody Fluorochrome Dilution Buffer 
anti-mouse 
CD107a 
FITC 1:200 
RPMI 1640 
medium 
anti-mouse CD8 PE 1:200 
Extracellular 
7AAD - 2µl/sample 
FACS buffer I 
Intracellular anti-mouse IFNγ APC 1:200 FACS buffer II 
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Tab. 4.8 CD107a degranulation assay of woodchucks PBMCs 
Staining Antibody Fluorochrome Dilution Buffer 
anti-mouse 
CD107a 
FITC 1:100 AIM-V medium 
anti-human CD4 APC 1:200 
Extracellular 
7AAD - 2µl/sample 
FACS buffer I 
rabbit  
anti-human CD3 
- 1:150 
Intracellular 
anti-rabbit IgG PE 1:250 
FACS buffer III 
 
4.10 Proliferation assay of woodchuck PBMCs 
After 5 days in vitro stimulation of woodchuck PBMCs with WHcAg- and WHsAg-
derived peptides (section 4.8.2), cells were labelled with 1 µCi of 2[3H]-adenine for 
16 h and transferred to glass fibre filters (Packard) using a cell harvester. Membranes 
were placed into 96-well TopSeal-A microplates and 20 µl of scintillator was added to 
every well. The 2[3H]-adenine absorption by dividing cells was measured by Top 
Count NXT counter. Results for triplicate cultures are presented as a mean 
stimulation index (SI). The SI value was calculated using the formula: 
 
 
The SI ≥2,7 was considered significant. 
 
4.11 In vivo cytotoxicity assay 
The assay allows to evaluate the CTLs effector function in vivo in three groups of 
vaccinated mice: mice immunized for 3 times with pCGWHc plasmid, mice 
immunized twice with pCGWHc plasmid and boosted with Ad5WHc and mice 
immunized twice with “empty” pCG and boosted with Ad5GFP as controls. The 
immunization protocol is described in section 4.4.3.2. Eight days after the last 
immunization, the in vivo cytotoxicity assay was performed. 
 
Lymphocytes were isolated from spleens and lymph nodes of naïve C57BL/6 mice. 
Single-cell suspensions were prepared using a 70 µm nylon cell strainer and the cells 
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were washed with 50 ml of sterile PBS. Mononuclear cells from the spleens were 
separated additionally by Percoll density gradient centrifugation. Splenocytes were 
suspended in 20 ml of RPMI 1640 medium supplemented with 10% FCS and 10U/ml 
penicillin-streptomycin and slowly overlaid on a 20 ml Percoll layer in 50 ml Falcon 
tube. After centrifugation (300× g, 10 min, without a brake) the lymphocytes-
containing middle layer were transferred to the fresh tube. Subsequently, cells were 
washed twice in 50 ml of sterile PBS. Cell suspensions from the spleens and lymph 
nodes were mixed together and divided in equal volume of 15 ml of medium into two 
tubes. The cells in one tube were loaded with 1 µM of WHcAg-specific epitope     
c13-21 (YQLLNFLPL) for 2 h at 37oC and afterwards stained with 36 nM CFSE 
(carboxyfluorescein succinimidyl ester) dye for 10 min at 37oC (target cells). The 
unloaded cells were stained with 9 nM CFSE, and served as a reference. The 
difference in the CFSE concentration allows to distinguish between the target and 
reference cell populations as well as the recipient cells during the FACS analysis. 
Peptide loaded and unloaded cells were counted using Trypan blue exclusion 
microscopy and suspended in sterile PBS in 1:1 ratio. Cells (2×107 of each 
population per mouse) were injected intravenously into immunized mice and naïve 
mice as a reference. After 8 hours, recipient mice were sacrificed and single-cell 
suspensions of the splenocytes were prepared (section 4.5). Up to 1×108 cells were 
suspended in 500 µl of FACS buffer and analyzed by flow cytometry. The percent 
killing was calculated as follows:  
 
 
 
4.12 Detection of WHV-specific antibodies in mouse and woodchuck 
serum 
WHV-specific antibodies were detected by enzyme-linked immunosorbent assay 
(ELISA). For that, 96-well immunoplates (NUNC) were coated with 10 µg/ml of 
WHcAg or 0,2 µg/ml of WHsAg diluted in carbonate buffer (50 µl of the antigen 
solution per well) and incubated for 1 h at 37oC. Plates were washed four times with 
200 µl of T-PBS. Unspecific binding of the serum components was avoided by 
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blocking with 5%FCS in PBS. Plates were incubated for 1 h at 37oC and afterwards 
washed four times with 200 µl of T-PBS. Murine sera were diluted 1:250; 1:1000 or 
1:5000 in 100 µl PBS and incubated on the plates for 1 h at 37oC. Alternatively, 
woodchuck sera were diluted 1:10 in 100 µl PBS. Plates were incubated for 1 h at 
37oC and afterwards washed four times with 200 µl of T-PBS. Detection of the murine 
WHV-specific IgG, IgG1 or IgG2a antibodies was performed using peroxidase-
conjugated anti-mouse IgG, IgG1 or IgG2a secondary antibodies diluted 1:1000 in 
100 µl of PBS per well, respectively. Woodchuck WHcAg- or WHsAg-specific 
antibodies were detected using peroxidase-conjugated protein G diluted 1:500 in 
100 µl of PBS per well. Plates were incubated for 1 h at 37oC and washed four times 
with 200 µl of T-PBS. After the final washing step, 100 µl of OPD substrate solution 
was added to each well. The plates were incubated in the dark for 15 min and the 
reaction was stopped by adding 100 µl of Stop solution (concentrated H2SO4). Finally 
the OD490nm was measured using an Elisa Reader. 
 
4.13 Detection of WHV DNA in the serum 
4.13.1 Extraction of WHV DNA from the serum 
Viral DNA from serum samples obtained from woodchucks and 1217 WHV Tg mice 
was extracted using QIAamp DNA Mini Kit (Qiagen) according to the manufacturer’s 
protocol. Extraction was performed on 100 µl serum samples from woodchucks and 
50-200 µl serum samples for 1217 WHV Tg mice. 
4.13.2 Detection of WHV DNA in the serum by standard PCR 
WHV DNA was detected by PCR using GoTaq polymerase (Promega) and the WHc-
specific primers wc1 and wc2 (Materials section, Tab. 3.5). The compounds of the 
reaction mixture are presented in table 4.9. Conditions of the PCR reaction were as 
described previously (Tab. 4.2). The annealing of the primers was carried out at 
50oC. 
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Tab. 4.9 The reaction mixture of WHV standard PCR 
Reagent Concentration Volume [µl] 
5x Reaction Buffer with MgCl2 1× 10 
dNTP-Mix 0,2 mM 1 
wc1 / wc2 primers 1 µM each: 5 
GoTaq Polymerase 0,5 U 0,25 
H2O - 23,75 
DNA - 5 
  total: 50 
 
4.13.3 Quantification of WHV DNA in the serum 
WHV DNA was quantified by real-time PCR using a LightCycler 2.0 (Roche). The 
reaction was prepared using Platinum SYBR Green Kit (Invitrogen) and the WHc-
specific primers wc1 and wc149s (Materials section, Tab. 3.5). The compounds of the 
reaction mixture and the PCR reaction conditions are presented in tables 4.10 and 
4.11, respectively. 
 
Tab. 4.10 The reaction mixture of WHV real-time PCR 
Reagent Concentration Volume [µl] 
Mastermix with MgCl2 1× 10 
MgCl2  total: 5 mM 0,8 
BSA (10×) 1× 1 
wc1 / wc149s primers 32 nM each: 0,4 
H2O - 5,4 
DNA - 2 
  total: 20 
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Tab. 4.11 The PCR conditions of WHV real-time PCR 
PCR step Temperature [oC] Time [s] Temperature 
changing rate [oC/s] 
Number of 
cycles 
Denaturation 50 
95 
120 
120 
20 
20 1 
PCR 
94 
60 
72 
15 
30 
10 
20 
20 
2 
40 
Melting curve 
95 
63 
95 
0 
15 
0 
20 
20 
0,1 
1 
 
Quantification of the CT values and WHV copy number per reaction (according to the 
standard curve) was performed using LightCycler Software 3.5.3. A plasmid 
containing a full-length WHV genome served as a standard. The quantification of the 
viral load (WHV GE per ml of serum) was performed according to the formula: 
 
 
 
The detection limit of this assay is 103 WHV GE per ml of serum. 
4.13.4 Detection of WHV DNA in the serum by a dot blot technique 
The woodchuck sera (volume 5 µl) were spotted on Hybond-N+ nylon membrane. 
Serial dilutions of DNA sample with a known concentration were used as a standard 
(106 to 109 GE/ml). After drying, the DNA on the membrane was denaturated and 
fixed by incubation in denaturation, neutralization and 20× SSPE buffers (each 
10 min, shaking) and UV crosslinking (150 J/cm2). The WHV DNA was detected by 
hybridization with [32P]-labelled plasmid containing the entire WHV strain 8 genome 
as a probe. The radioactive labelling of the probe was performed using DecaLabel 
DNA Labelling Kit (Fermentas), 50 ng of plasmid and [32P]-dCTPs, according to the 
manufacturer’s protocol. The probe was purified using MicroSpin columns and mixed 
with 100 µl of 10 mg/ml sonicated salmon sperm DNA. The membrane was 
incubated overnight at 65oC with [32P]-labelled probe in RapidHyb Buffer (GE 
Healthcare). The membrane was washed twice for 15 min at room temperature with 
washing buffer I, once for 20 min at 65oC with washing buffer II (Materials, section 
3.10) and left to dry. The membrane was exposed overnight on the phospho-screen 
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and the image was acquired using Cyclone phospho-imager. The detection limit of 
this assay is approximately 5×107 WHV GE per ml of serum. 
4.14 Detection of WHV replication in the liver 
4.14.1 Extraction of DNA 
Viral DNA from the woodchucks’ liver samples was extracted using QIAamp DNA 
Mini Kit (Qiagen) according to the manufacturer’s protocol. Liver samples were 
homogenized in liquid nitrogen and extraction was performed from approximately 
50 mg of the tissue (2 columns per sample). The DNA concentration was quantified 
by spectrophotometric OD260nm measurement (section 4.1.8). 
4.14.2 Southern blot 
Approximately 10 µg of the DNA samples was separated by agarose gel 
electrophoresis. Next, the DNA was denaturated by incubation in: 0,25 M HCl, 
denaturation and neutralization buffers (each 30 min, shaking). The DNA was 
transferred to Hybond-N+ nylon membrane using Vaccum blotter 785 (BioRad) by 
13 Hg pressure for 2 h in 20× SSC buffer and afterwards fixed by UV crosslinking 
(150 J/cm2). The WHV DNA was detected by hybridization with [32P]-labelled plasmid 
containing the entire WHV strain 8 genome as a probe as described in section 
4.13.4. 
 
4.15 Evaluation of serum GOT levels 
The glutamic oxaloacetic transaminase (GOT; also known as aspartate 
transaminase, AST) levels in the woodchuck sera were quantified using the standard 
diagnostic procedure at Zentrallabor (Universitätsklinikum Essen). 
 
4.16 Statistical analysis 
Statistical analyses were performed using Graph Pad Prism software version 5. 
Statistical differences (p-value) were analyzed by unpaired Student t test and 
Wilcoxon signed rank test. The p-values < 0,05 were considered significant. 
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5 Results 
5.1 Identification of CD8+ epitopes of WHcAg in C57BL/6 mice 
The scope of this work was to choose, improve and optimize the best vaccination 
strategy to induce a potent T cell response in chronically WHV infected woodchucks. 
To this purpose, vaccines expressing WHcAg were used. The various immunization 
protocols of preliminary experiments were performed in C57BL/6 mice in order to 
obtain the effective and economically beneficial model. Before analyzing the CD8+ 
T cell response, knowledge about CD8+ T cell epitopes in the antigen is required to 
prove the effectiveness of any immunization strategy. The first step was to 
characterize H-2b-restricted epitopes within the WHcAg since they had not been 
identified yet. 
For this purpose, C57BL/6 mice were immunized two or three times with plasmid 
DNA vaccines encoding complete WHcAg sequence and sacrificed two weeks after 
the last immunization. Isolated splenocytes were stimulated in vitro in the presence of 
6 peptide pools, containing 6 overlapping by 10 amino acid residues 15-mer synthetic 
peptides, spanning the whole WHcAg sequence of WHV strain 8 (Fig. 5.1). After 
7 days of culture, cells were restimulated for 6h and intracellular staining for IFNγ 
was performed as mentioned in the Methods section (4.9.1). 
 
Fig. 5.1 Schematic illustration of WHcAg peptide pools used for stimulation of 
murine splenocytes 
Thirty-six synthetic peptides covering the sequence of the WHcAg of WHV strain 8 were 
merged into six pools containing six peptides each. 
 
 
Detection of intracellular IFNγ in splenocytes from C57BL/6 mice stimulated with 
WHcAg-derived peptide pools demonstrated CD8+ T cell response directed against 
pool 1, containing peptides 1-6 (covering aa 1 to 40 of WHcAg) and pool 3, 
containing peptides 13-18 (aa: 61-100), as shown in Fig. 5.2. 
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A. Representative dotplots of splenocytes from C57BL/6 mouse immunized 3 times with 
DNA plasmid expressing WHcAg. Cells were expanded in vitro for 7 days in the presence 
of 6 WHcAg-derived peptide pools. CD8+ T cell response was evaluated by intracellular 
IFNγ staining. Presented values indicate the percentage of IFNγ+ CD8+ T cells in the 
CD8+ T cell population. Unstimulated cells and cells stimulated with unrelated CMV-
derived peptide served as negative controls. 
B. CD8+ T cell response in murine splenocytes stimulated with WHcAg-derived peptide 
pools. Bars represent the mean value obtained from ten DNA-immunized C57BL/6 mice 
including SEM (standard error of the mean). The statistical analysis between the groups 
was performed using the unpaired Student t test. Asterisks mark the significant difference 
(*** < 0,0005)
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Fig. 5.2 Determination of CD8+ T cell responses in mouse splenocytes after 
stimulation with WHcAg-derived peptide pools 
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The percentages of IFNγ+ CD8+ T cells detected in ten mice after stimulation with 
WHcAg-derived peptide pool 1 and 3 ranged between 5,7% – 17,9% (mean: 9,0%) 
and 4,0% – 27,3% (mean: 12,6%), respectively. CD8+ T cell response detected 
against peptide pool 1 and 3 were significantly higher than the background values of 
0,2% - 1,2% in unstimulated controls (P < 0,0005). Stimulation of splenocytes with 
WHcAg-derived peptide pools 2, 4, 5 and 6 did not lead to significant responses as 
compared to negative controls (Fig. 5.2B). 
For identification of CD8+ T cell epitopes within positive WHcAg-derived pools, 
splenocytes from DNA–immunized C57BL/6 mice were stimulated for 7 days with 12 
individual 15-mer peptides contained by pools 1 and 3. Stimulation of splenocytes 
with WHcAg-derived peptides 1 to 6 (p1-p6, pool 1) showed that peptides 
accountable for the IFNγ response detected in pool 1 are peptides 2 (c6-20) and 3 
(c11-25). Stimulation with the other peptides of this pool (c1-15 and c16-30 to c26-
40) induced no response (Fig. 5.3A). In contrast, stimulation with individual peptides 
from WHcAg-derived peptide pool 3 (peptides 13 to 18) pointed to only one positive 
peptide – peptide 18 (c86-100) - whereas other peptides (c61-75 to c81-95) 
remained negative after 7 days of stimulation (Fig. 5.3B). As shown in Fig. 5.4, the 
mean frequency of IFNγ+ CD8+ T cells in the CD8+ T cell population as measured in 
splenocytes of ten DNA–immunized mice was the highest after stimulation with 
peptide 2 (c6-20): 29,1%. The mean response detected for stimulation with peptide 3 
(c11-25) was 8,9% and for peptide 18 (c86-100) 16,8%. CD8+ T cell response 
detected against peptides 2, 3 and 18 were significantly higher than the background 
values in negative controls (P < 0,0005). 
It is known that murine MHC class I molecules bind peptides that are from 8 to 9 
amino acid long [Falk et al., 1991]. In these experiments 15-mer peptides which are 
overlapped by 10 aa residues were used for stimulation of splenocytes. Thus, the 
obtained results indicated the presence of two H-2b-restricted epitopes within 
WHcAg: firstly within the overlapping sequence of peptides 2 and 3 (aa 6 to 25), and 
secondly within the sequence covered by peptide 18 (aa 86 to 100). To test this 
hypothesis splenocytes of mice that had been immunized with DNA plasmid 
encoding WHcAg, were stimulated for 7 days with peptide 2 or 18 and then 
restimulated for 6h with shorter, overlapping by 8aa residues 9-mer peptides covering 
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the sequence of WHcAg from aa 7 to 22 and 86 to 100, as described in the Methods 
section (4.6.1 and 4.6.2). 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
Splenocytes were expanded in vitro for 7 days in the presence of 12 individual peptides from 
positive WHcAg-derived pools 1 and 3. CD8+ T cell response was evaluated by intracellular 
IFNγ staining. Presented values indicate the percentage of IFNγ+ CD8+ T cells in the CD8+ 
T cell population.  
A. Representative dotplots of splenocytes stimulated with individual peptides 1 to 6 (p1-p6) 
from pool 1 (c1-15 to c26-40).  
B. Representative dotplots of splenocytes stimulated with individual peptides 13 to 18 (p13-
p18) from pool 3 (c61-75 to c86-100). 
Fig. 5.3 Representative dotplots of mouse splenocytes after stimulation with 
individual peptides from WHcAg – derived pools 1 and 3 
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Fig. 5.4 CD8+ T cell response in mouse splenocytes after stimulation with 
individual peptides from WHcAg – derived pools 1 and 3 
Splenocytes from C57BL/6 mice immunized with DNA plasmid expressing WHcAg were 
expanded in vitro for 7 days in the presence of 12 individual peptides from positive WHcAg-
derived pools 1 and 3. Unstimulated cells and cells stimulated with unrelated CMV-derived 
peptide served as negative controls. The bars represent the mean value obtained from ten 
DNA-immunized mice including SEM. The statistical analysis was performed using the 
unpaired Student t test. Asterisks mark the significant difference (*** < 0,0005). 
 
 
Restimulation of splenocytes with 9-mer peptides covering the sequence of WHcAg 
from aa 7 to 22, previously expanded for 7 days in vitro in the presence of peptide 2, 
allowed to identify H-2b-restricted epitope (Fig. 5.5A). All ten analysed mice showed a 
robust IFNγ response after restimulation with peptide c13-21 (aa sequence: 
YQLLNFLPL), ranging from 14,5% to 57,5% (mean: 33%) of IFNγ+ CD8+ T cells. This 
result is significantly higher than the background of 0,2% - 1,5% detected in not-
restimulated controls (P < 0,0005). Restimulation of the splenocytes with other tested 
9-mer peptides (c7-15 to c12-20 and c14-22) induced no IFNγ response (Fig. 5.5B). 
Screening with 9-mer peptides covering the sequence of WHcAg from aa 86 to 100, 
after culturing of splenocytes with p18, pointed out the peptide c86-100 (aa 
sequence: VNHVNDTWG) to be the second CD8+ T cell epitope within WHcAg 
(Fig. 5.6A). The percentages of IFNγ+ CD8+ T cells detected in seven responding 
mice after stimulation with c86-94 ranged between 10,0% - 74,3% (mean: 28%). As 
Fig. 5.6B shows, there was an increased background of IFNγ+ CD8+ T cells in the 
not-restimulated control (mean 3,9%), as well as in other 9-mer peptides (mean 3,6% 
- 4,4%). Nevertheless, CD8+ T cell response detected against c86-94 was 
significantly higher than the background values (P < 0,005). 
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Fig. 5.5 Finemapping of CD8+ T cell epitope within WHcAg sequence aa 7-22  
A. Representative dotplots of splenocytes from C57BL/6 mouse immunized with DNA 
plasmid expressing WHcAg. Cells were expanded in vitro for 7 days in the presence of 
peptide 2 and then restimulated for 6h with eight overlapping 9-mer peptides covering the 
sequence of WHcAg from aa 7 to 22. CD8+ T cell response was evaluated by intracellular 
IFNγ staining. Presented values indicate the percentage of IFNγ+ CD8+ T cells in the 
CD8+ T cell population. Not-restimulated cells served as a negative control. 
B. CD8+ T cell response in murine splenocytes restimulated with 9-mers covering the 
sequence of WHcAg from aa 7 to 22. Bars represent the mean value obtained from ten 
DNA-immunized C57BL/6 mice including SEM. The statistical analysis between the 
groups was performed using the unpaired Student t test. Asterisks mark the significant 
difference (*** < 0,0005). 
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Fig. 5.6 Finemapping of CD8+ T cell epitope within WHcAg sequence aa 86-100 
A. Representative dotplots of splenocytes from C57BL/6 mouse immunized with DNA 
plasmid expressing WHcAg. Cells were expanded in vitro for 7 days in the presence of 
peptide 18 and then restimulated for 6h with seven overlapping 9-mer peptides covering 
the sequence of WHcAg from aa 86 to 100. CD8+ T cell response was evaluated by 
intracellular IFNγ staining. Presented values indicate the percentage of IFNγ+ CD8+ 
T cells in the CD8+ T cell population. Not-restimulated cells served as a negative control. 
B. CD8+ T cell response in murine splenocytes restimulated with 9-mers covering WHcAg 
sequence from aa 86 to 100. Bars represent the mean value obtained from seven 
responding DNA-immunized mice including SEM. The statistical analysis between the 
groups was performed using the unpaired Student t test. Asterisks mark the significant 
difference (** < 0,005). 
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The position of the identified CD8+ T cell epitopes in C57BL/6 mice (haplotype H-2b) 
within WHcAg sequence is schematically illustrated in Fig. 5.7. 
 
 
Fig. 5.7 The position of H-2b restricted CD8+ T cell epitopes within WHcAg 
C57BL/6 mice were immunized with WHcAg-expressing plasmid. Two weeks after the last 
immunization CD8+ T cell response was evaluated by intracellular IFNγ staining. At the 
beginning, the splenocytes were stimulated in vitro for 7 days with 6 pools containing 6 
overlapping 15-mer peptides covering the sequence of the whole WHcAg. The positions of 
positive pools 1 (aa 1-40) and 3 (aa 61-100) are marked schematically as orange boxes on 
the WHcAg sequence. Stimulation of the splenocytes with individual peptides from pool 1 
and 3 determined the 15-mer epitopes’ sequences: peptides c6-20 and c11-25 within pool 1 
and peptide c86-94 within pool 3 (marked as grey boxes). Finemapping with overlapping 9-
mer peptides pointed out the exact epitopes’ positions: c13-21 and c86-94 (aa sequences 
are given in blue boxes). Amino acid sequences of all peptides which were used for 
splenocytes stimulation are presented in the Appendix (Tab. 10.1 and Tab. 10.2). 
 
In silico prediction of MHC class I-restricted epitopes of WHcAg for D and K loci of 
the mouse haplotype H-2b was performed by using two independent algorithms: 
SYFPEITHI [Rammensee et al., 1999; http://www.syfpeithi.de/] and Bioinformatics 
and Molecular Analysis Section (BIMAS) MHC peptide binding prediction programme 
[Parker et al., 1994; http://bimas.cit.nih.gov/molbio/hla_bind/]. 
The list of the 8-10 aa in length peptides that obtained the highest scores is 
presented in table 5.1. Both algorithms assigned the best score for H2-Db–restricted 
nonamer c13-21. This outcome correlated with the results of in vivo studies, as the 
peptide c13-21 was identified as the CD8+ epitope within the WHcAg in C57BL/6 
mice. The second in vivo identified peptide c86-94 obtained the best score as        
H2-Db–restricted decamer (c86-95) by SYFPEITHI algorithm. On the contrary, the 
BIMAS programme indicated peptide c23-32 as the second best H2-Db–restricted 
decamer (after c12-21) and assigned the c86-95 a low score. The prediction of      
H2-Kb–restricted peptides typed a CD8+ H2-Kb–restricted epitope sequence between 
7th and 16th aminoacid of WHcAg. However, in vivo experiments with nonamers c7-15 
or c8-16 did not result in the detection of the WHcAg-specific CD8+ T cell response in 
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murine splenocytes after stimulation with those peptides. Correlation between the 
results obtained in mice and in silico confirm the usefulness of MHC class I epitope 
prediction softwares in the identification of epitopes. 
 
Tab. 5.1 The list of WHcAg predicted CD8+ epitopes for C57BL/6 mice 
(haplotype H-2b) using SYFPEITHI and BIMAS algorithms with scores 
Position Length Sequence Score 
H-2b 
restriction 
Programme 
13-21 9 Y Q L L N F L P L 24 Db 
86-95 10 V N H V N D T W G L 23 Db 
9-16 8 F G S S Y Q L L 21 Kb 
SYFPEITHI 
13-21 9 Y Q L L N F L P L 720.000 Db 
23-32 10 F F P D l N A L V D 33.000 Db 
86-95 10 V N H V N D T W G L 2.640 Db 
8-16 9 E F G S S Y Q L L 24.000 Kb 
7-16 10 K E F G S S Y Q L L 48.000 Kb 
BIMAS 
 
 
5.2 Construction of a DNA vaccine with optimized expression of WHcAg 
Several studies indicate that protein expression levels can be increased by the 
insertion of an intron sequences into the expression vectors [Hermering et al., 2004; 
Sakurai et al., 2004; Li et al., 2005]. The presence of an intron sequence protects 
mRNA molecules from degradation and facilitates their export into the cytoplasm 
[Kurachi et al., 1995; Luo et al., 1999]. Those factors result in a more efficient 
translation process and, as a consequence, increased gene expression. The 
improvement in the antigen expression may lead to a better presentation of the 
antigen and induction of a more robust and multifunctional immune response in vivo. 
To test this hypothesis a novel DNA plasmid (pCGWHc), encoding a β-globin intron 
sequence between the CMV promoter and WHcAg gene was constructed. The WHV 
strain 8 core protein gene was obtained from WHcAg-encoding pWHcIm plasmid. 
The pWHcIm plasmid was previously used as a DNA vaccine and proved to induce 
anti-WHc antibodies in mice [Lu et al., 1999]. Moreover, it provided protection against 
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infection after WHV challenge in woodchucks [Lu et al., 1999] and was investigated 
as a therapeutic vaccine in WHV chronic carriers [Lu et al., 2008]. 
WHcAg insert was cut out of the pWHcIm plasmid by using BamHI and XbaI 
restriction enzymes and then introduced into BamHI/XbaI site of pCG vector 
(Fig. 5.8A). The successful insertion of WHcAg into pCG plasmid was proved by 
BamHI/XbaI restriction digestion. The characteristic band of 675 bp, corresponding to 
WHcAg insert, was visualized on the agarose gel (Fig. 5.8B). Additionally, the 
sequence of pCGWHc plasmid was verified by DNA sequencing. The map of the 
pCGWHc plasmid is attached in the Appendix section (Fig. 10.2). 
 
 
Fig. 5.8 Scheme of the cloning strategy of pCGWHc plasmid (A). Control 
restriction digestion of pCGWHc (B) 
1 µg of DNA was digested with BamHI and XbaI restriction enzymes for 1h in 37oC and 
visualized on 1,5% agarose gel containing 0.5 µg/ml ethidium bromide. The arrow indicates a 
band of 675 bp corresponding to WHcAg insert. 
 
 
To confirm the expression of WHcAg by the pCGWHc plasmid, BHK cells were 
transiently transfected with pCGWHc and pWHcIm, that lacks the β-globin intron 
sequence, as a control. The levels of the protein expression were compared by 
indirect immunofluorescence staining and Western blot analysis, using WHcAg-
specific antibodies 24h after transfection, as mentioned in the Methods section 
(4.3.1). To estimate the variation in the total protein content of the cell lysates, the 
control β-actin immunoblotting was performed. 
In vitro transfection studies confirmed an increased WHcAg expression by the novel 
pCGWHc plasmid, containing the β-globin intron in the expression cassette. The 
indirect immunofluorescence staining demonstrated a strong WHcAg-specific signal 
in BHK cells transfected with pCGWHc, in comparison to a poor level of the protein in 
A B 
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pWHcIm-transfected cells (Fig. 5.9A). No WHcAg-specific immunofluorescence 
staining was observed in mock cells treated with the transfection reagent only. 
Comparable results were obtained by the Western blot analysis. The level of WHcAg 
in cells transfected with pCGWHc was significantly higher, than in those transfected 
with pWHcIm. No significant difference in β-actin levels between the lysates was 
observed (Fig. 5.9B). 
 
 
 
 
Fig. 5.9 Expression of WHcAg in BHK cells 24 h after transfection with pWHcIm 
and pCGWHc 
A.  BHK cells were transfected with 0,5 µg of plasmids using Effectene reagent. Cells were 
fixed with methanol and WHcAg was detected by indirect immunofluorescence staining with 
WHcAg-specific polyclonal rabbit antibody and a secondary FITC-coupled antibody.  
B. BHK cells were transfected with 1 µg of plasmids using Lipofectamine reagent. Cell 
lysates were separated by SDS-PAGE and transferred to a PVDF-membrane. Detection was 
done with the WHcAg-specific mouse monoclonal antibody 6C5C8E4 or β-actin-specifc 
antibody and a secondary antibody coupled to peroxidase. 
 
5.3 Improved WHcAg expression from pCGWHc plasmid induces 
stronger immune response in vivo 
The expression level of WHcAg from novel pCGWHc plasmid proved to be 
significantly higher in comparison to pWHcIm plasmid that does not contain β-globin 
intron. To determine whether the improvement in the antigen expression may induce 
a more vigorous T cell response in vivo, a series of immunization with both plasmids 
were performed in mice (as described in detail in the Methods section 4.4.3.1). As 
A    
B 
 mock            pWHcIm       pCGWHc 
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shown in Fig. 5.10, C57BL/6 mice were pretreated with cardiotoxin and one week 
later subsequently immunized for three times with pCGWHc or pWHcIm plasmids. 
Mice injected intramuscularly with PBS served as controls. Immunizations were 
performed in two week intervals. Two weeks after the last immunization the mice 
were sacrificed and splenectomy was performed.  
 
 
Fig. 5.10 Schedule of pCGWHc and pWHcIm immunization of C57BL/6 mice 
Ten weeks old female C57BL/6 mice were pretreated with cardiotoxin (grey arrow) and one 
week later immunized subsequently 3 times with 100µg WHcAg-expressing plasmids 
intramuscularly in two weeks intervals (week 0, 2 and 4; indicated by red arrows). Six mice 
received pWHcIm plasmid, seven – pCGWHc plasmid and four mice were injected 
intramuscularly with 100µl of PBS and served as controls. Blood withdrawing was performed 
two weeks after each immunization (week 2, 4 and 6). Two weeks after the last immunization 
the mice were sacrificed and splenectomy was performed. 
 
5.3.1 Evaluation of the humoral immune response 
The improvement of immunization using the new construct was evaluated by 
detection of WHcAg-specific IgG antibodies (anti-WHc) in the serum of mice two 
weeks after each immunization by ELISA, as described in the Methods section 
(4.12). Evaluation of humoral immune response in mice showed that immunization 
with pCGWHc plasmid (high WHcAg expression) had induced significantly higher 
levels of anti-WHc than immunization with pWHcIm (low WHcAg expression). As 
shown in Fig. 5.11, single immunization with WHcAg-expressing DNA vaccines 
induced detectable amounts of WHcAg-specific IgG antibodies. The levels of anti-
WHc increased significantly with the subsequent administration of the plasmids in 
both groups of mice (P < 0,0005). As expected, sera from mice injected with PBS 
solution as a control remained anti-WHc negative. Comparison of the antibodies 
levels between the groups of mice vaccinated with high-level expression plasmid 
pCGWHc and pWHcIm, just after one immunization, showed that pCGWHc 
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vaccination was able to induce anti-WHc more efficiently in vivo. The magnitude of 
humoral response induced by immunization with the pCGWHc plasmid was 
significantly higher (P < 0,0005) at every analysed time point, as compared to 
pWHcIm-vaccinated mice. 
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Fig. 5.11 Detection of WHcAg-specifc IgG antibodies in the sera of C57BL/6 
mice after pCGWHc and pWHcIm immunization 
Ten weeks old female C57BL/6 mice were immunized 3 times intramuscularly with 100µg of 
pWHcIm or pCGWHc plasmid at two week intervals. Four mice were injected intramuscularly 
with 100µl of PBS and served as controls. Sera of mice were obtained from blood samples 
collected two weeks after each immunization and diluted 1:1000 in PBS. WHcAg-specific 
ELISA was peformed using anti-mouse IgG antibody coupled to peroxidase. The statistical 
analysis between the groups was performed using the unpaired Student t test. Asterisks 
mark the significant difference (*** < 0,0005). 
 
Isotype of IgG antibodies secreted by antigen-specific B cells can be regulated by 
subsets of CD4+ helper T cells (TH). Antigen-specific TH1 cells that produce IFNγ, 
TNFα and IL-2 enhance the secretion of IgG2a, whereas IL-4-producing TH2 cells 
induce B cells to secrete IgG1 [Stevens et al., 1988]. It is known, that intramuscular 
immunization with DNA plasmids predominantly induce TH1 type of immune response 
[Siegel et al., 2001]. To examine the breadth of the immune response induced by 
immunization with the novel pCGWHc and pWHcIm plasmids, the IgG1 and IgG2a 
isotypes of WHcAg-specific antibodies were analyzed in murine sera by ELISA.  
As shown in Fig. 5.12, vaccinations with both plasmids expressing WHcAg induced 
predominantly IgG2a isotype of anti-WHc from antigen-specific B cells. Already one 
immunization with pCGWHc induced detectable amounts of IgG2a (P < 0,0005). By 
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contrast, the sera of mice immunized once with pWHcIm remained IgG2a negative, 
demonstrating a similar quantity of WHcAg-specific IgG2a as the PBS control group 
(Fig. 5.12A). The levels of IgG2a was significantly higher in the group of mice 
immunized with pCGWHc as compared to the pWHcIm group after each 
immunization (P < 0,0005). 
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Fig. 5.12 Detection of WHcAg-specifc IgG isotypes: IgG2a (A) and IgG1 (B), in 
the sera of C57BL/6 mice after pCGWHc and pWHcIm immunization 
Sera of mice were obtained from blood samples collected two weeks after each 
immunization and diluted 1:1000 in PBS. WHcAg-specific ELISA was performed using IgG 
isotype-specific (IgG2a or IgG1) anti-mouse antibodies coupled to peroxidase. The statistical 
analysis between the groups was performed using the unpaired Student t test. Asterisks 
mark the significant difference (** < 0,005; *** < 0,0005). 
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Detection of IgG1 demonstrated that vaccination with pCGWHc is able to induce IgG1 
isotype of anti-WHc, however only at a low level (Fig. 5.12B). This result indicates 
that pCGWHc immunization induces a very strong and broad TH1 type of response. 
The levels of IgG1 detected in the sera of mice after three immunizations with 
pCGWHc were significantly higher than background levels detectable in the sera 
from pWHcIm-immunized mice and PBS-injected mice (P < 0,005). 
Detection of low level of IgG1 accompanied by a high level of IgG2a antibodies 
indicates that pCGWHc immunization induces a robust TH1 type of response, more 
vigorous than immunization with the pWHcIm plasmid. 
5.3.2 Evaluation of the CD8+ T cell response 
Evaluation of WHcAg-specific CD8+ T cell response induced in C57BL/6 mice by 
vaccination with pCGWHc or pWHcIm plasmid, was performed by intracellular IFNγ 
staining of splenocytes isolated two weeks after the third immunization. Splenocytes 
were stimulated in vitro in the presence of two previously identified CD8+ T cell 
epitopes: c6-20 and c86-100. After 7 days of culturing, cells were restimulated for 6h 
with corresponding peptides and stained for IFNγ as mentioned in the Methods 
section (4.9.1). Splenocytes obtained from mice injected with PBS served as 
controls. 
The percentages of IFNγ+ CD8+ T cells detected in the spleens of mice vaccinated 
with pCGWHc plasmid were considerably higher compared to those detected in the 
pWHcIm-immunized group (Fig. 5.13). IFNγ response after stimulation of splenocytes 
with WHcAg-derived 15-mer peptide c6-20 ranged between 43,4% – 74,2% (mean 
57,4%) of IFNγ+ CD8+ T cells and 9,5% – 65,1% (mean 29,5%) in the pWHcIm group 
(Fig. 5.13B). The difference in the detected responses was statistically significant 
(P < 0,005). In addition, the mean percentage of IFNγ+ CD8+ T cells directed against 
peptide c86-100 in the pCGWHc-immunized group of mice was significantly higher 
(37,7%) than the value of 10,8% assessed for the pWHcIm group (P < 0,0005). 
Stimulation of splenocytes obtained from PBS-injected mice with the peptides c6-20 
and c86-100 induced no IFNγ response. The responses to stimulation with WHcAg-
derived epitopes measured in both plasmid-immunized groups of mice were 
significantly higher than the background values of 0,1% - 1,2% of IFNγ+ CD8+ T cells 
detected in PBS group (P < 0,05). No statistically significant difference between all 
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analysed groups of mice was demonstrated in unstimulated and unrelated peptide 
controls, proving that the detected positive IFNγ responses were WHcAg-specific. 
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Fig. 5.13 Comparison of the magnitude of CD8+ T cell responses induced by 
immunization with the novel pCGWHc and pWHcIm plasmids 
Splenocytes were expanded in vitro for 7 days in the presence of two identified CD8+ T cell 
epitopes: c13-21 and c86-94 and stained for intracellular IFNγ.  
A. Dotplots of splenocytes stimulated with c6-20 (upper panel) and c86-100 (lower panel) of 
representative mouse from the pCGWHc, pWHcIm, and PBS control groups. Presented 
values indicate the percentage of IFNγ+ CD8+ T cells in the CD8+ T cell population. 
B. CD8+ T cell response in murine splenocytes with c6-20 and c86-100. Unstimulated cells 
and cells stimulated with unrelated CMV-derived peptide served as controls. The bars 
represent the mean value obtained for each group of mice including SEM. The statistical 
analysis between the groups was performed using the unpaired Student t test. The 
asterisks shown directly above the bars mark the statistically significant difference 
between plasmid-vaccinated groups and control group: PBS-injected mice 
(* < 0,05;** < 0,005; *** < 0,0005; ns – not significant). 
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This experiment clearly demonstrates, that improved WHcAg expression from the 
novel pCGWHc plasmid results in the induction of a more vigorous humoral and 
cellular immune responses in vivo. 
5.4 Generation of recombinant adenoviral vectors serotype 5 (Ad5) and 
chimeric Ad5F35 (Ad35) with improved expression of WHcAg 
Vaccines based on recombinant adenoviruses are known to elicit vigorous and 
sustained humoral and cellular responses to the incorporated antigen [Tatsis et al., 
2004; Shiver et al., 2002; Zakhartchouk et al., 2005]. Nevertheless, recombinant 
adenoviruses are very immunogenic. Even single immunization may induce 
neutralizing antibodies to the vector and prevent the beneficial effect of additional 
administration of the vaccine. Thus, recombinant adenoviruses serotype 5 and 
chimeric Ad5 in which the fiber knob and shaft are replaced with those of Ad35 
(Ad5F35; named shortly Ad35) expressing WHcAg, were constructed. It is known, 
that the adenoviral hexon and the fiber protein contain most of the epitopes 
recognized by neutalizing antibodies. Apart from serotype-specific epitopes the 
hexon protein contains domains which are cross-reactive with all human serotypes 
[Norrby et al., 1970]. The epitopes localized on fiber proteins are predominantly 
group- and serotype-specific [Mei et al., 1993]. Therefore, subseqent immunization 
with chimeric Ad5, displaying the fiber from a distinct serotype Ad35, may partially 
overcome the presence of vector-specific immunity after vaccination with Ad5.  
Previous experiments demonstrated that the introduction of a β-globin intron 
sequence between the CMV promoter and the WHcAg gene results in improved 
antigen expression and leads to the induction of a more vigorous immune response 
in vivo (section 5.3). Therefore, the same strategy was used in the generation of the 
recombinant adenoviral vectors expressing WHcAg. 
The first step was to clone the gene of interest into a shuttle plasmid containing two 
“arms” of viral sequence for homologous recombination with the adenoviral backbone 
vectors. Generation of the AdV pShuttle plasmid expressing WHcAg was divided into 
two parts. First, the expression cassette containing the CMV immediate-early    
(CMV-IE) promoter, β-globin intron and polyadenylation signal was introduced into 
the multi cloning site (MCS) of pShuttle plasmid (Fig. 5.14A), and the DNA fragment 
encoding WHcAg was subcloned into the site between the β-globin intron and 
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polyadenylation signal (Fig. 5.14B), according to the protocols described in the 
Methods section. The expression cassette insert was amplified by PCR using pCG 
plasmid as a template and specific primers introducing KpnI/BglII restriction sites. 
The amplified fragment after restriction digestion with corresponding enzymes was 
cloned into MCS of pShuttle. The successful insertion of the expression cassette into 
pShuttle was proved by KpnI/BglII restriction digestion. The corresponding band of 
1815 bp was visualized on the agarose gel (Fig. 5.15A). The insert’s sequence of 
pCGWHc plasmid was verified by DNA sequencing. Secondly, the WHcAg sequence 
was amplified by PCR using the pWHcIm plasmid as a template. The specific primers 
used in the reaction included the sequence of XbaI and SbfI restriction enzymes. The 
insert was digested using XbaI and SbfI and then introduced into the XbaI/SbfI site 
located between the β-globin intron and polyadenylation signal of the expression 
cassette. The successful insertion of WHcAg into pShuttle/CG plasmid was proved 
by XbaI/SbfI restriction digestion. The characteristic band of 599 bp corresponding to 
the WHcAg insert was visualized on the agarose gel (Fig. 5.15B). The sequence of 
pShuttle/WHc plasmid was verified by DNA sequencing. The map of the 
pShuttle/WHc plasmid is attached in the Appendix section (Fig. 10.3). 
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Fig. 5.14 Scheme of the cloning strategy of AdV pShuttle plasmid encoding 
WHcAg 
A. Insertion of the expression cassette into pShuttle MCS. Insert was amplified by PCR 
using pCG plasmid as template and specific primers introducing KpnI/BglII restriction 
sites. The amplified fragment after restriction digestion with the corresponding enzymes 
was cloned into the MCS of pShuttle. LITR: left inverted terminal repeats. 
B. Subcloning of the WHcAg insert. WHcAg sequence was amplified by PCR using the 
pWHcIm plasmid as template and specific primers introducing the XbaI/SbfI restriction 
sites. The amplified fragment after restriction digestion with corresponding enzymes was 
cloned into the XbaI/SbfI site located between the β-globin intron and polyadenylation 
signal of the expression cassette. LITR: left inverted terminal repeats. 
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Fig. 5.15 Control restriction digestion of AdV pShuttle/WHc plasmid 
A. After insertion of expression cassette containing CMV-IE promoter, β-globin intron and 
polyadenylation signal. 1 µg of DNA was digested with KpnI and BglII restriction enzymes 
for 2h in 37oC and visualized on 1,0% agarose gel containing 0.5 µg/ml ethidium 
bromide. The arrow indicates a band of 1815 bp corresponding to expression casette 
insert. 
B. After insertion of the WHcAg sequence. 1 µg of DNA was digested with XbaI and SbfI 
restriction enzymes for 1h in 37oC and visualized on 1,5% agarose gel containing 0.5 
µg/ml ethidium bromide. The arrow indicates a band of 599 bp corresponding to the 
WHcAg insert. 
 
To show the expression of WHcAg from the pShuttle/WHc plasmid, BHK cells were 
transiently transfected with pShuttle/WHc containing the β-globin intron sequence 
and pShuttle that lacks β-globin intron as a control. The protein expression was 
detected 24 h after transfection by indirect immunofluorescence staining and Western 
blot analysis, using WHcAg-specific antibodies, as mentioned in the Methods section 
(4.3.1). To estimate the variation in the total protein content of the cell lysates, the 
control β-actin immunoblotting was performed. 
In vitro transfection studies demonstrated the successful cloning procedure – the 
WHcAg was expressed correctly by the AdV pShuttle/WHc plasmid. Moreover, the 
novel pShuttle plasmid containing the β-globin intron in the expression cassette, 
exhibited an increased WHcAg expression in comparison to the pShuttle plasmid that 
lacked the β-globin intron sequence. Both the indirect immunofluorescence staining 
(Fig. 5.16A) and Western blot analysis (Fig. 5.16B) of BHK cells transfected with 
pShuttle plasmids confirmed that result. No WHcAg-specific staining was observed in 
mock cells treated with the transfection reagent only. 
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Fig. 5.16 Expression of WHcAg in BHK cells 24 h after transfection with the 
pShuttle/WHc and the pShuttle that does not contain an intron 
BHK cells were transfected with 1 µg of plasmids, using Effectene reagent. 
A.  Cells were fixed with methanol and WHcAg was detected by indirect immunofluorescence 
staining with WHcAg-specific polyclonal rabbit antibody and a secondary FITC-coupled 
antibody.  
B. Cell lysates were separated by SDS-PAGE and transferred to a PVDF-membrane. 
Detection was done with the WHcAg-specific mouse monoclonal antibody 6C5C8E4 or        
β-actin-specifc antibody and a secondary antibody coupled to peroxidase. 
 
In the next step, recombinant adenoviral plasmids were generated by homologous 
recombination of PmeI-linerized pShuttle/WHc plasmid with E1 and E3-deleted 
pAdEasy-1 or pAdEasy-1/F35 backbone vectors in BJ5183 bacterial cells. The 
strategy of generating recombinant adenoviruses is described in the Methods section 
(1.2.7-1.2.9). Correct recombinants, containing pShuttle/WHc in the backbone, were 
propagated in the DH5α bacteria strain, purified and linerized with PacI. The maps of 
recombinant adenoviral plasmids expressing WHcAg: pAd5WHc and pAd5F35WHc 
are attached in the Appendix section (Fig. 10.4). Finally, recombinant adenoviral DNA 
was transfected into 293A cells that constitutively express E1 and E3 gene products. 
The vectors were amplified, purified and titrated by adenovirus plaque assay.  
Expression of WHcAg from recombinant adenoviral vectors was confirmed by 
Western Blot analysis of HEK-293A cell lysates 36 h post infection with Ad5WHc and 
Ad35WHc (Fig. 5.17). 
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Fig. 5.17 Expression of WHcAg in HEK-293A cells 36 h after infection with the 
recombinant adenoviral vectors: Ad5WHc and Ad35WHc 
HEK-293A cells were infected with 5×107 PFU of recombinant adenoviral vectors (MOI 10). 
Cell lysates were separated by SDS-PAGE and transferred to a PVDF-membrane. Detection 
was done with the WHcAg-specific mouse monoclonal antibody 10E11 or β-actin-specifc 
antibody and a secondary antibody coupled to peroxidase. 
 
5.5 DNA prime – AdV boost immunization elicits more robust and 
functional WHV-specific immune response than DNA immunization 
alone 
To investigate the potency of adenovirus-based vaccines to elicit a vigorous and 
multifunctional T cell response against WHcAg, immunization experiments in 
C57BL/6 mice were performed. It is widely known that recombinant adenoviruses are  
very immunogenic, inducing high levels of anti-AdV neutralizing antibodies. Even 
single immunization may induce neutralizing antibodies to the vector and thus 
prevent the beneficial effect of additional administration of the vaccine. To overcome 
this problem, mice were immunized in heterologous prime-boost regimen, using the 
plasmid DNA vaccine to prime the immune response. As shown in Fig. 5.18, 
C57BL/6 mice were pretreated with cardiotoxin. One week later they were 
subsequently immunized twice in a two-week interval with pCGWHc plasmid. Four 
weeks after the second DNA immunization, groups of mice were immunized with 
Ad5WHc or Ad35WHc or pCGWHc as a reference. As control, mice were immunized 
two times with “empty” pCG plasmid and boosted with Ad5 expressing green 
fluorescent protein (GFP). Two weeks after the last immunization the mice were 
sacrificed and splenectomy was performed. 
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Fig. 5.18 Schedule of heterologous prime-boost immunization in C57BL/6 mice 
Ten weeks old female C57BL/6 mice were pretreated with cardiotoxin (grey arrow) and one 
week later subsequently immunized 2 times with 100µg of pCGWHc plasmid intramuscularly 
in a two-week interval. At week 6 post first immunization, groups of seven mice were 
immunized with 2×109 PFU of Ad5WHc or Ad35WHc or 100µg pCGWHc. Immunization time 
points are indicated by red arrows. Five mice immunized with 100µg of “empty” pCG plasmid 
and 2×109 PFU Ad5 expressing GFP served as controls. Blood withdrawing was performed 
at the time point of each immunization (week 2, 6 and 8). Two weeks after the last round of 
immunization the mice were sacrificed and splenectomy was performed. 
 
5.5.1 Evaluation of the humoral immune response  
Evaluation of humoral immune response was performed by detection of WHcAg-
specific IgG antibodies in the serum of mice after each immunization by ELISA 
(Methods, section 4.12). As shown in Fig. 5.19, the levels of anti-WHc antibodies 
were comparable in all mice immunized with pCGWHc plasmids either once or twice. 
The levels of anti-WHc were significantly higher in comparison to the background 
values obtained from mice vaccinated with “empty” pCG plasmid: P < 0,05 and 
P < 0,0005 after one and two immunizations, respectively. The boosting 
immunization with both adenoviral vectors (Ad5WHc and Ad35WHc) led to the 
induction of higher levels of anti-WHc in comparison to the group of mice immunized 
just with pCGWHc plasmid (P < 0,05). There was no statistically significant difference 
between the levels of anti-WHc in the mice boosted with Ad5WHc or Ad35WHc. As 
expected, the immunization of control mice with Ad5GFP did not induce any anti-
WHc. 
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Mice were primed two times by immunization with the pCGWHc plasmid. Four weeks later, 
boosting immunization with Ad5WHc or Ad35WHc or pCGWHc for reference was performed. 
Mice immunized with “empty” pCG and Ad5GFP served as controls. The sera of mice were 
obtained from blood samples collected after each immunization and diluted 1:5000 in PBS. 
WHcAg-specific ELISA was peformed using an anti-mouse IgG antibody coupled to 
peroxidase. The statistical analysis between the groups was performed using the unpaired 
Student t test. Asterisks mark the significant difference (* < 0,05; ** < 0,005; *** < 0,0005). 
 
To evaluate the breadth of the immune response induced by the heterologous prime-
boost regimen, the IgG1 and IgG2a isotypes of WHcAg-specific antibodies were 
analyzed in murine sera by ELISA. Detection of IgG isotypes demonstrated that all 
tested immunization protocols induced predominantly IgG2a antibodies (Fig. 5.20A). 
Nevertheless, the levels of IgG2a were significantly higher in those groups of mice 
boosted with recombinant adenoviral vectors than in those immunized with the DNA 
vaccine pCGWHc plasmid (P < 0,005). The presence of WHcAg-specifc IgG1 
antibodies in murine sera detected after the last immunization was confirmed in DNA 
prime – AdV boost as well as in DNA only – vaccinated groups. The levels of IgG1 
were statistically significant in comparison to background values obtained from 
control mice: P < 0,05 and P < 0,005 for DNA only and DNA-AdV groups respectively 
(Fig. 5.20B). 
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Fig. 5.19 Detection of WHcAg-specifc IgG antibodies in the sera of C57BL/6 
mice immunized in heterologous prime-boost regimen, using pCGWHc 
plasmid and recombinant adenoviral vectors expressing WHcAg 
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The sera of mice were obtained from blood samples collected two weeks after each 
immunization and diluted 1:5000 in PBS. WHcAg-specific ELISA was peformed using IgG 
isotype-specific (IgG2a or IgG1) anti-mouse antibodies coupled to peroxidase. The statistical 
analysis between the groups was performed using the unpaired Student t test. Asterisks 
mark the significant difference (* < 0,05; ** < 0,005; *** < 0,0005). 
 
5.5.2 Evaluation of the CD8+ T cell response  
Comparison of WHcAg-specific CD8+ T cell responses induced by the heterologous 
DNA–Ad5WHc or DNA–Ad35WHc with DNA only immunization regimen was 
performed by the intracellular IFNγ staining of splenocytes isolated two weeks after 
the last immunization. Splenocytes were stimulated in vitro in the presence of two 
previously identified CD8+ T cell 9-mer epitopes: c13-21 and c86-94. After 7 days of 
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Fig. 5.20 Detection of WHcAg-specifc IgG isotypes: IgG2a (A) and IgG1 (B), in 
the sera of C57BL/6 mice immunized in the heterologous prime-boost regimen, 
using pCGWHc plasmid and recombinant adenoviral vectors expressing 
WHcAg 
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culturing, cells were restimulated for 6h with corresponding peptides and stained for 
IFNγ as mentioned in the Methods section 4.9.1. Splenocytes obtained from mice 
immunized with “empty” pCG plasmid and Ad5GFP served as controls. 
The percentages of IFNγ+ CD8+ T cells determined in the spleens of mice vaccinated 
in the DNA prime – AdV boost manner were considerably higher compared to those 
detected in the group of mice immunized only with DNA (Fig. 5.21). The mean IFNγ 
response after the stimulation of splenocytes with WHcAg-derived epitope c13-21 
were 21,9% for pCGWHc – immunized mice, 65,7% and 47% for pCGWHc-Ad5WHc 
and pCGWHc-Ad35WHc groups, respectively (Fig. 5.21B). Three-fold and over 2-fold 
increases in IFNγ producing CD8+ T cells were detected in the groups of mice 
immunized in DNA-AdV manner  compared to the DNA only – immunized group 
(P < 0,0005). The mean percentages of IFNγ+ CD8+ T cells directed against the 
peptide c86-94 were approximately 11,3% in pCGWHc - immunized group of mice 
and were significantly lower than the values 37,4% and 21,2% assessed for the 
pCGWHc-Ad5WHc and pCGWHc-Ad35WHc groups, respectively (P < 0,005). No 
statistically significant difference in IFNγ responses was obtained in comparison to 
the boosting effect of recombinant adenoviral vector serotype 5 to the chimeric 
Ad5F35 vector. Stimulation of splenocytes obtained from mice immunized with 
“empty” pCG plasmid and Ad5GFP with the peptides c13-21 and c86-94 induced no 
IFNγ response (0,1% to 0,3% of IFNγ+ CD8+ T cells). Comparison of the responses 
to stimulation with WHcAg-derived epitopes measured for groups immunized with 
WHcAg-expressing vaccines were significantly higher than those detected in control 
group (P < 0,0005). No statistically significant difference between all the analysed 
groups of mice was demonstrated in unstimulated and unrelated peptide controls. 
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Fig. 5.21 Comparison of the magnitude of CD8+ T cell responses induced by 
pCGWHc plasmid immunization and heterologous prime-boost regimen, using 
recombinant adenoviral vectors expressing WHcAg 
Splenocytes were expanded in vitro for 7 days in the presence of two identified CD8+ T cell 
epitopes: c13-21 and c86-94 and stained for intracellular IFNγ.  
A. Dotplots of the splenocytes stimulated with c13-21 (upper panel) and c86-94 (lower 
panel) of a representative mouse from each immunization group. 
B. CD8+ T cell response in murine splenocytes with c13-21 and c86-94. Unstimulated cells 
and cells stimulated with an unrelated CMV-derived peptide served as controls. The bars 
represent the mean value obtained for the analyzed group of mice including SEM. The 
statistical analysis between the groups was performed using the unpaired Student t test 
(** < 0,005; *** < 0,0005; ns – not significant). 
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To further study the effector functions of the CD8+ T cells induced by the 
heterologous prime-boost regimen their degranulation capacity was evaluated. As 
mentioned in the Introduction (section 1.6.1), CD107a is a suitable marker for 
detection of degranulating antigen-specific cytotoxic T lymphocytes [Betts et al., 
2003; Rubio et al., 2003]. CD107a protein is present in the membrane of T cell 
cytolytic granules. Recognition of the infected cells by CTLs results in releasing their 
content and the exposure of the CD107a molecule on the CTL surface, where it can 
be easily detected by flow cytometric analysis. 
The ability of the CD8+ T cells to degranulate was compared to IFNγ production in the 
splenocytes of mice immunized in the pCGWHc prime - Ad5WHc or Ad35WHc 
manner and three times only with the pCGWHc plasmid for reference, as mentioned 
in the Methods section (4.4.3.2). As a control, the splenocytes of mice primed two 
times with “empty” pCG plasmid and boosted with Ad5GFP were used. As presented 
in Fig. 5.22, the significant proportion of total IFNγ+ CD8+ T cells from splenocytes of 
all groups of mice immunized with WHcAg-expressing vaccines was positive for the 
CD107a degranulation marker (over 90%). However, the percentages of double-
positive CD107a+ IFNγ+ CD8+ T cells were significantly higher in the groups of mice 
boosted with Ad5WHc and Ad35WHc (mean values: 58,7% and 49,9%, respectively), 
than in the pCGWHc only immunized mice (mean value: 17,5%) [Fig. 5.22B]. 
Approximately a 3-fold increase in the number of CD107a+ IFNγ+ CD8+ T cells 
between the heterologous prime-boost regimen groups and the group vaccinated 
with DNA was statistically significant (P < 0,005). No CD107a+ IFNγ+ CD8+ T cells 
were detected in the spleens of mice immunized with “empty” pCG plasmid and 
Ad5GFP. Similar to CD8+ T cells co-expressing CD107+ and IFNγ+, the percentages 
of IFNγ-producing cells were significantly elevated in both groups immunized in the 
DNA prime – AdV boost manner as compared to only DNA–vaccinated mice (mean: 
4,6% vs 1,3%; P < 0,005 for group of mice boosted with Ad5WHc and 4,7% vs 1,3%; 
P < 0,0005 for group immunized with Ad35WHc). No significant difference in the 
amount of CD107a+ CD8+ T cells was detected between the groups immunized with 
pCGWHc plasmid and the heterologous prime-boost regimen. The mean percentage 
values of CD8+ T cells expressing the CD107a degranulation marker in those groups 
ranging between 2,3% and 2,4% were significantly higher than the background value 
of 0,4% detected in splenocytes of control mice (P < 0,0005).  
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Fig. 5.22 Evaluation of degranulation activity of IFNγ+ CD8+ T cells induced by 
pCGWHc immunization and heterologous prime-boost regimen 
Splenocytes were expanded in vitro for 7 days with the epitope c13-21 and subsequently 
restimulated for 5h in the presence of the CD107a antibody. Afterwards cells were stained for 
CD8 T cell marker and intracellularly for IFNγ.  
A. Dotplots of the splenocytes of a representative mouse from each immunization group. 
Presented values indicate the percentage of CD107a+ or/and IFNγ+ CD8+ T cells in the 
CD8+ T cell population. 
B. Degranulation capacity of IFNγ+ CD8+ T cells. The bars represent the mean value 
obtained for the analyzed group of mice including SEM. The statistical analysis between 
the groups was performed using the unpaired Student t test (** < 0,005; *** < 0,0005; ns 
– not significant). 
 
Apart from the direct cytotoxic activities, CD8+ T cells are able to produce cytokines 
that exhibit an antiviral activity. The secretion of IFNγ and TNFα by antigen-specific 
CD8+ T cells proved to suppress viral replication [Guidotti et al., 1994]. Moreover, 
multifunctional T cells, which are able to secrete simultaneously more than one 
cytokine, demonstrated a stronger protective potential and higher capacity to clear 
viral, bacterial or parasitic infections [Seder et al., 2008; Darrahet al., 2007]. To 
investigate the influence of the heterologous DNA prime – AdV boost regimen on the 
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production of TH1 type cytokines by CD8+ T cells, the expression of IFNγ, TNFα and 
IL-2 was measured in splenocytes stimulated in vitro for 6h with the peptide c13-21 
(Methods, section 4.9.1). 
As presented in Fig. 5.23A, the cytokine that had the strongest expression within the 
CD8+ T cell population in all immunized groups was IFNγ. TNFα was produced in 
slightly lower levels and the less abundant cytokine was IL-2 (approximately 4-fold 
lower expression than IFNγ). Splenocytes from the control mice demonstrated 
background levels of tested cytokines. Group of mice primed with pGCWHc and 
boosted with Ad5WHc exhibited the highest percentages of IFNγ, TNFα and IL-2 (the 
mean values: 5,3%, 4,2% and 1,2% respectively). The expression of all analysed 
cytokines in this group was significantly higher compared to the DNA only - 
immunized group (P < 0,05). The boosting immunization with Ad35WHc also led to 
the increased secretion of IFNγ and TNFα in comparison to the group of mice 
vaccinated only with plasmid DNA (P < 0,05). The difference in IL-2 production 
between those groups was not statistically significant, even though it was elevated for 
the mice immunized with pCGWHc – Ad35WHc. 
Determination of single, double and triple positive cells that produce IFNγ, TNFα and 
IL-2 within the CD8+ T cell population was performed. First, the absolute number of 
single, double and triple cytokine producing cells was quantified for every mouse in 
the group and the mean value was calculated. Second, percentages of cells 
secreting one, two or all cytokines were evaluated. As Fig. 5.23B shows, there was 
no difference in the “quality” of cytokines secreting CD8+ T cells between the 
heterologous prime – boost regimen groups, using recombinant adenoviral vectors 
expressing WHcAg, and in mice immunized only with WHcAg – expressing plasmid. 
The average values of single, double and triple cytokine producers were 
approximately 18%, 62% and 20% respectively. The highest proportion of the double 
producers was the CD8+ T cell group co-expressing IFNγ and TNFα – the cytokines 
with the highest antiviral activity (approximately 97%, data not shown). 
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Splenocytes were stimulated in vitro for 6h with the epitope: c13-21 and stained 
intracellularly for IFNγ, TNFα and IL-2. 
A. The expression profile of TH1 type cytokines IFNγ, TNFα and IL-2. The bars represent the 
mean value obtained for the analyzed group of mice including SEM. The statistical 
analysis between the groups was performed using the unpaired Student t test (* < 0,05; 
** < 0,005; ns - not significant). 
B. Evaluation of multifunctional CD8+ T cells. The percentage of single, double and triple 
producers in cytokine-positive CD8+ T cell population. The percentage values represent 
the mean value obtained for the analyzed group of mice. 
 
In vitro experiments proved that heterologous priming with the pCGWHc plasmid and 
boosting with recombinant AdV expressing WHcAg induces significantly stronger 
CTL response than immunization with the pCGWHc plasmid alone. Nevertheless, the 
“quality” of CD8+ T cells is comparable to those induced by the DNA vaccine alone. 
To address the question whether the more vigorous CD8+ T cell response induced by 
DNA prime - AdV boost immunization have a stronger cytotoxic potential than those 
induced by the DNA vaccination alone in vivo, an in vivo cytotoxicity assay was 
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Fig. 5.23 Evaluation of multiple cytokine production by CD8+ T cells induced by 
pCGWHc immunization and the heterologous prime-boost regimen 
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performed. This assay allows to in vivo evaluate the CTL’s effector ability to eliminate 
cells mimicking virus-infected cells (‘target cells’) [Barber et al., 2003; Zelinskyy et al., 
2009; Dietze et al., 2011]. In vivo cytotoxicity assay proved its usefulness in 
evaluating the antiviral therapies [Gibbert et al., 2010] and most recently the 
immunization strategies [Rigato et al., 2011]. The in vivo cytoxicity assay is described 
in detail in the Methods section (4.11). Briefly, three groups of mice were examined in 
the experiment: 6 mice were immunized three times with pCGWHc, 6 mice primed 
with pCGWHc were immunized two times and then boosted with Ad5WHc and 4 
control mice immunized with “empty” pCG plasmid in combination with Ad5GFP. The 
immunization schedule is presented in Fig. 5.18 (page 87). Eight days after the last 
immunization the mice were intravenously injected with the same number of 
lymphocytes loaded with CD8+ T cell epitope peptide c13-21 (“target cells”) and non-
loaded cells for the reference. The populations were labelled with different 
concentrations of CFSE dye. After 8 hours, immunized mice were sacrificed and the 
killing of the target cells was evaluated in the spleen. 
The mice immunized in the DNA prime – Ad5WHc manner showed an improved 
killing of the c13-21 loaded target cells, and mimicking WHV-infected cells were 
found in the spleen (Fig. 5.24). The mean percentage of killing determined for 6 mice 
in that group was 43,8% and was significantly higher than the 20,2% obtained for 
mice immunized only with the pCGWHc plasmid (P < 0,05) [Fig. 5.24B]. The 
background obtained in mice immunized with vaccines that do not express WHcAg 
was 1,9%. The percentages of eliminated cells in groups of mice immunized either 
with DNA alone or in combination with Ad5WHc were significantly higher in 
comparison to control mice (P < 0,05 and P < 0,005, respectively).  
Those data confirm that immunization in heterologous prime-boost regimen, using 
the recombinant AdVs not only induces CTL secreting more IFNγ, TNFα and IL-2, but 
it is also more effective in the elimination of cells loaded with the WHV epitope. 
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Fig. 5.24 Elimination of cells loaded with the WHcAg-derived peptide c13-21 in 
mice immunized with the pCGWHc plasmid and the heterologous prime-boost 
regimen 
Mice were immunized two times with pCGWHc and boosted with Ad5WHc or pCGWHc. Mice 
immunized with “empty” pCG and Ad5GFP served as control. At day 8 after the last 
immunization, mice were intravenously injected with the same number of lymphocytes 
loaded with the CD8+ T cell epitope c13-21 (“target cells”) and non-loaded cells for the 
reference. To distinguish between the two populations, they were labelled with different 
concentrations of CFSE dye. After 8 hours the mice were sacrificed and the killing of the 
target cells was evaluated in the spleen. To assess the difference in the number of cells 
between the populations naïve mice were used as a reference. 
A. Representative histograms of a CFSEhigh population of target cells (black peak) and 
CFSElow reference cells (white peak) in the spleens from each immunization group 
exhibiting the highest killing activity. The difference in the cell numbers between the 
peaks was calculated and presented as the percentage of killing (marked by grey 
arrows). 
B. The bars represent the mean value obtained from groups of six mice immunized with 
WHcAg-expressing vaccines and four control mice immunized with “empty” pCG plasmid 
in combination with Ad5GFP including SEM. The statistical analysis between the groups 
was performed using the unpaired Student t test (* < 0,05; ** < 0,005). 
 
5.6 DNA prime – AdV boost immunization elicits WHV-specific immune 
response in WHV transgenic mice 
The WHV transgenic mouse strain 1217 (1217 WHV Tg mice) is a promising new 
animal model for studies on hepadnaviral infection, especially for the development of 
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new antiviral strategies. 1217 WHV Tg mice that carry the wild-type WHV transgene 
were generated using C57BL/6 mice. Those mice are characterized by WHV 
replication in the liver and the secretion of the WHV particles into the bloodstream. 
Moreover, they do not show WHV-specific immune responses. Therefore, WHV Tg 
mice exhibit at least partial immune tolerance against WHV proteins. 
To investigate the potency of adenovirus-based vaccines to break the WHV-specific 
immune tolerance and reduce the WHV replication in WHV transgenic mice, 
heterologous prime-boost immunization trials were performed. As shown in Fig. 5.25, 
1217 WHV Tg mice were pretreated with cardiotoxin. One week later mice were 
subsequently immunized two times in a two-week interval with the pCGWHc plasmid. 
Four weeks after the second DNA immunization, the groups of mice were immunized 
with either Ad5WHc or pCGWHc as reference. As controls, mice were immunized 
two times with “empty” pCG plasmid and were boosted with Ad5 expressing GFP. 
Two weeks after the third immunization mice were sacrificed and splenectomy was 
performed. The group of mice immunized in the heterologous DNA-Ad5WHc regimen 
received a second boost immunization with Ad35WHc. The vaccination was 
performed four weeks after Ad5WHc immunization and the mice were sacrificed two 
weeks later.  
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Fig. 5.25 Schedule of heterologous prime-boost immunization of WHV Tg mice 
Ten to twelve weeks old 1217 WHV Tg mice were pretreated with cardiotoxin (grey arrow, 
marked as “+”). One week later they were subsequently i.m. immunized 2 times with 100µg 
of pCGWHc plasmid in a two-week interval (marked as “+”). At week 6, groups of seven mice 
were immunized with 2×109 PFU of Ad5WHc or 100µg pCGWHc. Immunization time points 
are indicated by red arrows. Four mice immunized with 100µg of “empty” pCG plasmid and 
2×109 PFU Ad5 expressing GFP served as controls. Mice were sacrificed at week 8 and 
splenectomy was performed. The group of mice that received a second boost immunization 
with 2×109 PFU Ad35WHc was sacrificed at week 12. Blood withdrawing was performed at 
the time point of each immunization (week 2, 6, 8 and 12).  
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5.6.1 Evaluation of the humoral immune response  
To evaluate whether immunizations with the new DNA plasmid and recombinant 
adenoviral vectors expressing WHcAg were able to induce an antibody response not 
only against the WHcAg but also WHsAg, the detection of anti-WHc and anti-WHs in 
the sera of 1217 WHV Tg mice was performed by ELISA (Methods, section 4.12). 
As Fig. 5.26 shows, all groups of mice had undetectable levels of anti-WHc 
antibodies after the first DNA immunization. The levels of anti-WHc increased in all 
mice immunized twice with pCGWHc plasmid and were significantly higher in 
comparison to the background values obtained for mice vaccinated with the “empty” 
pCG plasmid (P < 0,05). The boosting immunization with Ad5WHc led to the 
induction of higher levels of anti-WHc antibodies in comparison to the group of mice 
immunized a third time with pCGWHc plasmid (P < 0,005). As expected, the 
immunization of control mice with Ad5GFP did not induce any anti-WHc. The level of 
anti-WHc increased additionally in the group of mice after the 4th (second boost) 
immunization with Ad35WHc (P < 0,005).  
 
 
 
 
Mice were primed two times by immunization with the pCGWHc plasmid. Four weeks later, 
boosting immunization with Ad5WHc or pCGWHc was performed. The group of mice 
immunized 2x pCGWHc-Ad5WHc received a second boost immunization with Ad35WHc. 
Mice immunized with “empty” pCG and Ad5GFP served as controls. The sera of mice were 
obtained from blood samples collected after each immunization and diluted 1:250 in PBS. 
WHcAg-specific ELISA was peformed using anti-mouse IgG antibody coupled to peroxidase. 
The statistical analysis between the groups was performed using the unpaired Student t test. 
Asterisks mark the significant difference (* < 0,05; ** < 0,005; ns – not significant). 
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Fig. 5.26 Detection of anti-WHc IgG antibodies in the sera of 1217 WHV Tg mice 
immunized in the heterologous prime-boost regimen using recombinant 
adenoviral vectors expressing WHcAg 
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To evaluate the breadth of the immune response induced by the heterologous prime-
boost regimen, the IgG1 and IgG2a isotypes of anti-WHc antibodies were analyzed in 
murine sera by ELISA. Detection of IgG isotypes demonstrated that all tested 
immunization protocols induce predominantly IgG2a antibodies indicating a TH1 type 
of immune response (Fig. 5.27A). Nevertheless, the levels of IgG2a were significantly 
higher in the groups of mice boosted with Ad5WHc than in those immunized with the 
DNA vaccine pCGWHc plasmid (P < 0,005). WHcAg-specifc IgG1 antibodies were 
only present in the sera of mice that received the second boost immunization with 
Ad35WHc (Fig. 5.27B). Three out of five mice from this group demonstrated a very 
high levels of IgG1 antibodies (mean OD492 nm: 0,89).  
 
 
 
 
 
The sera of mice were obtained from blood samples collected two weeks after each 
immunization and diluted 1:250 in PBS. WHcAg-specific ELISA was peformed using IgG 
isotype-specific (IgG2a or IgG1) anti-mouse antibodies coupled to peroxidase. The statistical 
analysis between the groups was performed using the unpaired Student t test. Asterisks 
mark the significant difference (* < 0,05; ** < 0,005; ns – not significant). 
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Fig. 5.27 Detection of anti-WHc IgG isotypes: IgG2a (A) and IgG1 (B), in the sera 
of 1217 WHV Tg mice immunized in the heterologous prime-boost regimen 
using recombinant adenoviral vectors expressing WHcAg 
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Anti-WHs antibody-specific ELISA demonstrated that DNA immunization alone is not 
able to induce anti-WHs (Fig. 5.28). No anti-WHs antibodies were seen in mice 
immunized one, two and three times with pCGWHc. The levels of anti-WHs were 
comparable to the background values obtained from mice vaccinated with “empty” 
pCG plasmid. The anti-WHs antibodies were found in the sera of 13 out of 17 mice 
immunized in the heterologous DNA prime - AdV boost manner, after the boosting 
immunization with Ad5WHc. The level of anti-WHs in those mice was significantly 
higher in comparison to the control mice and mice immunized only with DNA 
(P < 0,005). The levels of anti-WHs increased additionally after the 4th (second boost) 
immunization with Ad35WHc. This result was statistically significant in comparison to 
mice boosted with adenoviral vector only once (P < 0,005). 
 
 
 
 
The sera of mice were obtained from blood samples collected after each immunization and 
diluted 1:250 in PBS. WHsAg-specific ELISA was performed using anti-mouse IgG antibody 
coupled to peroxidase. The statistical analysis between the groups was performed using the 
unpaired Student t test. Asterisks mark the significant difference (** < 0,005; *** < 0,0005;   
ns – not significant). 
 
5.6.2 Evaluation of the CD8+ T cell response  
To evaluate whether heterologous DNA-AdV immunization was able to break the 
tolerance against WHcAg, the evaluation of the CD8+ T cell response was performed 
in the immunized mice. The comparison of the WHcAg-specific CD8+ T cell 
responses induced by DNA–Ad5WHc or DNA–Ad5WHc-Ad35WHc with DNA only 
immunization regimen was performed by intracellular IFNγ staining of splenocytes. 
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Fig. 5.28 Detection of anti-WHs IgG antibodies in the sera of 1217 WHV Tg mice 
immunized in the heterologous prime-boost regimen using recombinant 
adenoviral vectors expressing WHcAg 
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Splenocytes were isolated two weeks after the last immunization and were stimulated 
in vitro with the CD8+ T cell epitope c13-21. After 7 days of culturing, the cells were 
restimulated for 6h with c13-21 and stained for IFNγ as mentioned in the Methods 
section (4.9.1). Splenocytes obtained from mice immunized with “empty” pCG 
plasmid and Ad5GFP served as controls. 
The percentages of IFNγ+ CD8+ T cells determined in the spleens of mice vaccinated 
in the DNA prime – Ad5WHc boost manner were higher in comparison to the only 
DNA-immunized group (Fig. 5.29A-B). The IFNγ response after the stimulation of 
splenocytes with c13-21 was ranging from 0,2% to 2,2% (mean 1,0%) for pCGWHc – 
immunized mice and 0,7% to 11,4% (mean 5,0%) for pCGWHc-Ad5WHc 
(Fig. 5.29B). A five-fold increase in IFNγ producing CD8+ T cells was found in mice 
immunized in DNA-Ad5WHc manner as compared to the DNA only – immunized 
mice (P < 0,005). Unexpectedly, the magnitude of IFNγ response did not increase in 
the group of mice that received the second boosting immunization with Ad35WHc. 
The mean percentages of IFNγ+ CD8+ T cells directed against c13-21 in this group 
were 3,8% and were slightly lower than in the DNA-Ad5WHc group. The stimulation 
of splenocytes with peptide c13-21 obtained from mice immunized with “empty” pCG 
plasmid and Ad5GFP induced no IFNγ response (0,1% to 0,3% of IFNγ+ CD8+ 
T cells). The comparison of the responses to stimulation with WHcAg-derived epitope 
measured for groups immunized with WHcAg-expressing vaccines was significantly 
higher than those detected for the control group (P < 0,05). No statistically significant 
difference between all analysed groups of mice was demonstrated in the 
unstimulated and unrelated peptide controls. 
To evaluate the magnitude of the WHcAg-specific CD8+ T cell response elicited in 
1217 WHV Tg mice, the comparison of the results with those obtained from C57BL/6 
mice was performed. As expected, the percentages of IFNγ-producing CD8+ T cells 
detected in the splenocytes of 1217 WHV Tg mice were significantly lower  compared 
to those in C57BL/6 mice (Fig. 5.29C). The mean percentages of IFNγ+ CD8+ T cells 
directed against c13-21 in the group of mice immunized only with DNA vaccine were 
1% in 1217 WHV Tg mice and 21,9% in C57BL/6 mice. In the groups of mice 
immunized in the heterologous pCGWHc-Ad5WHc manner the mean percentages of 
IFNγ+ CD8+ T cells directed against c13-21 were 5% in 1217 WHV Tg mice and 
65,7% in C57BL/6 mice. Those results were statistically significant (P < 0,0005). No 
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difference in the number of IFNγ producing cells between WHV Tg mice and 
C57BL/6 mice was observed in the control groups immunized with vaccines that do 
not express WHcAg. 
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Splenocytes were expanded in vitro for 7 days in the presence of CD8+ T cell epitope c13-21 
and stained for intracellular IFNγ.  
A. Dotplots of the splenocytes of a representative mouse from each immunization group. 
Presented values indicate the percentage of IFNγ+ CD8+ T cells in the CD8+ T cell 
population. 
B. CD8+ T cell response in murine splenocytes with c13-21. The bars represent the mean 
value obtained for the analyzed group of mice including SEM. Unstimulated cells and 
cells stimulated with unrelated CMV-derived peptide served as controls. The statistical 
analysis between the groups was performed using the unpaired Student t test (* < 0,05; 
** < 0,005; ns – not significant). 
C. Comparison of the magnitude of IFNγ responses obtained for 1217 WHV Tg and 
C57BL/6 mice after stimulation with c13-21. The statistical analysis between the groups 
was performed using the unpaired Student t test (*** < 0,0005; ns – not significant). 
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Fig. 5.29 Evaluation of CD8+ T cell responses induced by the heterologous 
prime-boost regimen using recombinant adenoviral vectors expressing WHcAg 
in 1217 WHV Tg mice 
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To further study the effector functions of the CD8+ T cells induced by the 
heterologous prime-boost regimen in 1217 WHV Tg mice, the capacity of CD8+ 
T cells to degranulate was evaluated. The expression of CD107a degranulation 
marker was compared to the IFNγ production in splenocytes of mice immunized in 
pCGWHc prime – AdV boost manner and only with pCGWHc plasmid. As controls 
the splenocytes of mice primed two times with “empty” pCG plasmid and boosted 
with Ad5GFP were used.  
As presented in Fig. 5.30, the percentages of the double-positive CD107a+ IFNγ+ 
CD8+ T cells were significantly higher in groups of mice boosted one time with 
Ad5WHc or two times with Ad5WHc/Ad35WHc (mean values for both groups: 2,8%), 
than in pCGWHc only immunized mice (mean value: 0,5%; P < 0,05). The 
percentages of cells co-expressing CD107a, IFNγ and CD8 detected in the DNA only 
immunized group were elevated in comparison to the control group immunized with 
“empty” pCG plasmid and Ad5GFP (mean values 0,5% vs 0,1%). However, this 
difference was not statistically significant. In addition, no statistically significant 
difference in the percentages of only IFNγ-producing cells was detected between the 
immunized groups and control mice, even though the values were elevated in 
pCGWHc-Ad5WHc immunized mice (mean values: 0,3% vs 1,7%). The mean 
percentage values of CD8+ T cells expressing the CD107a degranulation marker in 
both DNA prime–AdV boost groups (mean: 2,3%) were significantly higher than the 
background value of 0,8% detected in the splenocytes of control mice (P < 0,05). No 
significant difference in the amount of CD107a+ CD8+ T cells was detected between 
the DNA only immunized mice and control group (mean values: 0,8% vs 1,2%).  
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Fig. 5.30 Evaluation of degranulation activity of IFNγ+ CD8+ T cells induced by 
the heterologous prime-boost regimen in 1217 WHV Tg mice 
Splenocytes were expanded in vitro for 7 days with the epitope c13-21 and subsequently 
restimulated for 5h in the presence of the CD107a antibody. Afterwards the cells were 
stained for the CD8 T cell marker and intracellularly for IFNγ.  
A. Dotplots of the splenocytes of a representative mouse from each immunization group. 
The presented values indicate the percentage of CD107a+ or/and IFNγ+ CD8+ T cells in 
the CD8+ T cell population. 
B. Degranulation capacity of IFNγ+ CD8+ T cells. The bars represent the mean value 
obtained for the analyzed group of mice including SEM. The statistical analysis between 
the groups was performed using the unpaired Student t test (* < 0,05; ns – not 
significant). 
 
To further investigate the influence of the heterologous DNA prime – AdV boost 
regimen on multiple TH1 type cytokine production, the expression of IFNγ, TNFα and 
IL-2 was measured in splenocytes of WHV Tg mice stimulated in vitro for 6h with 
peptide c13-21 (Methods, section 4.9.1). 
As presented in Fig. 5.31A, the immune response detectable after 6h stimulation was 
quite low in the splenocytes of WHV Tg mice. The background percentages of the 
TH1 type cytokine producing CD8+ T cells obtained for most of the tested mice made 
the analysis impossible for the whole group of mice. Therefore, one mouse 
A 
B 
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demonstrating a positive percentage of the cytokines producers was chosen from 
each immunization group for the analysis (indicated by the arrows). The 
determination of single, double and triple positive cells that produce IFNγ, TNFα and 
IL-2 within the CD8+ T cell population was performed. The absolute number of single, 
double and triple cytokine producing cells was quantified for one mouse in the group 
and the percentages of cells secreting one, two or all cytokines was evaluated.  
Mouse number 58 which was immunized twice with pCGWHc plasmid and boosted 
with Ad5WHc demonstrated the highest percentages of IFNγ and TNFα expressing 
CD8+ T cells of all analysed mice (3,5% and 2,4% respectively). The percentage of 
IL-2 secreting CD8+ T cells detected for mouse 58 was 0,9% (Fig. 5.31A). Moreover, 
mouse 58 showed the highest proportion of triple and double cytokine producers: 
12% and 53% respectively. The highest proportion of double cytokine producers 
(75,1%) were the CD8+ T cells co-expressing cytokines with the strongest antiviral 
activity IFNγ and TNFα (Fig. 5.31C), and the most abundant cytokine in the single 
producers group was IFNγ (74,1%; Fig. 5.31D). Mouse number 56 which was 
immunized three times with the plasmid DNA vaccine and mouse number 52 from 
DNA-Ad5WHc-Ad35WHc group exhibited comparable results. The percentages of 
IFNγ, TNFα and IL-2 secreting CD8+ T cells were around 1,4%; 0,6%; 0,8% for 
mouse number 56 and 1,1%; 0,7%; 1,5% for mouse number 52, respectively 
(Fig. 5.31A). Approximately, 10% of triple cytokine producers and 38% of double 
cytokine producers were detected for mouse 56. The percentages of CD8+ T cells 
that simultaneously express two or three cytokines as detected in mouse 52 were  
7% and 35% (Fig. 5.31B). The highest proportion of the double producers detected 
for both mice was found in the CD8+ T cells co-expressing IFNγ and IL-2 
(approximately 60%). The IFNγ+ TNFα+ CD8+ T cells were detectable in a frequency 
of 36% (Fig. 5.31C). As Fig. 5.31D shows, the most common cytokine detected in the 
single cytokine producer population for mouse 56 was IFNγ (55,4%). Mouse 52 
showed comparable percentages of IFNγ and TNFα in the single producers group 
(41,9% and 38,7%, respectively). 
Results
 
107 
 
 
 
IFN
g T
NF
a
IFN
g I
L-2
TN
Fa
 
IL-
2
0
20
40
60
80
%
 
in
 
tw
o
-
c
yt
o
ki
n
e
s
po
s
iti
v
e
 
po
pu
la
tio
n
IFN
g
TN
Fa IL-
2
0
20
40
60
80
%
 
in
 
s
in
gl
e
 
c
yt
o
ki
n
e
po
s
iti
v
e
 
po
pu
la
tio
n
2x DNA - DNA (mouse 56) 2x DNA - Ad5WHc (mouse 58) 2x DNA -Ad5 - Ad35WHc ( mouse 52)
 
Fig. 5.31 Evaluation of multiple cytokine production by CD8+ T cells induced by 
the pCGWHc and heterologous prime-boost immunization in 1217 WHV Tg 
mice 
Splenocytes were stimulated in vitro for 6h with the epitope c13-21 and stained intracellularly 
for IFNγ, TNFα and IL-2. 
A. The expression profile of TH1 type cytokines: IFNγ, TNFα and IL-2. The arrows indicate 
the mice from each immunization group used for detailed analysis. 
B. Evaluation of multifunctional CD8+ T cells. The percentage of single, double and triple 
producers in cytokine-positive CD8+ T cell population as detected in chosen mice from 
each immunization group. 
C. The percentages of double cytokine producers as detected in chosen mice from each 
immunization group.  
D. The percentages of single cytokine producers as detected in chosen mice from each 
immunization group.  
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Those results indicate that the immunization of 1217 WHV Tg mice with heterologous 
DNA-AdV regimen breaks the immune tolerance and induces humoral and cellular 
immune responses against WHV proteins. Moreover, the immunizations with 
WHcAg-expressing vaccines were able to partially restore the multifunctionality of the 
CD8+ T cells in the 1217 WHV Tg mouse model.  
5.6.3 Impact of the immunizations on WHV replication 
To examine the impact of the WHcAg-based immunizations on the WHV replication 
in 1217 WHV Tg mice, the viral loads were monitored in the serum of mice before the 
immunizations were performed (time point of cardiotoxin pretreatment) and 
afterwards, at the time point of sacrifice (Fig. 5.32). The quantification of WHV DNA 
was performed using real-time PCR analysis as described in the Methods section 
(4.13.3). As expected, in the control group of mice immunized with unrelated vectors 
that did not express WHcAg, no difference in the viral loads in serum at the beginning 
and at the end of the experiment was observed (Fig. 5.32A). In the group immunized  
three times with plasmid DNA only vaccine – pCGWHc, two out of seven mice (29%) 
had undetectable viral loads at the end of the experiment (Fig. 5.32B). All the other 
mice except one, showed a statistically significant 1 to 2 log decrease in viral load 
after the immunizations (P < 0,05). As showed in Fig. 5.32C, mice immunized three 
times in the heterologous prime – boost manner using Ad5WHc demonstrated the 
most significant reduction in viral loads (P < 0,0005). At the end time point, the WHV 
DNA was undetectable in 10 out of 12 mice of this group (83%). In the group of mice 
that received the fourth immunization with Ad35WHc, all the mice showed a more 
than 2 log decrease in viral loads. Three out of five mice (60%) exhibited the WHV 
viremia below the detection limit at the end of the experiment (Fig. 5.32D).  
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Fig. 5.32 Quantification of the viral loads in the serum of 1217 WHV Tg mice 
before and after the immunization trials 
The viral load was evaluated by quantitative real-time PCR on DNA samples obtained from 
the serum of mice. The single pair of dots connected with the line represents values obtained 
from one mouse before and after the immunization trials (week 2 after the last immunization). 
The statistical analysis between the groups was performed using the Wilcoxon signed rank 
test (* < 0,05; ** < 0,005; *** < 0,0005; ns – not significant). GE – genome equivalents. 
 
The data obtained in the WHV Tg mouse model confirm that immunization in the 
heterologous prime-boost regimen, using the recombinant AdVs induces stronger 
humoral and cellular immune responses and suppresses the WHV replication more 
efficiently. 
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5.7 Heterologous Ad5WHc – Ad35WHc immunization in naïve 
woodchucks protects against infection with WHV 
It was demonstrated that DNA immunization of naïve woodchucks with plasmid 
encoding WHcAg protects the animals against infection after challenge with WHV 
[Lu et al., 1999]. Therefore, to determine the potency of recombinant adenoviral 
vectors to induce humoral and cellular immune responses and their protective 
efficacy in the challenge experiment in the woodchuck model, the animals were 
immunized in heterologous Ad5WHc – Ad35WHc regimen.  
As shown in Fig. 5.33, two naïve woodchucks (number: 46949 and 46957) were 
intramuscularly immunized with Ad5WHc and four weeks later boosted with 
Ad35WHc. Three woodchucks (number 58059, 58063 and 70096) were immunized 
three times with the pCGWHc plasmid and served as a reference. Both groups of 
woodchucks were intravenously challenged with 1×107 genome equivalents (GE) of 
WHV strain 8. As the controls, two naïve woodchucks (number: 58055 and 58056) 
were inoculated with WHV, without vaccination, and served as controls. 
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Fig. 5.33 Schedule of DNA or recombinant adenoviral vectors immunization of 
naïve woodchucks 
Three naïve woodchucks (58059, 58063 and 70096) were pretreated with cardiotoxin (grey 
arrow) and one week later subsequently immunized for 3 times with 1mg of pCGWHc 
plasmid intramuscularly in two to four weeks intervals. Two woodchucks (46949 and 46957) 
were intramuscularly immunized with 5×109 PFU Ad5WHc and four weeks later boosted with 
1×1010 PFU of Ad35WHc. Two weeks after the last immunizations woodchucks were 
intravenously challenged with 1×107 GE of WHV, together with two naïve woodchucks 
(58055 and 58056) which served as controls.  
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5.7.1 Evaluation of the CTL response after immunizations 
The T cell response in woodchucks was evaluated by flow cytometric analysis of 
CD107a expression on woodchucks PBMCs, as described in Methods section 
(4.9.1). Isolated PBMCs were stimulated in vitro for 3 days with WHcAg-derived 
epitope c96-110 or WHsAg-derived epitope s220-234 [Frank et al., 2007]. As controls 
unstimulated PBMCs and cells stimulated with unrelated CMV-derived peptide were 
used. Detection of degranulating cells was performed using cross-reactive anti-
mouse CD107a antibody incubated with PBMCs for 5h. As the cross-reactive 
antibody that recognizes woodchuck CD8 molecule is yet not available, the 
population of CD3+ CD4- lymphocytes was considered to be the cytotoxic            
CD8+ T cells.  
Vaccination with pCGWHc plasmid of the naïve woodchucks 58059 and 58063 
induced significant degranulation response directed against WHcAg epitope c96-110 
in woodchuck 58063 (Fig. 5.34). The WHcAg-specific CTL were detectable after two 
immunizations and the magnitude of response increased after the third plasmid 
injection. The percentage of 2,7% CD107a+ T cells in CD3+ CD4- population was     
4-fold higher than the background values of 0,7% and 0,6% in negative controls. The 
woodchuck number 58059 demonstrated slightly elevated percentage of WHcAg-
specific degranulating T cells: 0,9% (after three pCGWHc immunizations) in 
comparison to the controls (0,5%). Nevertheless, this result can be hardly considered 
as positive. Therefore, the experiment was repeated in woodchuck 70096. Three 
immunizations with WHcAg-expressing DNA vaccine induced the degranulation 
response directed against peptide c96-110. Nearly 5-fold increase in the percentage 
of CD107a+ CD3+ CD4- T cells detected after stimulation with WHcAg peptide (2,5%) 
was significantly higher than those detected for unstimulated and unrelated peptide 
controls (0,5% and 0,6%, respectively). 
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Fig. 5.34 Dotplots of PBMCs from woodchucks after three immunizations with 
pCGWHc plasmid 
PBMCs were expanded in vitro for 3 days with WHcAg-derived epitope c96-110. 
Unstimulated cells and cells stimulated with unrelated CMV-derived peptide served as 
negative controls. The T cell response was evaluated by CD107a degranulation assay. The 
cells were gated on lymphocyte population, 7AAD- and CD4- cells. Presented values show 
the percentage of CD107a+ CD3+ CD4- T cells in the CD3+ CD4- T cell population.  
 
 
Immunization of woodchucks 46949 and 46957 with newly constructed recombinant 
adenoviral vectors, expressing WHcAg, proved their potency to elicit a robust T cell 
response (Fig. 5.35). Just one immunization with Ad5WHc induced a comparable 
magnitude of WHcAg-specific degranulation responses as three plasmid DNA 
immunizations. The percentage of 2,8% WHcAg-specific CTLs were detected for 
woodchuck 46949 and 3,6% for 46957 (Fig. 5.35A). Those percentages were 5,6-fold 
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higher than the background value of 0,5% for woodchuck 46949 and 4,5-fold higher 
than the background value of 0,8% for woodchuck 46957. After immunization with 
Ad35WHc the induced WHcAg-specific CTL response was significantly boosted in 
both animals (Fig. 5.35B). Over 4-fold increase in the percentage of WHcAg-specific 
CD107a+ CD3+ CD4- T cells after boosting immunization (13,3%) was shown in 
woodchuck 46949. Woodchuck 46957 demonstrated a 2-fold increase in WHcAg-
specific CTLs (7,4%). 
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Fig. 5.35 Dotplots of PBMCs from woodchucks immunized with recombinant 
AdV: Degranulation response after immunization with Ad5WHc (A) and after 
booster immunization with Ad35WHc (B) 
PBMCs were expanded in vitro for 3 days with WHcAg-derived epitope c96-110. 
Unstimulated cells and cells stimulated with unrelated CMV-derived peptide served as 
negative controls. The T cell response was evaluated by CD107a degranulation assay. The 
cells were gated on lymphocyte population, 7AAD- and CD4- cells. Presented values show 
the percentage of CD107a+ CD3+ CD4- T cells in the CD3+ CD4- T cell population.  
 
A 
B 
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5.7.2 Monitoring of WHV infection after challenge 
All immunized woodchucks were intravenously inoculated with WHV (1×107 GE) and 
monitored weekly for markers of infection (Methods, section 4.4.4). Two naïve 
woodchucks 58055 and 58056 served as controls in the experiment. The infection of 
WHV in woodchucks was monitored by WHV PCR (detection limit approximately 
1×103 WHV GE per ml of serum) and the golden standard dot-blot hybridization (limit 
5×107 WHV GE per ml of serum), as described in Methods section (4.13.2 and 
4.13.4, respectively) Detection of WHV was correlated with WHcAg- and WHsAg-
specific CTL responses measured by CD107a degranulation assay and the level of 
the serum glutamic oxaloacetic transaminase (GOT) [Methods, section 4.15]. As 
WHV is a non-cythopatic virus, the elevation of GOT (value above 50 international 
units per l; IU/l) in the serum of the animals is a good indicator of CTL-mediated liver 
damage.  
The immunization of woodchuck 58063 with plasmid DNA vaccine: pCGWHc induced 
the WHcAg-specific T cell response. As shown in Fig. 5.36A, WHV DNA was 
detected in the serum at week 2 and 3 post-infection (pi). Detection of WHV DNA 
using dot-blot hybridization did not lead to any positive result. At week 4 and 12 pi, 
the WHcAg-specific CTLs were detected in the peripheral blood (2,3% and 1,8%, 
respectively). No WHsAg-specific T cell response and no elevation in GOT levels 
was observed. Monitoring the infection course of the woodchuck 70096, which also 
demonstrated WHcAg-specific T cell response after pCGWHc vaccination, showed 
similar results. The graph is presented in the Appendix section (Fig. 10.5). 
The woodchuck 58059, in which induction of WHcAg-specific CTLs by DNA 
immunizations was borderline, demonstrated viremia from week 2 to week 9 pi 
(Fig. 5.36B). The peak of viremia was detected by dot-blot hybridization at week 6 pi. 
At week 3 pi, the peak of WHcAg- and WHsAg-specific degranulation responses was 
detected in PBMCs (6,4% of WHcAg-specific CTLs and 1,9% of WHsAg-specific 
CTLs). In addition, the WHcAg-specific CTLs were detected at week 8, 11 and 12 pi. 
The elevation of GOT level in the serum at week 1 and week 6 to 13 pi indicated a 
massive influx of T cells into the liver and their increased cytotoxic activity. The peak 
of serum GOT level (117 IU/l) at week 10 pi correlated with WHV clearance from the 
blood stream.  
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58063 
 
 
58059 
 
 
 
 
Woodchucks were pretreated with cardiotoxin (grey arrow) and immunized intramuscularly 
three times with pCGWHc plasmid (black arrows). WHcAg- and WHsAg-specific T cell 
response was measured by CD107a degranulation assay of woodchuck PBMCs expanded in 
vitro for 3 days with epitope c96-110 and s220-234. Unstimulated cells served as negative 
controls. The values show the percentage of CD107a+ CD3+ CD4- T cells in the CD3+ CD4- T 
cell population. The “+” sign marks the positive responses. The T cell responses were 
correlated with the presence of WHV DNA and GOT levels in the serum.  
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Fig. 5.36 Correlation of WHcAg- and WHsAg-specific CTL responses with WHV 
presence and GOT levels in pCGWHc immunized woodchucks: 58063 (A) and 
58059 (B) 
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Heterologous immunization of the two naïve woodchucks, 46949 and 46957, with 
Ad5WHc/Ad35WHc induced the robust WHcAg-specific cellular immune response 
detectable at the time of the WHV inoculation (Fig. 5.37). After WHV challenge, 
woodchuck 46949 showed short-time low-level viremia at week 2 and 3 pi 
(Fig. 5.37A). The presence of WHV DNA in the blood was correlating with detectable 
WHcAg-specific T cell response (2,8% at week 2 and 2,1% at week 3 pi). At week 
3 pi, the low percentage of WHsAg-specific CTLs (1,9%) was detected in the 
peripheral blood of the animal. 
As shown in Fig 5.38B, WHV DNA was present in serum of woodchuck 46957 longer 
than in woodchuck 46949 (Fig. 5.37B). The viremia was detectable from week 2 and 
reached its peak at week 4 pi. At week 2 pi 6,7% of WHcAg-specific and 3,0% of 
WHsAg-specific CD107a+ CD3+ CD4- T cells were detected. The WHcAg-specifc 
CTLs were also present in the peripheral blood of woodchuck 46957 at week 3 pi 
(4,0%). At week 7 pi, a brief break-through of the infection was observed, followed by 
WHcAg-specific CTL detection at week 8 pi (3,1%), what resulted in the resolution of 
the infection. 
At week 4 pi, only a slight elevation of GOT levels in both woodchucks was detected: 
56 IU/l in serum of 46949 and 54 IU/l in serum of 46957, indicating a mild cytotoxic 
activity in the liver.  
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46949 
 
 
46957 
 
 
 
 
Woodchucks were immunized with Ad5WHc (red arrow) and four weeks later boosted with 
Ad35WHc (blue arrow). WHcAg- and WHsAg-specific T cell response was measured by 
CD107a degranulation assay of woodchuck PBMCs expanded in vitro for 3 days with epitope 
c96-110 and s220-234. Unstimulated cells served as negative controls. The values show the 
percentage of CD107a+ CD3+ CD4- T cells in the CD3+ CD4- T cell population. The “+” sign 
marks the positive responses. The T cell responses were correlated with the presence of 
WHV DNA and GOT levels in the serum.  
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Fig. 5.37 Correlation of WHcAg- and WHsAg-specific CTL responses with WHV 
presence and GOT levels in Ad5WHc/Ad35WHc immunized woodchucks: 
46949 (A) and 46957 (B) 
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Monitoring of WHV infection in the control woodchucks 58055 and 58056 revealed 
prolonged high-level viremia after the challenge in sera of both animals. As 
Fig. 5.38A shows, WHV DNA detected by WHV PCR was present between week 
3 and 20 pi in the peripheral blood of woodchuck 58055. The high viral load was 
confirmed by dot-blot hybridization with WHV-specific probe. The positive signal was 
observed from week 6 to 15 pi. The low percentage of WHcAg-specific CTLs (2,6%) 
was detected at the beginning of infection at week 3. Afterwards, WHV-specific 
cytotoxic response was not measurable in the peripheral blood before the week 
12 pi. The significant elevation of serum GOT level (100 IU/l) at week 20 pi and 
absence of WHV DNA in the blood at week 22 pi suggests the presence of effector 
WHV-specific T cells in the liver of 58055, that led to the resolution of WHV infection. 
The other control woodchuck 58056 did not resolve the infection after WHV 
challenge. The WHV DNA evaluated by PCR was detected from week 3 pi and by 
dot-blot hybridization from week 5 pi (Fig. 5.38B). Both assays were positive through 
the whole monitoring period till week 24 pi. The WHV-specific T cell responses were 
generally not detectable in the peripheral blood during the examined 13 weeks pi. 
Only a slight elevation in the percentage of WHcAg-specific CD107a+ CD3+ CD4- 
T cells (1,8%) was detected at week 3 pi and WHsAg-specific CTLs (2,0%) at week 
4 pi. No elevation of GOT levels above 50 IU/l was observed in the serum of the 
woodchuck 58056. Those results indicate lack of WHV-specific T cells activity in the 
liver, due to very high viral replication. 
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The woodchucks were intravenously inoculated with WHV. WHcAg- and WHsAg-specific 
T cell response was measured for 13 weeks by CD107a degranulation assay of woodchuck 
PBMCs expanded in vitro for 3 days with epitope c96-110 and s220-234. Unstimulated cells 
served as negative controls. The values show the percentage of CD107a+ CD3+ CD4- T cells 
in the CD3+ CD4- T cell population. The “+” sign marks the positive responses. The T cell 
responses were correlated with the presence of WHV DNA and GOT levels in the serum.  
WHV Dot-blot 
0     1      2      3     4      5     6     7     8     9     10   11   12   13    14   15    18   20   22   24 
WHV PCR 
+ + 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 18 20 22 24
0.0
2.5
5.0
7.5
10.0
12.5
15.0
0
50
100
150
200unstimulated
c96-110
s220-234
WHV
GOT
weeks after WHV challenge
%
 
CD
10
7a
+
 
CD
3+
 
CD
4-
G
O
T
 [IU/l]
WHV Dot-blot 
0     1       2     3      4     5     6     7      8     9    10   11   12    13   14   15    18   20   22   24 
WHV PCR 
+ + 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 18 20 22 24
0.0
2.5
5.0
7.5
10.0
12.5
15.0
0
50
100
150
200unstimulated
c96-110
s220-234
WHV
GOT
weeks after WHV challenge
%
 
CD
10
7a
+
 
CD
3+
 
CD
4-
G
O
T
 [IU/l]
A 
Fig. 5.38 Correlation of WHcAg- and WHsAg-specific CTL responses with WHV 
presence and GOT levels in control woodchucks: 58055 (A) and 58056 (B) 
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5.7.3 Monitoring of the viral load after infection with WHV 
The comparison of the viral loads between pCGWHc and Ad5WHc/Ad35WHc 
vaccinated woodchucks and control animals after WHV inoculation was performed by 
quantitative real-time PCR analysis (Methods, section 4.13.3).  
As shown in Fig. 5.39, the immunized animals demonstrated not only a shorter WHV 
viremia period and lower viral load as compared to the control group (3 to 4 logs). 
Woodchucks 58063, 70096, 46949 and 46957 that developed WHcAg-specific CTL 
responses after three immunizations with pCGWHc plasmid or Ad5WHc/Ad35WHc 
were WHV positive in the blood for 2 to 4 weeks after the challenge. The quantified 
viral loads in those animals were ranging between 7,3×104 and 2,5×106 WHV GE/ml 
of serum (Fig. 5.39A-B). The pCGWHc-immunized woodchuck 58059, which did not 
develop significant WHcAg-specific T cell response, was WHV positive for 8 weeks, 
from week 2 to 9 pi. The peak of WHV viremia was detected at week 6 pi (2,5×109 
WHV GE/ml of serum). Afterwards, the viral load decreased and remained at the 
range of 1×106 WHV GE/ml of serum, until the resolution of infection at week 10. All 
animals that received immunizations remained WHV negative until the end of the 
monitoring period (week 22 pi, woodchucks 46949, 46957 and 70096) or week 25 pi; 
woodchucks 58059 and 58063). 
The control woodchuck 58055 was WHV positive in the blood for 17 weeks after 
WHV infection (Fig. 5.39C). The peak of viral loads was detected at week 7 pi 
(4,4×109 WHV GE/ml of serum). The high-level viremia, ranging between 6,3×107 
and 1,3×109 WHV GE/ml of serum was observed until week 15 pi. At week 18 pi viral 
loads decreased and reached the value of 1,2×106 WHV GE/ml of serum. The 
woodchuck 58055 had undetectable viral loads (below 1×103 WHV GE/ml of serum) 
from week 22 to week 40 pi, the end of the monitoring period. The second control 
animal 58055 developed a chronic WHV infection. The viral loads reached the level 
of 1,4×108 WHV GE/ml of serum at week 5 pi and remained at a very high level: 
between 3,0×109 and 3,4×1010 WHV GE/ml of serum until the end of the monitoring 
period (week 40 pi). 
Those results indicate that the induction of a vigorous T cell response against 
WHcAg leads to the control of WHV and the rapid resolution of the infection. 
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The woodchucks were intravenously inoculated with 1×107 WHV GE (week 0). The viral DNA 
was extracted from woodchucks sera and the viral loads were quantified per ml of serum, 
using real-time PCR analysis.  
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Fig. 5.39 Viral loads after WHV challenge experiment in naïve woodchucks: 
immunized with plasmid DNA vaccine (A), immunized with 
Ad5WHc/Ad35WHc (B), control animals (C) 
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5.7.4 Evaluation of the humoral immune response 
Immunization with WHcAg-based vaccines induces the anti-WHc antibodies that do 
not possess the ability to neutralize the WHV virions [Roos et al., 1989; Schodel 
et al., 1993]. Induction of the neutralizing anti-WHs antibodies is crucial for the final 
clearance of the WHV infection [Cote et al., 1986; Lu et al., 1999]. To examine the 
impact of WHcAg-specific T cell response, elicited by pCGWHc or 
Ad5WHc/Ad35WHc immunization, on the induction of anti-WHs antibodies, the 
detection of anti-WHs antibodies was performed in the sera of woodchucks by ELISA 
(as described in Methods section 4.12). The effectiveness of the immunizations was 
evaluated by detection of anti-WHc antibodies by ELISA. 
As shown in Fig. 5.40, anti-WHc antibodies were detectable in the serum of pCGWHc 
and Ad5WHc/Ad35WHc immunized woodchucks already after one immunization. The 
woodchuck 58059 (Fig. 5.40C) developed detectable WHcAg-specific antibodies 
after three pCGWHc immunizations, indicating that the immune response after 
vaccinations was insufficient, maybe due to incorrect vaccination. The anti-WHc 
levels were comparable in all immunized woodchucks after the infection with WHV 
and the antibodies were present until the end of the monitoring period.  
The woodchucks 46949, 46957, 58063 and 70096, which were immunized in the 
proper way, anti-WHs antibodies were induced at week 2 pi. However, the levels of 
anti-WHs antibodies were higher in woodchucks vaccinated with recombinant 
adenoviral vectors, which demonstrated stronger WHcAg-specific T cell response 
after immunization. At the peak of anti-WHs antibodies level in the serum (week 3 pi), 
the OD492nm value detected for representative woodchuck 46949 from 
Ad5WHc/Ad35WHc immunization group was 2,175 (Fig. 5.40A). As Fig. 5.40B 
shows, representative woodchuck 58063 immunized for three times with pCGWHc 
plasmid showed over 2-fold lower anti-WHs antibodies level (OD492nm value 0,949) at 
the same time point. The amount of anti-WHs decreased in the animals from week  6 
to 10 pi, as the WHV infection was not longer present. Comparable results were 
obtained from woodchuck 46957 and 70096, as shown in Fig. 10.6A-B (Appendix 
section). The woodchuck 58059 became anti-WHs positive later than the other 
immunized animals, at week 9 pi (Fig. 5.40C). The low level of anti-WHs antibodies 
was still detectable at the end of the monitoring period (week 25). The appearance of 
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anti-WHs antibodies in the serum of woodchuck 58059 correlated with the clearance 
of WHV DNA in the blood. 
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Fig. 5.40 Detection of anti-WHc and anti-WHs antibodies in the sera of 
woodchucks immunized with pCGWHc (B and C) plasmid or using recombinant 
adenoviral vectors expressing WHcAg (A) 
Woodchuck 46949 was intramuscularly immunized with Ad5WHc (red arrow) and boosted 
with Ad35WHc (blue arrow). Woodchucks 58063 and 58059 were pretreated with cardiotoxin 
(grey arrow) and subsequently immunized for three times with pCGWHc plasmid (black 
arrows). The woodchucks were intravenously inoculated with 1×107 WHV GE (week 0). 
Woodchucks sera were diluted 1:10 in PBS. WHcAg- and WHsAg-specific ELISA was 
peformed using protein G coupled to peroxidase.  
A 
B 
C 
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The control woodchuck 58055 (Fig. 5.41), which was intravenously infected with 
WHV, showed detectable anti-WHc antibodies at week 7 pi. Starting from week 9 pi 
the WHcAg-specific antibody level became comparable to those reached by 
immunized woodchucks. The antibodies were still present at the last screened time 
point: week 35 pi. The monitoring of anti-WHc antibodies of the second control 
woodchuck 58056 showed similar results (Appendix section, Fig. 10.6C). The anti-
WHs antibodies were detected from week 18 to 24 pi. The appearance of WHsAg-
specific antibodies correlated with WHV clearance from the peripheral blood at week 
22 pi. The other control woodchuck, 58056, did not develop anti-WHc antibodies. 
Lack of anti-WHs correlates with WHV persistence through the monitoring period.  
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Fig. 5.41 Detection of anti-WHc and anti-WHs antibodies in the sera of control 
woodchuck 58055 
The woodchuck was intravenously inoculated with 1×107 WHV GE (week 0). Woodchucks 
sera were diluted 1:10 in PBS. WHcAg- and WHsAg-specific ELISA was performed using 
protein G coupled to peroxidase.  
 
Taken together, immunization of naïve woodchucks with heterologous 
Ad5WHc/Ad35WHc regimen induced stronger WHcAg-specific T cell response than 
immunization for three times with pCGWHc plasmid. The WHcAg-specific T cell 
response in immunized woodchucks led to early induction of anti-WHs antibodies and 
resolution of WHV infection. Those results emphasize the role of T cell response 
against WHcAg in control of hepadnaviral infections. WHcAg-specific TH cells help in 
rapid and more robust secretion of anti-WHs as compared to the natural infection 
[Millich et al., 1987]. 
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5.8 Evaluation of DNA prime – AdV boost immunization in combination 
with entecavir treatment of chronically WHV-infected woodchucks 
To evaluate the effectiveness of heterologous DNA prime – AdV boost immunization 
regimen as the therapeutic vaccine in chronic hepadnaviral infections, the experiment 
based on the combination of antiviral treatment (entecavir, ETV) with immunizations 
of chronically WHV-infected woodchucks was performed.  
Seven WHV chronic carriers were treated for 23 weeks with the guanosine 
nucleoside analogue ETV. For the first 12 weeks of therapy, the drug was 
administered in the dose of 0,2 mg per day by using osmotic pumps (Durect). From 
week 8 to 23 of the therapy, subcutaneous injections of 1mg of ETV were performed 
twice a week. At week 7, five of the seven ETV-treated animals were injected 
intramuscularly with cardiotoxin. Starting from week 8, the animals received 
subsequently 9 intramuscular immunizations with DNA plasmids, expressing WHcAg 
and WHsAg, Ad5WHc, and Ad35WHc as shown in Fig. 5.42. Two animals, treated 
only with ETV, served as a control in the experiment. 
0 7   8      10    12     14    16         19          22 23     25     27
weeks
ETV 0,2 mg/day
ETV 2 mg/week
pCGWHc + pWHsIm Ad5WHc + pWHsIm Ad35WHc + pWHsIm
 
Fig. 5.42 Schedule of therapeutic DNA prime – AdV boost immunization in 
combination with entecavir treatment in chronic WHV carriers 
Seven chronically WHV-infected woodchucks (number: 61786, 61787, 61789, 61791, 61792, 
61793 and 61795) were treated with entecavir for 23 weeks. Initially, the drug was 
administered for 12 weeks in dose of 0,2 mg ETV per day, by mean of the osmotic pumps 
(Durect) implanted surgically under the skin of the animals. From week 8 to 23 of the 
therapy, subcutaneous injections of 1 mg ETV were performed twice a week. At week 7, five 
of the seven ETV-treated animals (number: 61786, 61787, 61789, 61792 and 61793) were 
pretreated with cardiotoxin (grey arrow) and one week later the animals received 
subsequently 9 intramuscular immunizations with 0,5 mg of pCGWHc together with 0,5 mg of 
pWHsIm (time points of immunization marked by the green arrows; weeks 8, 10, 12, 25 and 
27), 1×1010 PFU of Ad5WHc together with 0,5 mg of pWHsIm (red arrows; weeks 14 and 19) 
or 1×1010 PFU of Ad35WHc together with 0,5 mg of pWHsIm (blue arrows; weeks 16 and 
22). Two animals (number 61791 and 61795) were treated only with ETV and served as 
controls. 
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The WHV chronic carrier number 61787 that received the therapeutic immunizations 
survived till week 25 of the therapy (development of HCC). Since the bleeding of the 
animal was not possible at week 25, the last examined time point for most of the 
experiments for this woodchuck was week 22 of the therapy. The other woodchucks 
were monitored untill week 31 or 33 of treatment.  
5.8.1 Evaluation of the TH response 
The WHV-specific proliferative responses were detected in woodchuck PBMCs using 
2[3H]-adenine labelling as described in Methods (section 4.10). Results of triplicate 
cultures are presented as a mean stimulation index (SI) indicating the mean total 
absorption for peptide stimulated PBMCs divided by the mean total absorption for 
unstimulated control. 
As Fig. 5.43A shows, the WHV-specific proliferative responses were detectable in 
PBMCs of chronically WHV-infected woodchucks that received the combination 
therapy (ETV and DNA/Ad5WHc/Ad35WHc vaccinations) already after two 
immunizations with plasmid DNA vaccine (week 12 of therapy). Three out of 5 
woodchucks from this group (number 61787, 61792 and 61793) showed significant 
proliferative responses characterized by a stimulation index above 2,7. The detected 
responses were mostly directed against WHsAg-derived peptides: s224-239, s252-
263 or s420-431 (SI ranging from 2,94 to 22,4). Moreover, one WHV chronic carrier 
(61787) demonstrated WHcAg-specific proliferative responses after stimulation with 
c64-79 and c109-124 (SI equal 3,06 and 3,15 respectively). After three DNA 
injections (week 14 of therapy), all five immunized woodchucks showed significant 
proliferative responses (SI ranging from 3,21 to 6,25) against the WHsAg-derived 
peptide s252-267 (Fig. 5.43B). In addition, 3 out of 5 woodchucks demonstrated 
WHcAg-specific TH responses. Woodchuck 61787 responded to stimulation with 
peptide c109-124 (SI = 3,01), woodchuck 61789 to peptide c78-94 (SI = 3,16) and 
woodchuck 61793 to peptide c117-132 (SI = 3,37). 
Overall, the positive proliferative responses were present in those woodchucks that 
received the combination therapy (ETV + vaccinations) until week 25. Two weeks 
after the last ETV treatment and 3 weeks after the second Ad35WHc/pWHsIm 
immunization all three tested animals (61786, 61789 and 61792) had detectable 
WHV-specific TH responses (Fig. 5.43C). The woodchucks 61789 and 61792 
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demonstrated positive responses after stimulation with WHsAg-derived peptides 
s224-239 and s392-407 (SI ranging from 2,7 to 4,68). Woodchuck 61786 showed 
WHcAg-specific proliferative responses against c117-132 (SI = 3,72).  
The WHV chronic carriers number 61791 and 61795 treated only with entecavir did 
not show any significant WHV-specific proliferative responses during the monitoring 
period.  
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Fig. 5.43 WHcAg-specific and WHsAg-specific proliferative responses in 
chronic WHV carriers at the representative time points of therapy: week 12 (A), 
week 14 (B) and week 25 (C) 
Seven chronically WHV-infected woodchucks (number: 61786, 61787, 61789, 61791, 61792, 
61793 and 61795) were treated with ETV for 23 weeks. Five of the seven ETV-treated 
woodchucks (number: 61786, 61787, 61789, 61792 and 61793) received subsequently 9 
intramuscular immunizations with DNA plasmids, expressing WHcAg and WHsAg, Ad5WHc, 
and Ad35WHc. The animals number 61791 and number 61795 were treated only with ETV 
and served as controls. The PBMCs were separated from the blood of the animals at every 
examined time point and stimulated with panel of 10 WHcAg-specific and 16 WHsAg-specific 
peptides in triplicates. After 5 days of stimulation, cells were pulsed with 2[3H]adenine for 16h 
and the incorporation of 2[3H]adenine was measured. Results for triplicate cultures are 
presented as a mean stimulation index (SI); n.d. – not done, † - dead. 
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The detailed data of evaluation of WHcAg- and WHsAg-specific proliferative 
responses in chronically WHV-infected woodchucks that received combination 
therapy during the monitoring period are attached in the Appendix section 
(Fig. 10.7A-E). 
5.8.2 Evaluation of the CTL response 
The evaluation of cytotoxic T cell response was performed by WHcAg- and WHsAg-
specific CD107a degranulation assay until week 29 (2 weeks after the last 
immunization) as described in Methods (section 4.9.1).  
The WHV-specific degranulation responses in CD3+ CD4- T cell population were not 
detectable in most of the animals before week 22 of the treatment. At week 4 of ETV 
therapy, only a brief elevation in percentages of WHcAg- and WHsAg-specific CTLs 
were observed in three WHV chronic carriers (woodchucks 61786, 61791, and 
61795), as shown in Fig. 5.44 (data from time points 10 to 19 is not shown, as there 
was no WHV-specific CTL response detectable). This result indicates that the 
treatment with ETV that leads to a decrease of WHV replication can transiently 
restore functions of virus-specific CTLs. All woodchucks from the combination 
therapy group and control animals had comparable background percentages of 
WHcAg- and WHsAg-specific CTLs at the beginning of the immunization phase 
(week 8) [Fig. 5.44A]. The WHcAg-specific T cell responses appeared in two 
immunized woodchucks 61787 and 61792 at week  22. The percentages of 1,43% 
and 1,51% of WHcAg-specific CTLs detected for woodchuck 61787 and 61792, were 
three fold higher than the mean background value of 0,43% calculated for the 
negative controls of all woodchucks at all time points. The WHcAg-specific 
degranulation response was present in all 4 woodchucks from combination therapy 
group that survived the end of ETV treatment until the last monitored time point week 
29. The peak of WHcAg-specific CTLs detected in peripheral blood of the immunized 
woodchucks was detected at week 27 of treatment; the percentages of CD107a+ 
CD3+ CD4- T cells were ranging between 1,2% - 2,1% (mean: 1,7%). The control 
animals that were treated only with ETV did not show any significant WHcAg-specific 
T cell response. The mean percentages of WHcAg-specific CTLs detected from week 
22 to 29 were ranging between 0,29% and 0,55% and were comparable with the 
mean background value (0,43%).  
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The impact of the therapeutic immunization on the induction of WHsAg-specific 
cytotoxic response is more difficult to assess. The WHsAg-specific CTL responses 
were not so prominent as the responses directed against WHcAg and appeared only 
transiently (Fig. 5.44B). Nevertheless, woodchucks that received the combination 
therapy demonstrated higher percentages of WHsAg-specific CTLs in comparison to 
background values detected for only ETV treated animals. The mean percentages of 
WHsAg-specific CTLs detected from week 25 to 29 of therapy were ranging between 
0,88% - 1,03% in immunized woodchucks and 0,31% - 0,44% in the controls. The 
peak of WHsAg-specific degranulation response detected in peripheral blood of WHV 
chronic carriers that received immunization differed in time. At week 22 the highest 
percentages of WHsAg-specific CTLs were detected for 61792 (1,38%), at week 25 
for 61789 (1,49%), at week 29 for 61786 and 61793 (1,63 and 1,34% respectively). 
Woodchuck 61787 did not show any significant WHsAg-specific degranulation 
response (the last examined time point was week 22 of treatment). 
The detailed data of evaluation of WHcAg- and WHsAg-specific CD107a+ 
degranulation responses detected in CD3+ CD4- T cell population for each single 
examined chronically WHV-infected woodchuck are attached in the Appendix section 
(Fig. 10.8A-G).  
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Fig. 5.44 Determination of degranulation responses in WHV chronic carriers at 
the representative time points of therapy: WHcAg-specific CTLs (A), WHsAg-
specific CTLs (B) 
Seven chronically WHV-infected woodchucks were treated with ETV for 23 weeks. Five of 
the seven ETV-treated woodchucks received subsequently 9 intramuscular immunizations 
with DNA plasmids, expressing WHcAg and WHsAg, Ad5WHc, and Ad35WHc. Two animals 
were treated only with ETV and served as controls. PBMCs were expanded in vitro for 3 
days with WHcAg-derived epitope c96-110 or WHsAg-derived epitope s220-234. 
Unstimulated cells and cells stimulated with unrelated CMV-derived peptide served as 
negative controls. The background value was calculated as a mean of all values detected for 
negative controls in all woodchucks at all time points. The T cell response was evaluated by 
CD107a degranulation assay. Presented values show the percentage of CD107a+ CD3+ 
CD4- T cells in the CD3+ CD4- T cell population.  
A 
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5.8.3 Evaluation of the viral loads kinetics 
To investigate the effect of the combination therapy on WHV replication, the sera of 
chronically WHV-infected woodchucks were quantified by real-time PCR analysis 
(Methods, section 4.13.3).  
As Fig. 5.45 shows, the basal level of the viral loads prior to ETV therapy (at week 0) 
in WHV chronic carriers enrolled in the experiment was ranging from 3,1×109 to 
1,2×1011 WHV GE/ml of serum. Approximately a 5-log decrease in the viral loads 
was observed during the first 8 weeks of the ETV pre-treatment period in all 
examined woodchucks. At the time of the first immunization (week 8), no significant 
difference in the viral loads between the groups of woodchucks was observed. The 
chronic carrier number 61792 had already undetectable WHV viremia below 1,0×103 
WHV GE/ml of serum. Between weeks 12 to 19 of therapy all woodchucks remained 
WHV negative in the blood. The rebound of viremia in ETV-only treated woodchucks 
was observed at week 22 of treatment. At week 25 the two control chronic carriers 
(61791 and 61795) showed viral loads around 5,4×104 and 2,4×107 WHV GE/ml of 
serum, whereas the woodchucks that were treated with the combination therapy were 
still WHV negative. Two out of four woodchucks (61786 and 61789) that survived 
through the whole monitoring period demonstrated a detectable viral load at week 27 
and 29, respectively. Woodchucks number 61786 and 61789 reached the basal level 
of the WHV viremia ten weeks after the end of ETV treatment (week 33). The viral 
loads were 5,3×1010 and 2,9×1010 WHV GE/ml of serum, respectively and were 
comparable to the level of WHV GE in the control animals. The other two 
woodchucks from the combination therapy group were WHV negative until the end of 
the monitoring period. Woodchuck 61792 had an undetectable viral load at week 33 
and still remained WHV negative at week 43 (data not shown). Woodchuck 61793 
had an undetectable viral load until week 31. At this time point, the animal had to be 
sacrificed due to serious health problems not related to WHV infection (paralysis of 
the hind limbs). 
The detailed data of the viral loads monitoring for all examined chronically WHV-
infected woodchucks are attached in the Appendix section (Fig. 10.9A-G).  
Those results demonstrate that immunization of chronically WHV-infected 
woodchucks with heterologous DNA prime – AdV boost regimen leads to prolonged 
suppression of viremia after the end of the ETV treatment. During the follow-up the 
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rebound of viremia in those woodchucks was observed up to 21 weeks later (end of 
the study) as compared to ETV-only treated controls. 
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Fig. 5.45 Determination of the viral loads in WHV chronic carriers at the 
representative time points of therapy 
Seven chronically WHV-infected woodchucks were treated with ETV for 23 weeks. Starting 
from week 8, five of the seven ETV-treated woodchucks received subsequently 9 
intramuscular immunizations with DNA plasmids, expressing WHcAg and WHsAg, Ad5WHc, 
and Ad35WHc. Two animals were treated only with ETV and served as controls. The viral 
DNA was extracted from woodchuck sera and the viral loads were quantified per ml of 
serum, using real-time PCR analysis.  
 
5.8.4 Seroconversion to anti-WHs 
Apart from undetectable viral loads, the seroconversion of HBsAg to anti-HBs is the 
most important criterion of the resolution of HBV infection in humans [Chisari et al., 
1995]. To check whether the examined chronic WHV carriers developed anti-WHs 
antibodies, the woodchuck sera were tested by ELISA (Methods, section 4.12). 
As presented in table 5.2, only woodchucks 61792 and 61793 that demonstrated an 
undetectable viral load at the end of the monitoring period became αWHs positive. 
Woodchuck 61793 developed anti-WHsAg specific antibodies at week 19 of therapy 
and woodchuck 61792 at week 22. The other woodchucks that were treated with a 
combination of immunization and ETV treatment remained anti-WHs positive, as well 
as the control woodchucks treated only with ETV. 
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Tab. 5.2 Presence of anti-WHsAg specific antibodies in the sera of WHV 
chronic carriers 
 weeks 0 2 4 6 8 10 12 14 16 19 22 25 27 29 31 33 
61786 - - - - - - - - - - - - - - n.d. - 
61787 - - - - - - - - - - - † 
61789 - - - - - - - - - - - - - - n.d. - 
61792 - - - - - - - - - - + + + + + + 
ET
V 
+
 
va
cc
in
e
 
61793 - - - - - - - - - + + + + + + † 
61791 - - - - - - - - - - - - - - n.d. - 
ET
V 
61795 - - - - - - - - - - - - - - n.d. - 
n.d. – not done; † - dead 
5.8.5 Evaluation of WHV replication in the liver 
To evaluate the replication of WHV (replicative intermediates) in the liver of 
chronically WHV-infected woodchucks, the Southern blot analysis of DNA obtained 
from the liver samples collected post-mortem or through liver biopsy was performed. 
As a probe [32P]-labelled plasmid containing the entire WHV strain 8 genome was 
used (Methods, section 4.14.2). 
As shown in Fig. 5.46, Southern blotting showed WHV replicative intermediates, 
corresponding to the single-stranded DNA (ssDNA) and relaxed circular DNA 
(RC DNA). The WHV chronic carrier number 61787 died at week 25 shortly after the 
last ETV treatment. The low replication of WHV in the liver of this animal 
demonstrates the successful inhibition of the WHV replication by antiviral treatment. 
Only ssDNA replicative intermediates were detected in the liver of 61787. The 
woodchucks 61792 and 61793 had undetectable WHV in the blood at the end of the 
monitoring period (week 43 and 31, respectively) and developed anti-WHsAg 
antibodies. Nevertheless, only woodchuck 61792 was WHV negative in the liver at 
week 43. Woodchuck 61793 demonstrated a low level of WHV replication confirmed 
by detection of WHV ssDNA. The formation of RC DNA was still impaired in the liver 
of this animal at week 31 (8 weeks after the end of ETV therapy). This result shows 
that woodchuck 61793 did not completely clear the WHV replication. The other WHV 
chronic carriers treated with the combination therapy (61786 and 61789) and the 
control woodchucks (61791 and 61795) showed comparable levels of WHV 
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replication at the time points of sacrifice. All WHV replicative intermediates were 
detected in the livers of those animals from week 35 to week 38.  
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Fig. 5.46 Determination of WHV replication in the livers of WHV chronic carriers 
Southern blot analysis was performed on the DNA obtained from the liver samples collected 
post-mortem or by liver biopsy from chronically WHV-infected woodchucks at given time 
points. Woodchucks number 61786, 61787, 61789, 61792 and 61793 were treated with 
combination therapy. Woodchucks 61791 and 61795 were treated only with ETV and served 
as controls. WHV replicative intermediates were detected by hybridization with [32P] labelled 
plasmid containing the entire WHV strain 8 genome as a probe. The arrows indicate the 
relaxed circular WHV DNA (RC DNA; 3,0 kbp) and single-stranded WHV DNA (ssDNA; 
approximately 1,5 kbp). 
 
5.8.6 Monitoring of serum transaminases levels 
The high values of liver transaminases in the serum of chronically HBV-infected 
patients or chronically WHV-infected woodchucks may indicate not only the T cell 
activity in the liver but also the damage induced by the development of hepatocellular 
carcinoma (HCC) [Chisari et al., 1995; Cote et al., 2000; Wang et al., 2004; 
Rehermann et al., 2005]. Therefore, the monitoring of the GOT levels in the sera of 
the WHV chronic carriers during the experiment was performed (Methods, section 
4.15).  
As shown in Fig. 5.47, two animals from the combination therapy group (61786 and 
61787) and one control animal (61795) demonstrated elevated GOT level in the 
serum at the beginning of ETV treatment (67, 87 and 150 IU/l, respectively). During 
the ETV treatment the serum GOT reached levels below 50 IU/l and fluctuated 
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around slightly elevated values in the sera of all examined woodchucks. Starting from 
week 23, correlating with the end of ETV treatment, the serum GOT levels 
significantly increased in both control chronic carriers treated only with entecavir and 
reached the values 106 IU/l in woodchuck 61791 and 845 IU/l in woodchuck 61795 at 
the end of monitoring period (week 33). At the same time point, the GOT values in 
woodchucks treated with ETV and additionally immunized, the elevated GOT levels 
were detected only in woodchuck 61789 (71 IU/l). The other woodchucks from this 
group demonstrated GOT levels within the “normal” range (from 12 to 21 IU/l). 
The detailed data of GOT levels in the sera of all examined chronically WHV-infected 
woodchucks are presented in the Appendix section (Fig. 10.9A-G). 
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Fig. 5.47 Determination of GOT levels in the sera of WHV chronic carriers at the 
representative time points of therapy 
Seven chronically WHV-infected woodchucks were treated with ETV for 23 weeks. Starting 
from week 8, five of the seven ETV-treated woodchucks received subsequently 9 
intramuscular immunizations with DNA plasmids, expressing WHcAg and WHsAg, Ad5WHc, 
and Ad35WHc. Two animals were treated only with ETV and served as controls. The GOT 
levels in woodchuck sera were quantified using the standard diagnostic methods. Elevation 
of GOT level is assumed above 50 IU/l (border level). 
 
5.8.7 Development of HCC 
The chronic WHV infection is nearly always associated with the development of HCC 
in the woodchucks. The tumours appear usually in the third year of life [Popper 
et al.,1987; Tennant et al., 2004]. As wild-trapped WHV chronic carriers were used in 
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the study, the determination of their age is not possible. The presence of HCC was 
confirmed in the livers of woodchucks post-mortem or through liver biopsy procedure.  
The only chronically WHV-infected woodchucks that did not develop HCC were 
61792 and 61793 from the group of animals that were treated with ETV and 
additionally received therapeutic vaccine. At week 43 and 31, respectively, the liver 
tissue of those animals were indistinguishable from the ‘healthy’ liver. The other WHV 
chronic carriers in this group showed the tumours at the time of sacrifice. Woodchuck 
61787 that died shortly after the end of ETV treatment showed one HCC nodule 
approximately 3,5 cm in diameter. The early occurrence of the tumour together with 
very low WHV replication detected in the liver of this woodchuck (Fig. 5.46; 
page 135) at the time point of death suggests the presence of HCC already at the 
beginning of the experiment. At week 35, in the liver of woodchuck 61789 one HCC 
nodule approximately 4 cm in diameter and two smaller ones (0,5 - 1 cm in diameter) 
were present. The representative woodchuck 61786 sacrificed at week 38 showed 
two small nodules approximately 3,5 cm in diameter presented in the Fig. 5.48A. The 
tumours in the combination therapy group were significantly smaller than the HCC 
detected in the ETV control group. As shown in Fig. 5.48B, the woodchuck 61791 
had one big HCC nodule approximately 6,5 cm in diameter and two smaller ones (2,5 
cm in diameter) at week 36. The largest tumour was detected for the control 
woodchuck 61795. At week 35, the woodchuck demonstrated two large nodules 
around 6 cm in diameter and three smaller ones ranging from 4 to 2 cm in diameter 
distributed all over the liver (data not shown). 
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Fig. 5.48 The demonstration of the HCC in the livers of WHV chronic carriers 
The representative photography for woodchuck 61786 treated with combination therapy at 
week 38 (A). The representative photography of the ETV control woodchuck 61791 at week 
36 (B). The arrows indicate HCC nodules. 
 
 
 
Taken together, the data clearly demonstrates that the combination therapy of 
chronically WHV-infected woodchucks based on ETV and heterologous DNA prime – 
AdV boost immunizations leads to induction of a robust WHcAg- and WHsAg-specific 
T cell response, prolonged suppression of WHV replication, and delay of HCC 
development in comparison to ETV only treated controls. Moreover, two WHV 
chronic carriers number 61792 and 61793 developed the sustained antiviral 
response, which was confirmed by the detection of anti-WHs antibodies and the 
absence of WHV DNA in the blood. Woodchuck number 61792 completely cleared 
WHV infection also in the liver. 
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6 Discussion 
Since the introduction of preventive vaccination programmes against hepatitis B in 
over 170 countries, the number of new infections has been continuously decreasing. 
Despite the success of the prophylactic vaccines, chronic HBV infection is still 
a global health problem. The WHO estimates that over 360 million people are 
persistently infected with HBV, of whom 1 million die each year from HBV associated 
liver cirrhosis or hepatocellular carcinoma. 
Currently, two types of antiviral therapies of chronic hepatitis B are approved: 
treatment with pegylated interferon alpha 2a (PEG-IFNα) or nucleoside analogues, 
such as adefovir, entecavir, lamivudine, telbivudine and tenofovir [Conjeevaram 
et al., 2003; Janssen et al., 2005; Lau et al., 2005; Dienstag, 2008]. Nevertheless, 
the efficacy of those therapies is still limited. On the one hand, treatment with PEG-
IFNα leads to a sustained antiviral response in only one third of the patients. On the 
other hand, treatment with nucleoside analogues can significantly suppress HBV 
replication, but cannot completely eradicate the virus. After withdrawal of the drug, 
the rebound of viremia is observed in the majority of patients. Furthermore, the long-
term treatment is subsequently associated with the appearance of drug-resistant 
HBV strains [Raney et al., 2003; Locarnini et al., 2006]. Therefore, the new 
approaches in treating chronic hepatitis B are urgently needed. 
It is well documented that an appropriate adaptive immune response is required to 
efficiently control the HBV infection. Humoral immune response, especially 
neutralizing anti-HBs antibodies, play a key role in preventing HBV spread to non-
infected hepatocytes [Chisari et al., 1995; Rehermann et al., 2005]. Nevertheless, an 
early, vigorous, polyclonal and multi-specific T cell immune response directed against 
hepatitis B virus antigens, is crucial for the resolution of the infection [Ferrari et al., 
1990; Penna et al., 1996; 1997; Guidotti et al., 1999; Maini et al., 2000; Thimme et 
al., 2003]. In contrast, chronic HBV carriers demonstrate weak, transient or often 
undetectable CD8+ T cell response that correlates with HBV persistence [Jung et al., 
1991; Penna et al., 1991; Rehermann et al., 2005; Yang et al., 2010]. Therefore, the 
therapeutic vaccination approaches able to boost a functional antiviral T cell 
response may be a promising strategy to overcome the viral persistence.  
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Numerous clinical trials of therapeutic immunization exploited the conventional 
HBsAg-based protein vaccines. However, the anti-viral effect was only transient and 
did not lead to an effective control of the HBV [Pol et al., 1994; 2001; Couillin et al., 
1999; Jung et al., 2002; Dikici et al., 2003; Ren et al., 2003; Safadi et al., 2003; 
Yalcin et al., 2003]. The strategies designed to specifically stimulate HBV-specific 
T cell response were also not successful. The DNA vaccine expressing small and 
middle envelope proteins resulted just in a transient induction of the HBV-specific 
T cell response in chronic HBV carriers [Mancini-Bourgine et al., 2004]. It was shown 
that high-level viremia negatively influences the virus-specific T cell response 
[Webster et al., 2004]. Therefore, the reduction of HBV replication by the antiviral 
treatment may be a rational strategy to enhance the effect of therapeutic 
immunization. Nevertheless, the combination of the HBsAg-based vaccines with 
antiviral treatment using lamivudine did not lead to a satisfactory improvement of the 
therapies either [Dahmen et al., 2002; Horiike et al. 2005; Vandepapelière et al., 
2007]. Those findings clearly imply that new concepts of therapeutic vaccination are 
needed. 
The woodchuck (Marmota monax) is a useful preclinical model for developing new 
therapeutic approaches in chronic hepadnaviral infections. Recently described 
advancements in the characterization and monitoring of the woodchuck T cell 
response and the natural occurrence of chronic WHV infection allow to evaluate 
potentially new therapeutic strategies in this model. Even though several innovative 
approaches combining antiviral treatment with nucleoside analogues, DNA vaccines, 
and protein vaccines were tested in chronically infected woodchucks, the 
effectiveness of those strategies was very limited [Roggendorf et al., 1995; Hervas-
Stubbs et al, 1997; 2001; Menne et al., 2000; 2002; Lu et al., 2003; 2008]. However, 
the application of DNA vaccine expressing WHcAg in combination with antivirals in 
chronic WHV carriers led to a prolonged control of viral replication [Lu et al., 
unpublished results]. This result clearly shows that the induction of WHcAg-specific 
T cells using more potent vaccines, such as recombinant viral vectors, may be a way 
to achieve a sustained antiviral response. Therefore, in the presented study the novel 
therapeutic vaccination approach based on improved DNA vaccine and recombinant 
adenoviral vectors expressing WHcAg was evaluated in the preclinical model - 
woodchucks.  
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Considering the limited number of woodchucks that can be used in the experimental 
group, as well as the still limited number of markers and techniques available for this 
model, the preliminary experiments were performed in mice. Usage of mouse models 
for evaluation and optimization of the vaccination regimens is a common and rational 
approach. It allows the measurement of multiple parameters, providing sufficient 
number of animals to obtain statistically significant results. To take advantage of the 
mouse models for the evaluation of the various immunization strategies in the 
presented study, the WHcAg-specific CD8+ T cell response was characterized in 
mice.  
6.1 Characterization of the WHcAg-specific CD8+ T cell response after 
DNA and DNA-AdV immunization in mice 
The H-2b-restricted epitopes within the WHcAg sequence were identified, to 
efficiently evaluate the CD8+ T cell response elicited by vaccination in C57BL/6 and 
WHV transgenic mice. The strategy for the epitope finemapping was based on in vitro 
expansion of WHcAg-specific CD8+ T cells subsequently with peptide pools, 15-mer 
peptides and finally with 9-mer peptides. This approach allowed identification of two 
H-2b-restricted epitopes within the WHcAg sequence (Fig. 5.5 and Fig. 5.6; pages 70-
71). The first epitope c13-21 is located within the N-terminus and the second c86-94 - 
within the central region of the WHcAg sequence (Fig. 5.7; page 72). The epitope 
c13-21 was more frequently recognized in mice immunized with plasmid DNA 
vaccine. Moreover, the IFNγ response detected in the splenocytes of mice after 
stimulation with c13-21 was stronger than with c86-94. Therefore, it can be 
considered as an immunodominant epitope. Many characterized woodchuck 
TH epitopes and the dominant CTL epitope c96-110 are located in the N-terminal or 
central region of WHcAg [Menne et al., 1998; Frank et al., 2007]. Interestingly, the 
human immunidominant HLA-A2-restricted epitope c11-27 is also located within the 
N-terminus of HBcAg [Bertoletti et al., 1997]. The structure of the core protein is 
highly conserved among hepadnaviruses and the amino acid homology between 
WHcAg and HBcAg accounts for approximately 70% [Ganem et al., 2001]. The co-
localization of the mouse, human, and, woodchuck epitopes on the N-terminal or 
central α-helix of the core protein indicates that these regions are highly 
immunogenic in vivo and may be preferentially presented in the context of various 
MHC class I molecules. 
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In silico prediction of MHC class I epitopes has been exploited for their identification 
in humans and in mice. Therefore, the question was raised whether the results of 
epitope finemapping correlate with the computational prediction. Indeed, the results 
of CD8+ T cell epitope finemapping in mice confirmed the prediction determined by 
MHC class I epitope prediction algorithms (SYFPEITHI and BIMAS). Both softwares 
assigned the best score for identified H2-Db–restricted nonamer c13-21. The 
algorithms also typed the other peptide c86-94, although with variable scores 
(Tab. 5.1; page 73). A recently published study, described the epitopes of WHcAg in 
BALB/c mice (genetic background H-2d) basing on the computational prediction. This 
strategy resulted in the identification of two CD8+ T cell H-2d -restricted epitopes   
c19-27 and c61-69 [Ochoa-Callejero et al., 2010].  
These findings imply that in silico prediction may be a more rational approach in the 
characterization of the epitopes for MHC molecules of known genetic background.  
6.1.1 Immunization with vaccines demonstrating improved WHcAg expression 
induces a more vigorous immune response in mice 
Previously described reports clearly imply that available therapeutic vaccines need 
further improvement. Therefore, the following issues were addressed in the 
presented study. Firstly, whether optimization of the WHcAg expression can be 
achieved by a simple genetic modification of the vaccine vectors. Secondly, whether 
this improvement may influence the magnitude of the elicited immune response after 
immunization in vivo. Thus, the strategy based on insertion of the intron sequences 
into the expression vectors was evaluated. 
The presence of intron sequences protects mRNA molecules from degradation and 
facilitates their export into the cytoplasm [Kurachi et al., 1995; Luo et al., 1999]. 
Those factors result in a more efficient translation process and, as a consequence, 
increased gene expression. The construction of the novel DNA plasmid (pCGWHc) 
and recombinant adenoviral vectors (Ad5 and Ad5F35) containing a β-globin intron 
sequence between the CMV promoter and WHcAg gene proved that the raised 
hypothesis was true. The presence of a β-globin intron in the expression cassette of 
the vectors indeed resulted in a significant increase of WHcAg expression in 
comparison to the constructs that lacked the intron sequences (Fig. 5.9; page 75 and 
Fig. 5.16; page 85).  
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As the improvement in the antigen expression may lead to a better presentation of 
the antigen and the induction of a more robust immune response in vivo, the 
immunization of mice with the improved DNA vaccine (pCGWHc) and DNA vaccine 
that shows low expression of WHcAg (pWHcIm) was performed. The aim of the study 
was to develop the vaccines that are able to elicit potent cellular immune response in 
chronically WHV-infected woodchucks. Therefore, the appropriate delivery of the 
DNA vaccines needed to be taken into consideration. It was shown that intramuscular 
delivery of the DNA vaccines results in an induction of TH1-dominant type of immune 
response [Siegel et al., 2001], whereas intradermal application, e.g. by gene gun, 
preferentially primes TH2 type of response [Feltquate et al., 1997]. Therefore, the 
intramuscular route of immunization was chosen to preferentially induce a vigorous 
CD8+ T cell response in vivo (TH1). 
The results of the presented study clearly showed that the improved WHcAg 
expression by the novel DNA vaccine (pCGWHc) resulted in a very strong humoral 
and cellular immune responses in mice, as compared to the plasmid that showed low 
antigen expression. As expected, both plasmids induced a TH1 type of response 
confirmed by IgG2a subtype of anti-WHc (Fig. 5.12A; page 78) and a secretion of 
IFNγ by CD8+ T cells (Fig. 5.13A; page 80). The broader immune response induced 
by the novel DNA vaccine was proven by the detection of low level IgG1 (IgG2a: IgG1 
ratio = 4:1) [Fig. 5.12B; page 78]. The antibodies of IgG1 subtype are predominantly 
detected during TH2 type of response [Stevens et al., 1988]. Nevertheless, it was 
shown that the appearance of low level of IgG1 accompanied with high level of IgG2a 
indicates a very strong TH1 type of response. In addition, the optimized plasmid 
elicited approximately 3-fold higher percentages of IFNγ+ CD8+ T cells detected in 
splenocytes expanded in vitro with both previously characterized WHcAg epitopes 
(Fig. 5.13B; page 80). These results confirm that the high antigen expression 
provided by the optimized DNA vaccine induces more vigorous humoral and cellular 
immune responses. Moreover, the results are consistent with previous findings, 
which show that an improved antigen expression may be also achieved by using the 
codon optimization strategy, inclusion of a consensus Kozak sequence or more 
potent hybrid promoters in construction of adenoviral-based vaccines. In those 
studies the immunization of mice with optimized adenoviral vectors led to the 
induction of a more vigorous antibody and T cell responses and provided an 
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enhanced protection against infection with Ebola virus and venezuelan equine 
encephalitis virus (VEEV) [Richardson et al., 2009; Williams et al., 2009]. The 
strategy based on the insertion of intron used in the presented study suggested that 
this approach can also be successfully used for the optimization of the vaccines.  
As the generation of the vaccines that demonstrate better efficacy in vivo was 
accomplished, the question was raised whether the further optimization of the 
vaccination regimen may lead to an additional improvement of the induced immune 
response. 
6.1.2 Optimization of the vaccination regimen by usage of AdVs leads to 
induction of the increased magnitude of response in mice 
Vaccines based on recombinant viruses have gained a great interest because of their 
ability to stimulate robust humoral and cellular immune responses. The successful 
generation of the optimized adenoviral vectors raised the question whether their 
application may be beneficial for the improvement of the DNA vaccination protocol. 
Taking into consideration that the induction of an effective immune response in the 
chronic WHV carriers would definitely require multiple vaccinations, the benefits of 
using AdVs displaying the fibers from distinct serotypes was also evaluated.  
The levels of anti-WHc antibodies were significantly higher in groups of mice boosted 
with Ad5WHc or Ad35WHc than in those boosted with pCGWHc (Fig. 5.19; page 88). 
Those results support the findings of Yang et al., who demonstrated higher 
antibodies titer against Ebola virus glycoprotein (GP) in mice immunized in DNA-Ad5 
manner than in mice immunized only with DNA vaccine [Yang et al., 2003]. The 
strong antibody response correlated with significantly higher frequencies of 
IFNγ+ CD8+ T cells detected in both AdV-boosted groups than in DNA-only 
immunized mice (Fig. 5.21; page 91). Similar results were obtained in mice and non-
human primates during the evaluation of several immunization strategies in the 
development of prophylactic vaccines against HIV and Ebola virus [Casimiro et al., 
2003; Yang et al., 2003]. A slightly lower percentage of IFNγ+ CD8+ T cells detected 
in mice immunized with DNA-Ad35WHc than with DNA-Ad5WHc may be due to the 
fact that those vectors use different receptors to be internalized into the cells. The 
recombinant adenoviral vector serotype 5 interacts with CAR receptor and the 
chimeric Ad35 fiber binds to CD46 [Bergelson, 1999]. Concordant with the presented 
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results, a slightly less effective performance of Ad5F35 than Ad5 immunization in 
mouse model was shown previously [Bayer et al., 2008]. 
The obtained results clearly indicate that the addition of recombinant adenoviral 
vectors to the DNA vaccination regimen further improved the magnitude of the 
induced CD8+ T cell response. Therefore, the question whether the DNA-AdV 
immunization induces the T cells of a different phenotype as the DNA immunization 
alone was addressed. 
6.1.3 DNA-AdV immunization induces the same phenotype of CD8+ T cells as 
DNA immunization 
Recent developments in the multicolor flow cytometry technology have made it 
possible to simultaneously examine several functionality markers on a cellular level. 
Antigen-specific CD8+ T cells that concurrently display multiple functions, 
e.g. degranulation and various cytokine production, have been associated with non-
progressive HIV infection [Betts et al., 2006] and protective immunity against vaccinia 
virus vaccination [Precopio et al., 2007]. Defects in the cytokine production by CD8+ 
T cells during chronic HBV and progressive HIV infection have been recently 
reported [Zimmerli et al., 2005; Das et al., 2008]. Therefore, induction of a potent 
multifunctional CD8+ T cell response is highly desirable. The immunization of healthy 
individuals with DNA and Ad5, expressing HIV-1 gag protein, induced a distinct CD8+ 
T cell response profile in comparison to Ad5-Ad5 immunization. The DNA-Ad5 
regimen elicited a more diverse sets of phenotypes, particularly those which 
displayed the multiple markers, in a higher proportion of the vaccinees [Cox et al., 
2008]. Those findings show that heterologous DNA prime – AdV boost might be more 
effective in inducing the multifunctional CD8+ T cell response. To address this 
hypothesis the CD8+ T cell response induced by DNA-AdV and only DNA vaccination 
regimens was examined in two functionality assays. The first assay combined the 
evaluation of the CD8+ T cell degranulation functions (detected by CD107a 
degranulation marker) with the production of most potent anti-viral cytokine IFNγ. The 
percentages of the CD8+ T cells that co-expressed both markers were significantly 
higher (approximately 3-fold) in splenocytes of mice immunized in heterologous DNA-
Ad5WHc or DNA-Ad35WHc than in mice immunized only with DNA (Fig. 5.22; page 
93). Nevertheless, the “quality” of induced cells was comparable. More than 90% of 
all IFNγ+ CD8+ T cells were also CD107a+ in splenocytes of mice from all vaccinated 
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groups. The second analysis evaluated simultaneous secretion of TH1 type cytokines 
such as IFNγ, TNFα, and IL-2 by CD8+ T cells. Mice immunized with DNA-Ad5WHc 
or DNA-Ad35WHc exhibited significantly higher percentages of IFNγ+, TNFα+ and   
IL-2 CD8+ T cells, compared to the group only immunized with DNA (Fig. 5.23A; page 
95). Determination of single, double and triple positive cells that produce IFNγ, TNFα 
and IL-2 within the CD8+ T cell population, demonstrated that there was no difference 
in “quality” of cytokines secreting CD8+ T cells between the groups (Fig. 5.23B; 
page 95).  
These results clearly demonstrate that heterologous DNA prime – recombinant 
adenovirus boost immunization induced an extremely robust immune response in 
comparison to DNA vaccination alone. Even though the magnitude of immune 
response was significantly higher, there was no apparent difference in the phenotype 
of the CD8+ T cells induced by DNA or DNA-AdV regimen. This finding can be a 
result of using the same priming strategy for all immunization regimens. The DNA 
vaccines proved to be a very potent tool in priming the T cell response [Barouch 
et al., 2001]. In absence of the protein content of the viral vector, DNA immunization 
facilitates the development of the T cell response specific against the antigen of 
interest. The DNA immunization effectively induces a long-term memory T cell 
response [Michel et al., 2001]. Though the response might be at a relative low level, it 
may select the T cells with receptors of increased affinity [Busch et al., 1999]. The 
immunization with a very immunogenic recombinant adenoviral vector results in 
a robust boosting of the primary antigen-specific response. Those findings provide 
a possible explanation of the difference in the quantity but not in the “quality” of CD8+ 
T cell response between the DNA and DNA-AdV vaccination regimens. The efficacy 
of the heterologous DNA-AdV immunization was further evaluated by the 
characterization of CD8+ T cell functions in vivo. 
6.1.4 DNA-AdV immunization induces CD8+ T cells with stronger cytotoxic 
potential in vivo than DNA immunization 
The evaluation of the CTL’s effector functions after DNA -AdV immunization directly 
in vivo, gives an insight whether this regimen elicits more CD8+ T cells with stronger 
cytotoxic potential than DNA vaccination alone. The results of in vivo cytoxicity assay 
showed that, indeed, the mice immunized in DNA-Ad5WHc manner showed 
significantly improved killing of the c13-21 loaded ‘target cells’ than mice immunized 
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only with DNA (Fig. 5.24; page 97). This result proves that the CD8+ T cells, induced 
by DNA prime-Ad5WHc boost immunization, show a stronger cytotoxic activity in 
vivo.  
Taken together, these findings led to the conclusion that improvement of the vaccines 
and optimization of the vaccination regimen by addition of AdV brought an synergistic 
effect. The innovative heterologous prime-boost regimen does not only result in an 
induction of the extremely robust CD8+ T cell response, but also seems to be 
potentially more effective in killing WHV-infected cells than only DNA regimen.  
6.2 The DNA prime – AdV boost breaks the immune tolerance against 
WHV antigens in WHV transgenic mice 
The preliminary results obtained from C57BL/6 mice showed that the utility of 
improved vaccines and optimization of the immunization protocol induces a more 
potent WHcAg-specific response than previously investigated strategies. Therefore, 
the question whether the improved DNA-AdV immunization is able to overcome the 
immune tolerance to WHV-antigens in 1217 WHV Tg mice was raised. As 1217 WHV 
Tg mice show an undetectable T cell response to the WHV antigens, they can model 
chronic hepadnaviral infection. Therefore, the issue whether improved vaccination is 
able to induce anti-WHc antibodies was addressed. 
It was shown previously that immunization of 1217 WHV Tg mice with pWHcIm 
plasmid, expressing WHcAg, induces significant levels of IgG2a subtype of anti-WHc 
antibodies [Meng et al., manuscript in preparation]. In the presented study similar 
results were obtained after immunization of mice with optimized pCGWHc plasmid. 
Mice immunized in DNA-Ad5WHc manner developed significantly higher levels of 
anti-WHc in comparison to the group of immunized only with DNA, as it was shown in 
C57BL/6 mice. All mice immunized with DNA vaccine or DNA-Ad5WHc demonstrated 
only IgG2a subtype of anti-WHc antibodies (Fig. 5.27; page 100). Interestingly, the 
additional increase in anti-WHc levels after second boosting immunization with 
Ad35WHc (DNA-Ad5-Ad35WHc) correlated with the development of high levels of 
IgG1 in several mice (Fig. 5.27B; page 100). Almost the same levels of IgG2a and 
IgG1 antibodies detected in three out of five mice (IgG2a:IgG1 ratio = 4:3) may indicate 
the development of a mixed TH1/TH2 responses. As the robust humoral immune 
response could be elicited by the improved DNA-Ad5WHc or DNA-Ad5-Ad35WHc, 
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next, the impact of vaccination on induction of WHcAg-specific CD8+ T cell response 
was evaluated.  
The immunization experiments of 1217 WHV Tg mice showed that WHcAg CD8+ 
T cell response can be elicited upon pWHcIm immunization. Nevertheless, the 
magnitude of the response was significantly lower than in normal mice [Meng et al., 
manuscript in preparation]. The results obtained in the study reveal the same 
tendency. Immunization with optimized pCGWHc vaccine induced a low IFNγ 
response, that was significantly higher in the splenocytes of mice immunized with 
heterologous DNA-AdV regimen (Fig. 5.29A-B, page 103). The CD8+ T cell response 
obtained for groups of 1217 WHV Tg mice immunized with DNA or DNA-Ad5 was 
significantly lower than this being induced in respective groups of C57BL/6 mice (Fig. 
5.29C; page 103). These results indicate that there is only a partial immune tolerance 
to the WHV antigens in 1217 WHV Tg mice. This tolerance suppresses the induction 
of the vigorous T cell response, which may also be the case in chronically infected 
woodchucks or patients.  
As mentioned previously, there was no apparent change in the “quality” of the CD8+ 
T cells induced by DNA or DNA-AdV regimen in C57BL/6 mice. Nevertheless, in the 
tolerogenic host, in which the magnitude of the induced immune response is lower, 
the different immunization protocols might induce CD8+ T cells of different phenotype. 
Moreover, the phenotype of the cells may vary from those elicited in the wild-type 
mice. Indeed, the multifunctional analysis of the CD8+ T cells induced in 1217 WHV 
Tg and C57BL/6 mice showed the difference in the phenotype of the CD8+ T cells. 
The evaluation of the CD107a and IFNγ co-expression, showed that there is 
significantly smaller proportions of the double-positive cells (CD107a+ IFNγ+) in 1217 
WHV Tg mice in comparison to C57BL/6 mice. It was shown that approximately 90% 
of total IFNγ+ or CD107a+ CD8+ T cells co-express both markers in C57BL/6 mice in 
response to stimulation with c13-21 (Fig. 5.22; page 93). In 1217 WHV Tg mice this 
frequency was merely 41% (Fig.5.30; page 105). Moreover, in mice boosted twice 
with Ad5WHc and Ad35WHc the proportion of IFNγ-secreting cells was lower than in 
mice which were boosted with Ad5WHc only once. The obtained results show that 
there is impaired IFNγ production correlating with comparable CD107a expression 
after the second booster vaccination. Those findings together with the change of anti-
WHc antibody profiles, might suggest that immunization with Ad35WHc changes the 
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phenotype of the elicited CD8+ T cells. In order to fully explain and understand those 
findings, a more detailed phenotypic study needs to be performed to confirm the 
change of the T cell response profile in those mice.  
The evaluation of the TH1 cytokine secretion (IFNγ, TNFα and IL-2) was not possible 
for the whole experimental group of mice because of a very low CD8+ T cell response 
detected after 6h stimulation with c13-21 (Fig. 5.31A; page 107). Unfortunately, 
expansion of splenocytes of mice in culture for 7 days resulted in a complete loss of 
IL-2 production [data not shown]. This outcome seems to be related to the addition of 
recombinant IL-2 into the cell culture in quite high concentration to maintain the 
growth of the cells. Nevertheless, the strategy based on choosing one mouse from 
every vaccination group that exhibited the significant CD8+ T cell response allowed 
for a very limited insight in the phenotype of the cells. Apparently, the highest 
proportion of cells producing all three cytokines was shown for mouse from the DNA-
Ad5 group (Fig. 5.31B; page 107). This mouse also showed the highest proportion of 
IFNγ+ TNFα+ CD8+ T cells in the double cytokine producing cells. Interestingly, the 
mice from DNA-Ad5-Ad35WHc group demonstrated the highest proportion of IFNγ+ 
IL-2+ CD8+ T cells (Fig. 5.31D; page 107). Recent data reported the defects in the   
IL-2 production by CD8+ T cells during chronic HBV infection [Das et al., 2008]. 
Moreover, the high proportion of IFNγ+ IL-2+ CD8+ T cells correlates with the non-
progressive HIV infection [Zimmerli et al., 2005]. Those findings, suggest that the 
possible change in phenotype of the CD8+ T cells in 1217 WHV Tg mice that 
received the double AdV boost might be beneficial for controlling persistent viral 
infections. However, the results need further investigation on the bigger cohort of 
mice in order to obtain the statistical significance. 
6.2.1 Heterologous DNA-AdV immunization induces anti-WHs antibodies. 
To address the question whether the potent WHcAg-specific T cell response is able 
to brake the immune tolerance against the WHsAg, the detection of anti-WHs was 
performed. Surprisingly, 76% of mice immunized by combinating plasmid DNA and 
Ad5 or Ad5-Ad35 expressing WHcAg developed anti-WHs antibodies (Fig. 5.28; 
page 101). It was shown previously that mice immunized with primed with HBcAg-
specific TH epitope can induce anti-HBs antibodies after “challenge” with HBV 
particles in contrast to mice that were not immunized [Millich et al., 1987]. This 
experiment shows that core-specific helper response is able to prime WHsAg-specific 
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B cells. In the presented study the development of anti-WHs was restricted to groups 
of mice immunized in DNA-AdV manner that exhibited the strongest WHcAg-specific 
CD8+ T cell response. It can be assumed that stronger CD8+ T cell response is also 
correlated with potent CD4+ T cell response in those mice. This T cell response, 
induced by heterologous prime-boost immunization, was able to brake the tolerance 
against WHsAg. It was previously shown that 1217 WHV Tg mice may develop low 
levels of anti-WHc with increasing age. However, the development of anti-WHs 
antibodies was never demonstrated [Meng et al., manuscript in preparation]. 
Nevertheless, it could be speculated that 1217 WHV Tg mice may develop a very low 
level of anti-WHs, not detectable by routinely used techniques. In that case, induction 
of a potent WHcAg-specific T cell response would easily facilitate anti-WHs 
development.  
The induction of anti-WHs antibodies in 1217 WHV Tg mice upon DNA-AdV 
immunization is of great impact as the chronic hepadnaviral infections correlate with 
a lack of antibodies against the surface proteins. Consequently, this result implies 
that the novel immunization strategy may be more effective in control of chronic WHV 
infection in woodchucks and possibly in patients. 
6.2.2 The immunization of 1217 WHV Tg mice in DNA-AdV manner leads to 
a significant reduction in the viral loads 
The 1217 WHV Tg mouse model gave the possibility to examine the impact of the 
vaccination on WHV replication. As the previous experiments, based on 
immunization with pWHcIm plasmid did not lead to reduction of WHV replication 
[Meng et al., manuscript in preparation]. Therefore, the question whether the newly 
developed optimized immunization strategy may result in significant reductions in the 
viral loads in 1217 WHV Tg mice was addressed. The results of the presented study 
showed that the immunization with optimized vaccines is able to significantly reduce 
WHV replication, as all tested vaccination protocols resulted in the significant 
reduction in WHV viral load (Fig. 5.32; page 109). However, the pronounced 
suppression in WHV replication was observed in DNA-Ad5WHc or DNA-Ad5-
Ad35WHc vaccination group, in which 83% and 60% of the mice respectively had 
undetectable viral loads at the end of the experiment (Fig. 5.32C-D; page 109). 
These results prove that immunization of WHV transgenic mice with the optimized 
DNA and AdV-based vaccines is able to effectively suppress WHV replication. 
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The promising results, using the optimized heterologous DNA prime-AdV boost 
immunization regimen in C57BL/6 and 1217 WHV Tg mouse models, raised the 
important question whether the improved vaccines would also be effective in the 
woodchuck model. 
6.3 Heterologous Ad5WHc–Ad35WHc or improved DNA immunization 
protects naïve woodchucks against WHV infection 
The vaccination trial with improved DNA vaccine or recombinant adenoviral vectors 
(Ad5WHc/Ad35WHc) in naïve woodchucks allowed to address the following 
questions: do the optimized constructs induce a potent CTL response in woodchucks 
and does this response provide a protection against the WHV infection? 
The results clearly show that immunization of woodchucks with the new pCGWHc 
plasmid or Ad5WHc/Ad35WHc expressing WHcAg induced WHcAg-specific immune 
response that indeed resulted in the control of a subsequent WHV infection. 
Previously described study already demonstrated that immunization of woodchucks 
with plasmid expressing WHcAg (pWHcIm) protected woodchucks from WHV 
infection. Three vaccinations with pWHcIm induced anti-WHc antibodies, but a very 
low T cell response, evaluated by 2[3H]-adenine-based proliferation assay detectable 
only in several woodchucks [Lu et al., 1999]. Recently established CD107a 
degranulation assay [Frank et al., 2007] allowed, for the first time, the detection of 
WHcAg-specific CTLs, elicited by vaccination in the peripheral blood of woodchucks. 
Vaccination with pCGWHc plasmid of the naïve woodchucks induced significant 
degranulation responses directed against WHcAg epitope c96-110 in two out of three 
woodchucks (Fig. 5.34; page 112). As the successful DNA vaccination depends on a 
very precise delivery of the plasmid, the borderline T cell response, detected in the 
third woodchuck (58059), might have been a result of incorrect immunization (Fig. 
5.34A; page 112). The percentages of WHcAg-specific CD107a+ CD3+ CD4- T cells 
detected in two responder woodchucks after three immunizations with pCGWHc 
plasmid were comparable to those induced just by one immunization with 
recombinant adenoviral vector (Ad5WHc) [Fig. 5.35A; page 114]. The magnitude of 
WHcAg-specific degranulation responses significantly increased after boosting 
immunization with Ad35WHc in both woodchucks immunized in heterologous 
Ad5WHc/Ad35WHc manner. This observation confirms that usage of the chimeric 
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Ad5F35 vector avoids the vector-specific immunity after immunization with Ad5 
(Fig. 5.35B; page 114). The high percentages of 13,3% and 7,4% of WHcAg-specific 
CTLs after Ad35WHc immunization are comparable to those detected during the 
acute phase of WHV infection [Frank et al., 2007]. These results clearly demonstrate 
the potency of adenoviral vectors to the induce vigorous CTL response in 
woodchucks. The elicited WHcAg-directed CTL response was significantly higher 
than the “classical” DNA vaccination. Similar results were obtained in rhesus 
macaques immunized three times with plasmid DNA or twice with Ad5 expressing 
HIV-1 gag gene. The T cell response against HIV-1 gag antigen, induced by 
homologous Ad5 immunization, was stronger in magnitude than this induced by DNA 
vaccination alone or with addition of the adjuvant [Casimiro et al., 2003]. Moreover, 
Ad5 immunization elicited protective immunity against the infection with simian 
immunodeficiency virus (SIV) or HIV-SIV hybrid virus [Shiver et al., 2002; Casimiro et 
al., 2005], as well as Ebola virus [Sullivan et al., 2006] in nonhuman primates. In 
addition, heterologous Ad5/Ad5F35 immunization of mice resulted in an improved 
immune protection against Friend retrovirus infection in comparison to homologous 
Ad5 immunization [Bayer et al., 2008]. The results of this study imply the usefulness 
of Ad5WHc/Ad35WHc immunization against hepadnaviral infections in the 
woodchuck model. 
The levels of anti-WHc antibodies, induced by plasmid or by heterologous 
Ad5WHc/Ad35WHc immunizations, were comparable in all animals. Anti-WHc 
antibodies are not able to neutralize the virions of WHV and are not able to prevent 
the infection of the hepatocytes [Roos et al., 1989; Schodel et al., 1993]. Therefore, 
a limited infection of hepatocytes occurred in vaccinated woodchucks after challenge. 
In all successfully immunized woodchucks only a short-time viremia (2 to 4 weeks) 
was observed, compared to the control woodchucks that were just infected with 
WHV. Moreover, the viral loads detected in immunized woodchucks were 3 to 4 logs 
lower than those reached in the control woodchucks (Fig. 5.39; page 122). The short-
time low level viremia was accompanied by the appearance of WHV-specific CTLs in 
the blood and no or low level elevation of GOT, indicating that only a small number of 
hepatocytes was eliminated by cytotoxic T cells (Fig. 5.36A; page 116 and Fig. 5.37; 
page 118). Altogether, the data confirm the small-scale infection of hepatocytes in 
those woodchucks. Woodchuck 58059, which partially responded to vaccination, 
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showed a prolonged viremia concurrent with high elevation in GOT level, compared 
to all the other responder woodchucks (Fig. 5.36B; page 116). Those data 
demonstrate a bigger-scale WHV infection that correlates with increased number of 
lysed WHV-infected hepatocytes. A similar course of infection was shown for one of 
the control woodchucks (58055) [Fig. 5.38A; page 120]. Nevertheless, the WHV viral 
load in the partially responder woodchuck was significantly shorter (12 weeks) than in 
the control animal. This finding shows that even the partial response, induced by 
immunization, is able to clear the WHV more efficiently. The other control woodchuck 
developed a persistent WHV infection after WHV inoculation. In adult woodchucks 
infection with WHV usually leads to chronic infection in about 5-10% of the animals 
[Cotte et al., 2000]. The control woodchuck that established chronic WHV infection 
did not show any WHV-specific T cell responses over the monitoring period 
(Fig. 38B; page 120). Those findings correlate with the previously described reports 
showing that WHV chronic carriers demonstrate weak or no virus-specific T cell 
responses [Menne et al., 1998; Frank et al., 2007].  
The development of neutralizing antibodies directed against the surface antigen 
epitopes, is crucial for the resolution of the HBV infection in humans [Hoofnagle, 
1981; Chisari et al., 1995], as well as, for the resolution of WHV infection in 
woodchucks [Cote et al., 1986; Lu et al., 1999]. The appearance of anti-WHs 
antibodies correlated with the time of the WHV clearance in all examined 
woodchucks. The presence of anti-WHs antibodies in the woodchucks, which 
responded to vaccination already at week 2 after WHV challenge, shows, that 
priming of WHsAg-specific B cell response occurred as a result of the immunization. 
Those results are consistent with Lu et al. where it is shown that immunization of 
woodchucks with plasmid expressing WHcAg led to an early induction of high levels 
of anti-WHs antibodies and a limited WHV infection [Lu et al., 1999]. Levels of anti-
WHs correlated with the magnitude of the WHcAg-specific T cell response after 
vaccination. The most prominent anti-WHs response, as well as the WHcAg-specific 
T cell response, was detected in woodchucks immunized in heterologous 
Ad5WHc/Ad35WHc manner (Fig. 5.40A; page 124). The intermediate levels of anti-
WHs were detected in two woodchucks which responded to pCGWHc immunization. 
As mentioned above, one of the two control woodchucks established a chronic WHV 
infection after WHV and as expected did not develop anti-WHs (Fig. 10.6C; page 
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184). The other one, developed low-level anti-WHs at a later stage of the infection 
(week 18 pi) than the immunized woodchucks did (Fig. 5.41; page 125). Those 
observations show that WHcAg-specific T cells, elicited by the vaccination provided 
help to the WHsAg-specific B cells. The intermolecular help results in a rapid and 
more robust production of anti-WHs, compared to the natural infection [Millich et al., 
1987].  
In contrast to anti-WHc, the levels of anti-WHs decreased in time. This finding reflects 
the observations in humans. It is known, that anti-HBs antibodies become 
undetectable over time after acute HBV infection in humans, whereas anti-HBc 
antibodies persist life-long [Shepard et al., 2006].  
6.4 Heterologous prime-boost immunization in combination with 
entecavir treatment may lead to control of chronic WHV infection 
The results obtained in mice and naïve woodchucks clearly showed, that the novel 
vaccines induce a more potent WHV-specific immune response than previously 
investigated strategies. Therefore, the final evaluation of the DNA-AdV regimen was 
performed in chronic WHV carriers. 
The reduction of viral load by the nucleoside analogues pre-treatment is necessary to 
enhance the effect of therapeutic immunization. The results from the previous studies 
clearly confirm the poor efficacy of the lamivudine treatment in woodchucks [Mason 
et al., 1998; Hervas-Stubbs et al., 2001; Lu et al., 2008]. Lamivudine treatment of 
chronic HBV infection is associated with a frequent resistance to the therapy found in 
approximately 70% of the patients after 4 years of treatment [Chang et al., 2004]. 
Moreover, lamivudine-resistant strains were isolated from chronically WHV-infected 
woodchucks treated with lamivudine [Jacob et al., 2004]. The evaluation of various 
nucleoside analogues in woodchucks revealed also potent antivirals suitable for this 
model, such as clevudine [Menne et al., 2002] and telbivudine [Bryant et al., 2001]. 
In the presented study, WHV chronic carriers were treated with guanosine nucleoside 
analogue entecavir. Entecavir proved to efficiently suppress the viral replication 
during chronic HBV infection in patients [Karino et al., 2010; Yuen et al., 2011], as 
well as chronic WHV infection in woodchucks [Genovesi et al., 1998; Colonno et al., 
2001; Lu et al., unpublished data]. As expected, the rapid decrease in the viral load in 
chronically WHV-infected woodchucks was observed during the first weeks of ETV 
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therapy. WHV became undetectable in the blood of all animals by week 12 of the 
treatment (Fig. 10.9A-G; page 192). It was assumed that the WHV suppression by 
antiviral treatment may be also beneficial during the first stage of the immunization 
phase [Lu et al., personal communication]. Therefore, the immunizations were 
performed together with a continuous entecavir treatment until week 23. 
6.4.1 Heterologous prime-boost immunization in combination with ETV leads 
to induction of WHV-specific T cell response in all treated chronic 
carriers 
Previous reports indicate that combination therapy (antivirals + vaccine) of chronic 
WHV infection may restore WHV-specific T cell responses. The first study was based 
on lamivudine treatment combined with immunization with plasmid DNA vaccine 
(expressing WHsAg, WHcAg and woodchuck IFNγ) and antigen-antibody 
WHsAg/anti-WHs IC vaccines together. The study demonstrated significant 
lymphoproliferative responses only in one out of 8 woodchucks after the last 
immunization [Lu et al., 2008]. The second study examined clevudine therapy in 
combination with protein WHsAg vaccine. The treatment led to the induction of rapid 
and sustained proliferative responses against WHsAg approximately in 70% of the 
woodchucks [Menne et al., 2002]. Therefore, the question whether the novel prime-
boost strategy inducing a very potent T cell response in the previous models can lead 
to the improved TH and CTL responses in chronic WHV carriers. 
In this study, WHV-specific T helper responses were detected in PBMCs of all 
chronically WHV-infected woodchucks that received therapeutic vaccine combined 
with ETV, but not in controls treated only with ETV. The woodchucks from the 
combination therapy group developed early and sustained WHsAg- and WHcAg-
specific proliferative responses (Fig. 5.43; page 128). The responses were detected 
in some woodchucks already after two DNA immunizations. All woodchucks that 
received the combination therapy had significant proliferative responses after three 
DNA immunizations, that were detectable until week 25 (two weeks after the end of 
the ETV treatment and 3 weeks after the second Ad35WHc/pWHsIm immunization). 
The proliferative responses were predominantly directed against the two WHsAg-
derived TH peptides s224-239 and s252-267. The position of the epitope s224-239 
overlapped with the peptide s226-245 preferentially recognized in WHV chronic 
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carriers after clevudine/WHsAg combination therapy [Menne et al., 2002]. Those 
findings indicate that amino acid sequences at the N-terminus of WHsAg are 
a preferable target for T cell response. Moreover, several WHcAg-derived 
TH epitopes identified in woodchucks with acute self-limited WHV infection [Menne et 
al., 1998] were recognized in WHV carriers. The WHcAg-specific proliferative 
responses were most frequently directed against the peptides c64-79, c109-124 and 
c117-132. 
Following the appearance of T helper cells, WHcAg- and WHsAg-specific CTLs were 
detectable in all woodchucks that received combination therapy, but not in ETV 
treated controls. Only brief CTL responses were detected shortly after the beginning 
of ETV treatment at week 4. The 3 to 4 logs decrease of the viral load led to induction 
of WHsAg-specific CTLs in one of seven ETV treated woodchucks (61795; 
Fig. 10.8G; page 189) and WHcAg-specific CTLs in two chronic carriers (61786 and 
61791; Fig. 10.8A,F; page 189). Those findings are consistent with the data obtained 
from chronic HBV patients treated with nucleoside analogues. The treatment with 
lamivudine could transiently restore HBV-specific T cell immune response in some of 
the patients [Boni et al., 2001; 2003]. The appearance of sustained WHcAg-specific 
CTL response after the vaccinations correlated with the phase of Ad5WHc and 
Ad35WHc administration. The WHcAg-specific degranulation response was present 
in the woodchucks from combination therapy from week 22 until the last monitored 
time point week 29 (Fig. 5.44A; page 131). In addition, all four woodchucks treated 
with combination therapy that survived the end of ETV treatment demonstrated 
prominent WHsAg-specific CTL responses. The WHsAg-specific CTL responses 
were not so prominent as responses directed against WHcAg and appeared only 
transiently (Fig. 5.44B; page 131). 
The data obtained from HBV infection in patients underline the role of core-specific 
T cell responses as a factor leading to the virus clearance [Ferrari et al., 1990; Penna 
et al., 1997; Guidotti et al., 1999; Maini et al., 2000; Thimme et al., 2003]. The 
immunotherapy examined in the presented work demonstrated that sustained 
WHcAg-specific T helper response and CTL response could be induced in WHV-
chronically infected woodchucks. The novel prime-boost immunization induced 
a more potent WHV-specific immune response than previously investigated 
strategies also in chronically WHV-infected woodchucks. Significant WHV-specific TH 
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and CTL responses were elicited for the first time in all chronic carriers from 
combination therapy group. Since ETV-only treatment did not induce significant T cell 
responses in the control animals, this outcome was an effect of the therapeutic DNA 
prime–recombinant adenovirus boost immunization. Those results also prove that 
high WHV replication during the chronic infection correlates with hyporesponsiveness 
of the T cells, as it was shown in chronically HBV-infected patients [Webster et al., 
2004]. Potent antiviral drugs such as ETV are crucial to enhance the therapeutic 
effect of the vaccination. 
6.4.2 Heterologous prime-boost immunization in combination with ETV leads 
to sustained antiviral response in treated chronic carriers 
All four woodchucks from the combination therapy group that survived the whole 
monitoring period demonstrated a prolonged suppression of WHV replication, 
compared to ETV-only treated controls. Two woodchucks (61786 and 61789) 
became WHV positive 5 and 7 weeks later than ETV-only treated controls. The other 
two (61792 and 61793) were WHV negative until the end of the monitoring period, 
suggesting that those animals might clear the chronic WHV infection (Fig. 5.45; 
page 133). 
To confirm this finding, the detection of anti-WHs antibodies was evaluated, as the 
seroconversion of HBsAg and the presence of anti-HBsAg specific antibodies is the 
most important criterion in the resolution of HBV infection in humans [Chisari et al., 
1995]. Indeed, both woodchucks that demonstrated undetectable viral loads at the 
end of the monitoring period (61792 and 61793) developed anti-WHs antibodies what 
prove that the sustained antiviral response was developed in those animals (Tab. 5.2; 
page 134). Nevertheless, only woodchuck 61792 was WHV negative in the liver. 
Woodchuck 61793 demonstrated low level of WHV replication confirmed by the 
detection of WHV ssDNA replicative intermediate (Fig. 5.46; page 135).  
The data obtained from woodchuck 61792 clearly demonstrate that the novel 
combination strategy (ETV + prime-boost vaccination) led to the complete clearance 
of WHV infection in one of four woodchucks. Premature euthanasia of the woodchuck 
61793 did not allow to interpret the results fully. The fact that WHV ssDNA replicative 
intermediate was present in the liver of this woodchuck shows that woodchuck 61793 
was not able to completely clear the WHV infection in the liver. This might imply that 
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the WHV replication could be restored in this animal. Nevertheless, the formation of 
RC DNA that indicates the assembly of progeny virions was still impaired. This 
finding correlates with the fact that the patients who recovered from acute hepatitis B 
may show residual HBV replication in the liver. However, those patients are not 
viremic due to the high neutralizing anti-HBs antibody concentration, which prevent 
the spread of the infection [Rehermann et al., 1996; Yuki et al., 2003]. As woodchuck 
61793 had an undetectable WHV load and developed anti-WHs (in contrast to other 
woodchucks which showed full WHV replication in the liver), it can also be assumed 
that a long-term control of WHV infection was achieved in this animal. 
The previously described study based on ETV treatment in combination with DNA 
(plasmids encoding WHcAg and WHsAg) together with protein (WHcAg and WHsAg) 
immunization resulted in the clearance of WHV infection in 2 out of 6 WHV chronic 
carriers [Lu et al., unpublished results]. Nevertheless, the period of ETV treatment 
was much longer (1 year) and animals received 12 immunizations. In the presented 
study, the ETV treated period was shortened from 52 to 23 weeks and the number of 
immunizations was reduced from 12 to 9. Nevertheless, the efficacy of the presented 
therapy was similar, which proves that the immunization with optimized plasmids and 
recombinant adenoviral vectors shows a great potential. The utility of optimized 
WHsAg expressing plasmids and recombinant viral vectors encoding WHsAg could 
bring additional benefit in the treatment of chronic WHV infection.  
It was shown that the high values of liver transaminases in the serum of chronic 
hepatitis B patients or woodchucks may indicate the progression of the liver disease 
[Chisari et al., 1995; Cote et al., 2000; Wang et al., 2004; Rehermann et al., 2005]. 
Therefore, the question was addressed whether the novel therapeutic strategy may 
prevent the liver damage by the HCC development and, as a consequence, may lead 
to a normalization of the liver enzymes. 
During ETV treatment, the serum GOT levels returned to normal levels in the sera of 
all examined woodchucks. However, the GOT levels remained low in the group that 
received a combinatory treatment, but not in ETV-only treated controls. It is known 
that the inhibition of the viral replication by antiviral treatment suppresses the 
progression of liver disease. The treatment of WHV chronic carriers with potent 
antiviral drugs as clevudine leads to a sustained decrease of liver enzymes levels in 
the serum [Menne et al., 2002]. Similar results were obtained in chronically HBV-
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infected patients who demonstrated normalization of ALT levels during ETV 
treatment [Karino et al., 2010; Yuen et al., 2011]. Nevertheless, in the presented 
study the effect was more pronounced in the woodchucks that were additionally 
vaccinated (Fig. 5.47; page 136). The prolonged suppression of WHV replication 
achieved by heterologous DNA prime – AdV boost immunization also resulted in 
delaying the onset of HCC development (Fig. 5. 48; page 138). 
Discussion
 
160 
 
6.5 Conclusion 
It can be concluded that by improved vectors for vaccination, by the optimization of 
the vaccination protocol, and by the addition of a potent antiviral treatment a novel 
and potent strategy in treatment of chronic hepadnaviral infections was obtained. The 
results of this study proved that the combination of DNA vaccine and recombinant 
adenoviral vectors led to the induction of improved TH and CTL WHV-specific 
responses for the first time in all treated chronic WHV carriers. Moreover, the long-
term control of WHV was achieved in 2 out of 4 carriers. These findings indicate that 
the therapeutic approach evaluated in this study induces a potent T cell response 
and seems to be an effective strategy to achieve a sustained control of chronic 
hepadnaviral infections. In addition, this new approach may have an impact on 
clinical trials of the therapeutic vaccination in chronically HBV-infected patients. A 
latest study of a French group from the Pasteur Institute in Paris reported that the 
combination of antiviral treatment with DNA vaccine expressing HBsAg failed 
completely in eliminating the HBV infection in chronic HBV carriers [Stanislas Pol, 
personal communication]. Therefore, the results obtained in this study using a 
preclinical model present a promising alternative strategy. The combination of potent 
antivirals with the therapeutic vaccines which are focusing on the induction of 
a strong anti-core T cell response may be a more beneficial immunotherapy of 
chronic hepatitis B. 
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7 Summary 
More than 360 million people worldwide are persistently infected with the hepatitis B 
virus (HBV). The recommended treatment of chronic hepatitis B with interferon-α 
and/or nucleoside analogues does not lead to satisfactory results. It is well 
documented that the viral persistence is caused by an absence of the effective virus-
specific T cell response. Therefore, the induction of HBV-specific T cells by 
therapeutic vaccination may be an innovative strategy to overcome virus persistence. 
Vaccination with commercially available HBV vaccines and DNA vaccines in patients 
did not result in an induction of the immune response, which would effectively control 
the HBV infection. Due to this, a more potent therapeutic vaccines are needed. The 
woodchuck (Marmota monax) is a useful preclinical model for developing new 
therapeutic approaches in chronic hepadnaviral infections. Several approaches using 
classical protein and DNA vaccines were tested previously in the woodchuck model 
without success. The high viral load observed in chronic hepadnaviral infections may 
have impaired the induction of an effective virus-specific T cell response. Therefore, 
the application of more potent vaccines, e.g. recombinant viral vectors in combination 
with antiviral treatment, may be required to achieve sustained antiviral response.  
In the presented study, an innovative therapeutic strategy, combining vaccination 
with optimized DNA and recombinant adenoviral vectors (AdV), as well as potent 
antiviral treatment with entecavir (ETV), was evaluated in the woodchuck model. 
It was hypothesized that this approach may be an effective strategy to improve WHV-
specific immune responses and as a result lead to the resolution of chronic WHV 
infection. 
For that purpose, an improved DNA vaccine (pCGWHc), adenoviral vector serotype 5 
(Ad5WHc) and chimeric Ad5 displaying Ad35 fiber (Ad35WHc) expressing high levels 
of woodchuck hepatitis core antigen (WHcAg) were constructed. The efficacy of the 
improved vaccines was tested first in mice and in naïve woodchucks. The improved 
WHcAg expression by pCGWHc caused a detection of significantly stronger CD8+ 
T cell response (interferon-γ production) and higher anti-WHc levels in C57BL/6 
mice, compared to the previously used DNA plasmid vaccine. Immunization of mice 
by pCGWHc prime-AdV boost regimen enhanced CD8+ T cell response even more, 
compared to immunization with DNA alone. Moreover, the vigorous cytotoxic activity 
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of these WHcAg-specific CD8+ T cells could be demonstrated in vivo. To further 
evaluate the efficacy of the new prime-boost regimen the vaccination of WHV 
transgenic mice (1217 WHV Tg) was performed. The immunizations elicited an 
unexpected anti-WHc and anti-WHs antibodies and WHcAg-specific CD8+ T cell 
response which led to a significant suppression of WHV replication in those mice. 
Next, the heterologous Ad5WHc/Ad35WHc immunization was performed in naïve 
woodchucks. The immunization resulted in the induction of a strong cellular immune 
response in woodchucks and protected them from WHV infection after the challenge. 
Altogether, these results clearly showed, that heterologous DNA-AdV immunization 
induces a more potent WHV-specific immune response than previously investigated 
strategies in mice and woodchucks. Therefore, this novel DNA prime-AdV boost 
regimen was used to treat chronically WHV-infected woodchucks in combination with 
entecavir (ETV) to induce a proper CTL response. Seven animals were treated with 
ETV for 23 weeks. Starting from week 8, five of them received additional 
9 immunizations with DNA plasmids, expressing WHcAg and WHsAg, Ad5WHc and 
Ad35WHc. For the first time, the significant WHsAg- and WHcAg-specific proliferative 
responses (CD4) and degranulation responses (CD8) were detected in all chronic 
carriers that received immunizations in combination with ETV treatment. Moreover, 
2 of 4 immunized woodchucks, which completed the ETV and vaccination treatment, 
demonstrated sustained antiviral response (undetectable viral load and development 
of anti-WHs).  
These findings indicate that the therapeutic approach evaluated in this study induces 
a potent T cell response and seems to be an effective strategy to achieve sustained 
control of chronic hepadnaviral infections. These results obtained in a preclinical 
model might be the base for the clinical trials of therapeutic vaccines which induce 
strong anti-core T cell response in combination with antivirals as a possible 
immunotherapy in chronically HBV-infected patients. 
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8 Zusammenfassung 
Weltweit sind derzeit mehr als 360 Millionen Menschen mit dem Hepatitis B Virus 
(HBV) chronisch infiziert. Die empfohlenen Behandlungsstategien bei chronischer 
Hepatitis B, bestehend aus Interferon-α und/oder Nukleosid-Analoga, zeigen keine 
zufriedenstellenden Erfolge. In der Literatur ist beschrieben, dass die Viruspersistenz 
durch das Fehlen einer effektiven virus-spezifischen T-Zellantwort mitunter 
verursacht wird. Daher stellt die Induktion einer HBV-spezifischen T-Zellantwort 
durch eine therapeutische Vakzinierung eine innovative Strategie zur Behandlung 
dar, um die Viruspersistenz zu überwinden. Die Schutzimpfung mit kommerziell 
erhältlichen HBV-Impfstoffen und DNA-Vakzinen in Patienten führt zu keiner 
ausreichenden Immunantwort, die HBV effektiv kontrolliert. Infolgedessen werden 
neue wirksame therapeutische Impfstoffe dringend benötigt. Das nordamerikanische 
Waldmurmeltier (Marmota monax; engl. woodchuck) ist ein nützliches, prä-klinisches 
Modell zur Entwicklung neuer therapeutischer Ansätze in chronischen 
hepadnaviralen Infektionen. Bisherige Therapieansätze im Murmeltier Model, unter 
Verwendung von klassischen Protein- und DNA-Vakzinen waren ohne Erfolg. Die 
hohe Viruslast, die in chronischen hepadnaviralen Infektionen beobachtet wird, kann 
die effektive, virus-spezifische T-Zellantwort beeinträchtigen.  Aus diesem Grund 
werden wirksamere Impfstoffe, wie zum Beispiel eine Kombination aus 
rekombinanten viralen Vektoren und antivirale Behandlung benötigt, um eine 
andauernde antivirale Antwort zu erzielen. 
In der vorliegenden Arbeit wurde eine innovative therapeutische Strategie im 
Murmeltier-Model verfolgt, die in einer kombinierten Vakzinierungsstrategie aus 
optimierten DNA- und rekombinanten Adenoviralen Vektoren (AdV) sowie aus einer 
wirksamen, antiviralen Behandlung mit Entecavir (ETV) bestand. Es wurde 
angenommen, dass dieser Ansatz eine effektive Immunisierungsstrategie darstellt, 
um eine spezifische Immunantwort gegen das Murmeltier Hepatitis Virus (WHV) zu 
verbessern und als Ergebnis zu einer Eliminierung der chronischen WHV-Infektion 
führt.  
Zu diesem Zweck wurden Vektoren konstruiert, die das Murmeltier Hepatitis Core 
Antigen (WHcAg) stark exprimieren: ein verbesserter DNA-Impfstoff (pCGWHc), ein 
Adenoviraler Vektor des Serotyps 5 (Ad5WHc) und einen chimären Ad5 mit 
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präsentierenden Ad35 Fibern. Die Wirksamkeit dieser verbesserten Impfstoffe wurde 
zuerst in Mäusen und in naiven Murmeltieren getestet. Die durch pCGWHc 
verbesserte WHcAg Expression bewirkte eine signifikant stärkere CD8+ T-Zellantwort 
(Interferon γ Produktion) und höhere anti-WHc Level in C57BL/6 Mäusen als in zuvor 
verwendeten DNA Plasmid-Vakzinen. Im Vergleich zu DNA-Immunisierung konnte 
eine weitere Verbesserung der CD8+ T-Zellantwort erzielt werden, indem eine 
pCGWHc „prime-AdV boost“ Immunisierungsstrategie in Mäusen angewandt wurde. 
Darüber hinaus konnte gezeigt werden, dass diese WHcAg-spezifischen CD8+ T-
Zellen eine starke zytotoxische Aktivität in vivo besaßen. Zur weiteren Beurteilung 
der neuen „prime-boost“ Strategie wurden WHV-transgene Mäuse (1217 WHV Tg) 
immunisiert. Die Immunisierung rief eine unerwartete anti-WHc und anti-WHs 
Antikörperproduktion sowei eine WHcAg-spezifische CD8+ T-Zellantwort aus, die zu 
einer signifikanten Verminderung der WHV Replikation in den Mäusen führte. Im 
Anschluss wurde die heterologe Ad5/Ad35WHc Immunisierung in naiven 
Murmeltieren durchgeführt, welche eine starke zelluläre Immunantwort ausgelöste. 
Des Weiteren bot diese Immunisierungsstrategie effektiven Schutz vor einer WHV-
Infektion. Zusammenfassend zeigen diese Ergebnisse, dass eine heterologe DNA-
AdV Immunisierung eine weitaus stärkere WHV-spezifische Immunantwort 
induzieren kann, als die zuvor in Mäusen und Murmeltieren angewandten 
Immunisierungsstrategien. Zu diesem Zweck wurde diese neuartige DNA „prime-AdV 
boost“ Strategie dazu verwendet, chronisch WHV-infizierte Murmeltiere in 
Kombination mit ETV für 23 Wochen zu behandeln. Ausgehend von Woche 8 
erhielten 5 der chronisch WHV-infizierten Murmeltiere 9 Immunisierungen mit den 
DNA-Plasmiden, welche WHcAg und WHsAg sowie Ad5WHc und Ad35WHc 
exprimieren. Zum ersten Mal konnte eine signifikante WHsAg- und WHcAg-
spezifische Proliferationsantwort (CD4) und Degranulationsantwort (CD8) in allen 
chronisch infizierten Murmeltieren detektiert werden. Des Weiteren konnte gezeigt 
werden, dass 2 aus 4 immunisierten Murmeltieren, die die Behandlung mit ETV und 
Vakzine abgeschlossen hatten, eine anhaltende antivirale Immunantwort aufwiesen. 
Diese Ergebnisse verdeutlichen, dass der gewählte therapeutische Ansatz eine 
wirksame T-Zellantwort induziert und eine effektive Behandlungsstrategie zu sein 
scheint, um eine anhaltende Kontrolle von chronischen hepadnaviralen Infektionen 
zu erzielen. Die in dieser Arbeit beschriebenen Befunde im prä-klinischen Model 
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könnten die Basis für eine klinische Studie zur therapeutischen Vakzinierung zur 
Immuntherapie chronischer HBV-infizierter Patienten darstellen, die in Kombination 
mit antiviralen Agentien in der Lage ist eine starke anti-Core T-Zellantwort zu 
erzielen. 
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10 Appendix 
10.1 WHcAg and WHsAg amino acid sequences of WHV strain 8 
 
WHcAg (188 amino acids) 
MDIDPYKEFG SSYQLLNFLP LDFFPDLNAL VDTATALYEE ELTGREHCSP 
HHTAIRQALV CWDELTKLIA WMSSNITSEQ VRTIIVNHVN DTWGLKVRQS 
LWFHLSCLTF GQHTVQEFLV SFGVWIRTPA PYRPPNAPIL STLPEHTVIR 
RRGGARASRS PRRRTPSPRR RRSQSPRRRR SQSPSANC 
 
WHsAg (431 amino acids) 
MGNNIKVTFN PDKIAAWWPA VGTYYTTTYP QNQSVFQPGI YQTTSLINPK 
NQQELDSVLI NRYKQIDWNT WQGFPVDQKL PLVSRDPPLK PHINQSAQTF 
EIKPGPIIVP GIRDIPRGLV PPQTPTNRDQ GRKPTPPTPP LRDTHPHLTM 
KNQTFRLQGF VDGLRDLTTT ERYHNAYGDP FTTLSPVVPT VSTILSPPST 
TGDPALSPEM SPSSLLGLLA GLQVVYFLWT KILTIAQNLD WWWTSLSFPG 
GIPECTGQNS QFQTCKHLPT SCPPTCNGFR WMYLRRFIIY LLVLLLCLIF 
LLVLLDWKGL IPVCPLQPTT ETTVNCRQCT LSVQDTYTPP YCCCLKPTAG 
NCTCWPIPSS WALGNYLWEW ALARFSWLNL LVPLLQWLGG ISLIAWFLLI 
WMIWFWGPAL LSILPPFIPI FVLFFLIWVY I 
 
10.2 Sequences of peptides used for in vitro stimulation 
WHcAg- and WHsAg-derived synthetic peptides used for in vitro stimulation of 
murine splenocytes and woodchuck PBMCs for flow cytometric analysis and 
proliferation assays are presented in tables below (Tab. 10.1- Tab. 10.4). The amino 
acid sequences, the position of the peptide in the protein sequence and used 
abbreviations are given. 
 
Tab. 10.1 Amino acid sequence of WHcAg-derived 9-mer peptides used for in 
vitro stimulation of murine splenocytes 
Abbr. Position Sequence Abbr. Position Sequence 
p2n1 c7-15 KEFGSSYQL p18n1 c86-94 VNHVNDTWG 
p2n2 c8-16 EFGSSYQLL p18n2 c87-95 NHVNDTWGL 
p2n3 c9-17 FGSSYQLLN p18n3 c88-96 HVNDTWGLK 
p2n4 c10-18 GSSYQLLNF p18n4 c89-97 VNDTWGLKV 
p2n5 c11-19 SSYQLLNFL p18n5 c90-98 NDTWGLKVR 
p2n6 c12-20 SYQLLNFLP p18n6 c91-99 DTWGLKVRQ 
p2n7 c13-21 YQLLNFLPL p18n7 c92-100 TWGLKVRQS 
p2n8 c14-22 QLLNFLPLD   
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Tab. 10.2 Amino acid sequence of WHcAg-derived 15-mer peptides used for in 
vitro stimulation of murine and woodchuck lymphocytes 
Abbr. Position Sequence Abbr. Position Sequence 
p1 c1-15 MDIDPYKEFGSSYQL p19 c91-105 DTWGLKVRQSLWFHL 
p2 c6-20 YKEFGSSYQLLNFLP p20 c96-110 KVRQSLWFHLSCLTF 
p3 c11-25 SSYQLLNFLPLDFFP p21 c101-115 LWFHLSCLTFGQHTV 
p4 c16-30 LNFLPLDFFPDLNAL p22 c106-120 SCLTFGQHTVQEFLV 
p5 c21-35 LDFFPDLNALVDTAT p23 c111-125 GQHTVQEFLVSFGVW 
p6 c26-40 DLNALVDTATALYEE p24 c116-130 QEFLVSFGVWIRTPA 
p7 c31-45 VDTATALYEEELTGR p25 c121-135 SFGVWIRTPAPYRPP 
p8 c36-50 ALYEEELTGREHCSP p26 c126-140 IRTPAPYRPPNAPIL 
p9 c41-55 ELTGREHCSPHHTAI p27 c131-145 PYRPPNAPILSTLPE 
p10 c46-60 EHCSPHHTAIRQALV p28 c136-150 NAPILSTLPEHTVIR 
p11 c51-65 HHTAIRQALVCWDEL p29 c141-155 STLPEHTVIRRRGGA 
p12 c56-70 RQALVCWDELTKLIA p30 c146-160 HTVIRRRGGARASRS 
p13 c61-75 CWDELTKLIAWMSSN p31 c151-165 RRGGARASRSPRRRT 
p14 c66-80 TKLIAWMSSNITSEQ p32 c156-170 RASRSPRRRTPSPRR 
p15 c71-85 WMSSNITSEQVRTII p33 c161-175 PRRRTPSPRRRRSQS 
p16 c76-90 ITSEQVRTIIVNHVN p34 c166-180 PSPRRRRSQSPRRRR 
p17 c81-95 VRTIIVNHVNDTWGL p35 c171-185 RRSQSPRRRRSQSPS 
p18 c86-100 VNHVNDTWGLKVRQS p36 c176-188 PRRRRSQSPSANC 
 
Tab. 10.3 Amino acid sequence of WHcAg-derived peptides used for in vitro 
stimulation of woodchuck lymphocytes (Proliferation assay) 
Abbr. Position Sequence Abbr. Position Sequence 
cp1 c1-16 MDIDPYKEFGSSYQLL cp13 c85-100 IVNHVNDTWGLKVRQS 
cp2 c8-23 EFGSSYQLLNFLPLDF cp14 c93-108 WGLKVRQSLWFHLSCL 
cp10 c64-79 ELTKLIAWMSSNITSE cp15 c101-116 LWFHLSCLTFGQHTVQ 
cp11 c71-86 WMSSNITSEQVRTIIV cp16 c109-124 TFGQHTVQEFLVSFGV 
cp12 c78-93 SEQVRTIIVNHVNDTW cp17 c117-132 EFLVSFGVWIRTPAPY 
 
Tab. 10.4 Amino acid sequence of WHsAg-derived peptides used for in vitro 
stimulation of woodchuck lymphocytes (Proliferation assay) 
Abbr. Position Sequence Abbr. Position Sequence 
sp1 s210-225 MSPSSLLGLLAGLQVV sp17 s322-337 TTVNCRQCTLSVQDTY 
sp3 s224-239 VVYFLWTKILTIAQNL sp19 s336-351 TYTPPYCCCLKPTAGN 
sp5 s238-253 NLDWWWTSLSFPGGIP sp21 s350-365 GNCTCWPIPSSWALGN 
sp7 s252-267 IPECTGQNSQFQTCKH sp23 s364-379 GNYLWEWALARFSWLN 
sp9 s266-281 KHLPTSCPPTCNGFRW sp25 s378-393 LNLLVPLLQWLGGISL 
sp11 s280-295 RWMYLRRFIIYLLVLL sp27 s292-407 SLIAWFLLIWMIWFWG 
sp13 s294-309 LLLCLIFLLVLLDWKG sp29 s406-421 WGPALLSILPPFIPIF 
sp15 s308-323 KGLIPVCPLQPTTETT sp31 s420-431 IFVLFFLIWVYI 
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10.3 Vector maps 
The maps of all plasmids that were generated and used during the experiments are 
presented below (Fig. 10.1 - Fig. 10.4). 
 
 
 
 
Fig. 10.1 Vector maps of pWHcIm (A) and pWHsIm (B) plasmids 
Plasmids were constructed on the basis of pcDNA3 vector (Invitrogen). The inserts were 
amplified by PCR with specific primers and cloned into pCRII vectors (Invitrogen). 
Afterwards, the inserts were cloned into EcoRI site of the vector. The expression of WHcAg 
from pWHcIm plasmid and WHsAg from pWHsIm plasmid is under control of CMV-IE 
promoter of the vector. Plasmids were kindly provided by Prof. Mengji Lu (Institut für 
Virologie, Universitätsklinikum, Essen). 
 
A 
B 
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Fig. 10.2 Vector map of pCGWHc plasmid 
Plasmid was constructed on the basis of pCG vector (kindly provided by Prof. Ulf Dittmer, 
Institut für Virologie, Universitätsklinikum, Essen). pCG contains a β-globin intron sequence 
between CMV-IE promoter and the polyadenylation signal and the ampicillin resistance gene: 
Amp(R). The WHcAg insert was obtained from pWHcIm vector, by cutting with BamHI and 
XbaI restriction enzymes, and then introduced into BamHI/XbaI site of pCG vector. 
 
 
Fig. 10.3 Vector map of pShuttle/WHc plasmid 
pShuttle plasmid (Qbiogene) contains two “arms” of viral sequence for homologous 
recombination with the adenoviral backbone vectors. Moreover, it contains adenoviral left 
and right inverted terminal repeats (LITR and RITR, respectively) and the kanamycin 
resistance gene: Kan(R). The expression cassette (CMV-IE promoter, β-globin intron and 
polyadenylation signal) was amplified by PCR using pCG plasmid as template and primers 
introducing KpnI/BglII restriction sites. The amplified fragment was cloned into MCS of the 
pShuttle. The WHcAg sequence was obtained from pWHcIm plasmid by PCR with specific 
primers introducing XbaI/SbfI restriction sites and cloned into XbaI/SbfI site of the vector. 
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Fig. 10.4 Vector maps of pAd5WHc (A) and pAd5F35WHc (B) plasmids 
The recombinant adenoviral plasmids were constructed on the basis of replication defective 
E1/E3-deleted pAdEasy-1 (pAd5WHc) and modified pAdEasy-1/F35 (pAd5F35WHc) 
backbone vectors (Qbiogene). The pShuttle/WHc plasmid, expressing WHcAg under the 
CMV-IE promoter, was linerized with PmeI and introduced in the E1 region by homologous 
recombination into the backbone vectors. The pAd5WHc and pAd5F35WHc contain all 
necessary adenoviral sequences to produce recombinant AdV particles in E1 supporting cell 
lines. The kanamycin resistance gene: Kan(R) originates from pShuttle plasmid. Restriction 
digest with PacI releases the linear recombinant adenoviral genomes. 
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10.4 Supplementary figures 
 
 
Woodchuck was pretreated with cardiotoxin (grey arrow) and immunized intramuscularly 
three times with pCGWHc plasmid (black arrows). WHcAg- and WHsAg-specific T cell 
response was measured by CD107a degranulation assay of woodchuck PBMCs expanded 
in vitro for 3 days with epitope c96-110 and s220-234. Unstimulated cells served as negative 
controls The values show the percentage of CD107a+ CD3+ CD4- T cells in the CD3+ CD4- 
T cell population. The “+” sign marks the positive responses. The T cell responses were 
correlated with the presence of WHV (detected by WHV PCR and golden standard dot-blot 
hybridization) and GOT levels in the serum. 
Fig. 10.5 Correlation of WHcAg- and WHsAg-specific CTL responses with WHV 
presence and GOT levels in pCGWHc immunized woodchuck: 70096 
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Fig. 10.6 Detection of anti-WHc and anti-WHs antibodies in the sera of 
woodchucks immunized with pCGWHc plasmid or Ad5WHc/Ad35WHc. Data of 
woodchuck 70096 (A), 46957 (B) and control 58056 (C) 
Woodchuck 70096 was pretreated with cardiotoxin (grey arrow) and subsequently 
immunized for three times with pCGWHc plasmid (black arrows). Woodchuck 46949 was 
intramuscularly immunized with Ad5WHc (red arrow) and boosted with Ad35WHc (blue 
arrow). Immunized woodchucks and the control animal 58056 were intravenously inoculated 
with 1×107 WHV GE (week 0). Woodchucks sera were diluted 1:10 in PBS. WHcAg- and 
WHsAg-specific ELISA was performed using protein G coupled to peroxidase.  
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Fig. 10.7 WHcAg-specific and WHsAg-specific proliferative responses in WHV 
chronic carriers that were treated with combination therapy (A-E) 
The WHV chronic carriers (number: 61786, 61787, 61789, 61792 and 61793) were treated 
with entecavir for 23 weeks. Starting from week 8 woodchucks received subsequently 9 
intramuscular immunizations with pCGWHc/pWHsIm (time points of immunization marked by 
the green arrows), Ad5WHc/pWHsIm (red arrows) and Ad35WHc/pWHsIm (blue arrows). 
The PBMCs were separated from the blood of the animals at every examined time point and 
stimulated with panel of 10 WHcAg-specific and 16 WHsAg-specific peptides in triplicates. 
After 5 days of stimulation, cells were pulsed with 2[3H]adenine for 16h and the incorporation 
of 2[3H]adenine was measured. Results for triplicate cultures are presented as a mean 
stimulation index (SI): mean total absorbtion for peptide stimulated PBMCs divided by the 
mean total absorption for unstimulated control; n.d. – not done; † - dead. 
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Fig. 10.8 Determination of CD107a+ degranulation responses in WHV chronic 
carriers at all monitored time points of therapy: combination therapy group   
(A-E), ETV only treated controls (F-G) 
Seven chronically WHV-infected woodchucks were treated with entecavir for 23 weeks. Five 
of the seven ETV-treated woodchucks (61786, 61787, 61789, 61792 and 61793) received 
subsequently 9 intramuscular immunizations with pCGWHc/pWHsIm (time points of 
immunization marked by the green arrows), Ad5WHc/pWHsIm (red arrows) and 
Ad35WHc/pWHsIm (blue arrows). Two animals (61791 and 61795) were treated only with 
ETV and served as controls. PBMCs were expanded in vitro for 3 days with WHcAg-derived 
epitope c96-110 or WHsAg-derived epitope s220-234. Unstimulated cells and cells 
stimulated with unrelated CMV-derived peptide served as a negative controls. The T cell 
response was evaluated by CD107a degranulation assay. Presented values shows the 
percentage of CD107a+ CD3+ CD4- T cells in the CD3+ CD4- T cell population. The positive 
CTL responses are marked with “+” sign; n.d. – not done, † - dead. 
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Fig. 10.9 Correlation of WHV viral load and serum GOT levels in WHV chronic 
carriers at all monitored time points of therapy: combination therapy group (A-
E), ETV only treated controls (F-G)  
Seven chronically WHV-infected woodchucks were treated with entecavir for 23 weeks. Five 
of the seven ETV-treated woodchucks (61786, 61787, 61789, 61792 and 61793) received 
subsequently 9 intramuscular immunizations with pCGWHc/pWHsIm (time points of 
immunization marked by the green arrows), Ad5WHc/pWHsIm (red arrows) and 
Ad35WHc/pWHsIm (blue arrows). Two animals (61791 and 61795) were treated only with 
ETV and served as controls. The viral DNA was extracted from woodchucks sera and the 
WHV viral load was quantified per mililiter of serum, using real-time PCR (the detection limit: 
1×103 WHV GE/ml of serum). The GOT levels in woodchucks sera were quantified using the 
standard diagnostic methods. Elevation of GOT level is assumed above 50 IU/ml (border 
level); † - dead. 
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